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ABSTRACT OF THE DISSERTATION 
Synthesis, Characterization, and Biological Activity of  
Spherical Nucleic Acid (SNA) Constructs  
for Cancer Therapy and Imaging 
by 
Colin Calabrese 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2017 
Professor John-Stephen Taylor, Chair 
 
 
 This dissertation focuses on the development of biocompatible oligonucleotide-based 
nanomaterials, known as spherical nucleic acids (SNAs), as therapeutic and diagnostic agents for 
intracellular gene regulation and in vivo cancer imaging by positron emission tomography (PET). 
SNAs consist of a nanoparticle core functionalized with a dense shell of oligonucleotides such as 
deoxyribonucleic acid (DNA).   Detailed synthetic procedures and characterization of novel 
SNAs with purpose-built biocompatible core materials are described.  The SNAs exhibit 
comparable chemical, physical and biological properties regardless of core composition. The 
functionalities of the SNAs were further tailored by deliberate design and chemical modification 
of their oligonucleotide sequences. 
 The SNA nanostructures studied in this dissertation include those with cores made from 
infinite coordination polymers (ICPs), self-assembled block copolymer micelles, 64Cu-alloyed 
gold nanoclusters, and commercially-available monodisperse gold nanoparticles. In vitro and in 
vivo investigations of each SNA type are described. The first two examples, functionalized on 
their surface with DNA, entered a variety of cell lines without the need for transfection agents, 
xii 
 
and inhibited the translation of disease-related messenger RNA (mRNA).  The 64Cu-alloyed gold 
nanoclusters, functionalized on their surface with either DNA or phosphorodiamidate 
morpholino (PMO) oligonucleotides, were evaluated in vivo to determine their pharmacokinetics 
and biodistribution in mice. The blood circulation time of PMO-modified nanoclusters was far 
superior to DNA-modified nanoclusters, enabling their use in tumor pre-targeting studies 
wherein a non-radioactive nanocluster was first injected, allowed to accumulate at the tumor site, 
and then probed by injection of a complementary oligonucleotide labeled with 64Cu. Studies in 
mouse tumor models demonstrated the feasibility of in vivo hybridization-based pre-targeting 
using SNA nanomaterials. Furthermore, the basic chemical and biophysical properties of PMO-
modified commercial gold nanoparticles were studied. It was determined that PMO-based SNAs 
display very similar cellular interactions as compared to their DNA analogues, including the 
capability of entering cells in a transfection-free manner and effecting gene knockdown. The 
neutral charge of the SNAs based upon PMO oligonucleotides exhibit more rapid capture 
kinetics of complementary oligonucleotides compared to DNA SNAs, as well as higher melting 
temperatures of hybridized duplexes. Taken together, the chemical versatility of SNAs has led to 
significant advances in understanding their basic properties and improving their viability for in 
vivo translation for biomedical applications. 
Specifically, we uncovered further evidence for the central hypothesis that the unique 
properties of SNAs, specifically active cellular uptake and their sharp thermal denaturation 
curves, are core-independent and rely on the spherical orientation of DNA around a nanoparticle 
core. We also discovered that the cellular interactions of SNAs, mainly active uptake, are 
likewise independent of the charge of the nucleic acid shell.  However, the chemical composition 
of the SNA-bound oligonucleotides strongly influences their in vivo pharmacokinetics, with 
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neutral oligonucleotides conferring much longer blood circulation times compared to negatively-
charged SNAs. We also found that the kinetics and thermodynamics of hybridization of neutral 
SNAs to complementary oligonucleotides are superior to those of negatively-charged SNAs, 
expanding their potential uses not only as biomedical agents but also as in vivo “click chemistry” 
tools capable of the bioorthogonal connection of multiple components under in vivo 
physiological conditions.  Collectively, the studies presented herein demonstrate that the rational 
design of the core material and oligonucleotide shell impart novel properties to SNAs that 
expand their capabilities as therapeutic, diagnostic, and bioorthogonal assembly agents.
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Chapter 1 
Introduction 
 Nucleic acids are best known as nature’s universal storage medium for genetic 
information. The ability of nucleic acids to encode and transmit data arises from Watson-Crick 
base pairing among the five canonical nucleobases found in ribonucleic acid (RNA) and 
deoxyribonucleic acid (DNA) oligonucleotides: the purines adenine (A) and guanine (G), and the 
pyridmidines cytosine (C), thymine (T), and uracil (U) which pair in the fashion A:T, G:C, and 
A:U. (Figure 1.1). Uracil is found exclusively in RNA whereas thymine is found in DNA.  
 
Figure 1.1. Chemical structures of nucleic acids. Left: The five naturally-occurring nucleobases (dotted lines 
represent point of attachment to sugar backbone). Right: Structure of RNA and DNA repeating units (5´3´). 
An additional feature of the specific hydrogen bond-mediated hybridization between nucleic acid 
strands is their capacity to spontaneously form more complex secondary, tertiary and quaternary 
three-dimensional structures.1 Perhaps one of the most important biological examples is transfer 
RNA (tRNA), whose three-dimensional folded structure serves as a macromolecular adapter to 
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translate the data in messenger RNA (mRNA) into the corresponding amino acids during protein 
synthesis in the ribosome.2 Similarly, ribozymes are RNA molecules whose supramolecular, 
highly organized structures enable them to catalyze biochemical reactions inside cells just like 
traditional protein enzymes.3 Thus, in living organisms, nucleic acids not only store information 
but also behave as nanoscale building blocks for precise assembly of functional endogenous 
nanomaterials that are crucial to cellular functioning.  
 
Figure 1.2. Comparison of natural and synthetic assembly of functional 3D nucleic acid nanostructures. 
 Researchers have harnessed the programmable nature of nucleic acid hybridization to 
build synthetic nucleic acid nanomaterials with a wide variety of applications ranging from 
electronic materials to biomedicine.4-10 With the advent of automated solid-phase nucleic acid 
synthesis enabled by advances in phosphoramidite chemistry, chemists can easily generate large 
libraries of custom oligonucleotides with high chemical purity on large scales.11-12 One type of 
artificial nucleic acid nanomaterial, termed “DNA origami,” relies on computer-aided design to 
fold a multicomponent mixture of oligonucleotides into atomically precise and molecularly 
identical three-dimensional structures.13 Such structures can be stimuli-responsive, such as a 
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DNA origami “box” which can carry cargo and open in response to a “key” oligonucleotide 
(Figure 1.2).14 The naturally-occurring nucleic acids, however, possesses limited chemical 
functionality. To design more advanced functional nanomaterials, oligonucleotides can be 
conjugated to small organic molecules,15-23 other biomacromolecules,24-27 polymers,28-32 and 
nanoparticles.33-38 Such hybrid building blocks can then be assembled into higher-order 
structures based on the programmed hybridization of the attached DNA base sequences.39-45  
 
Figure 1.3. Structures of selected synthetic nucleic acid analogues. 
 In addition, synthetic nucleic acids have been developed that possess artificial backbones 
imparting novel chemical attributes. RNA derivatives such as 2´-fluoro-RNA and 2´-OMe-RNA 
exhibit enhanced resistance to base-catalyzed decomposition and nuclease degradation.46-47 
Locked nucleic acids (LNAs) possess a modified bicyclic sugar backbone that restricts their 
conformational flexibility, imparting higher stability to their duplexes with DNA and RNA.48 
Fully neutral nucleic acid analogues have also been synthesized, namely peptide nucleic acids 
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(PNA) and phosphorodiamidate morpholino oligonucleotides (PMO) which possess no net 
charge, and as a consequence form extremely stable duplexes with complementary nucleic acids 
due to the absence of electrostatic repulsion.49-50 Chemists thus have a useful toolbox of 
chemically varied nucleic acids to select from when designing nanomaterials (Figure 1.3). 
 One of the emerging classes of hybrid nucleic acid nanomaterials are spherical nucleic 
acids (SNAs), which are comprised of a nanoparticle core decorated with a dense shell of 
oligonucleotides (Scheme 1.1).51 The first examples utilized thiolated oligonucleotides which 
readily adsorb onto the surface of gold nanoparticles (AuNPs) with a bond dissociation energy of 
40-50 kcal/mol, approaching the strength of a covalent bond (80-90 kcal/mol).52 Gradually 
increasing the NaCl concentration during the adsorption process, called “salt aging,” screens the 
negative charge of the phosphodiester backbone of the DNA molecules as they associate with 
Na+ cations, thereby increasing the density of DNA packing on the surface.53  
 
Scheme 1.1. Functionalization of gold nanoparticles to afford spherical nucleic acids (SNAs). 
Consequently, the behavior of nucleic acid oligonucleotides changes dramatically when they are 
arranged around a spherical core. The binding affinity of SNAs for complementary 
oligonucleotides is higher than linear DNA, resulting in higher melting transition temperatures 
(Tm) and sharper thermal denaturation curves.
54 Initially, AuNP-based SNAs saw great promise 
in biodetection schemes due to their ability to detect target oligonucleotides with high specificity, 
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such as in colorimetric sandwich-type assays that rely on the aggregation-dependent color 
change of gold nanoparticles in the presence of a complementary strand.55-56 Chemically-
amplified biodetection schemes using SNAs have also been described, where target proteins can 
be detected down to attomolar concentrations.57 SNAs have also been employed in the detection 
of toxic heavy metal ions.58-59 More broadly, SNAs can be thought of as “programmable atom 
equivalents” which self-assemble into extended superlattices of a desired symmetry and 
morphology based on the oligonucleotide sequences attached to the nanoparticle core(s).60-62 
This approach enables the synthesis of macroscopic nanoparticle “alloys,” for example by 
alternating gold and platinum nanoparticles in a well-defined repeating binary lattice structure.63 
SNA superlattices have found applications primarily in catalysis, for example in the gold-
mediated oxidation of alcohols to aldehydes,64 as well as the assembly of bioactive enzyme-
cored SNAs into catalytic superlattices.65 
 A major discovery was realized when the interaction of SNAs with cell membranes was 
first probed. In cell culture, linear oligonucleotides exhibit poor cellular uptake due to their 
negative charge, and typically must be transfected with polycations or cationic lipids to deliver 
them across the cell membrane via passive diffusion.66-67 Counterintuitively, SNAs were found to 
undergo active cell uptake and rapidly cross cell membranes without the need for transfection 
agents, despite their higher negative charge density and larger size.68  In fact, higher density of 
the oligonucleotide loading on the surface was found to correlate directly with improved cellular 
uptake.69 These striking findings prompted efforts to discover the mechanism by which SNAs are 
taken up and internalized by cells. The evidence points to an active uptake mechanism triggered 
by recognition of SNAs by class A scavenger receptors (SR-As), which were first discovered in 
macrophages but are now known to be widely expressed on the surface of mammalian cells.70-71 
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SR-As bind naturally-occurring endogenous and exogenous polyanions, triggering their 
endocytosis for eventual destruction in lysosomes.72 SNAs were found to enter cells via SR-A-
mediated endocytosis, with sufficient escape of nucleic acids from the endosome to engage in 
knockdown of target messenger RNA.73 
 Recognition of SNAs by SR-As is believed to be due to the natural affinity of the 
receptor for poly(guanosine) (poly-G) DNA.74 Poly-G spontaneously assembles into three-
dimensional four-stranded helical structures known as G-quadruplexes, which are stabilized by 
Hoogsteen hydrogen bonding and monovalent cations, particularly potassium. It is believed that 
the dense, highly oriented packing geometry of oligonucleotides on the SNA surface mimics the 
3D structure of the G-quadruplex, leading to recognition by SR-As and subsequent endocytosis. 
Supporting this hypothesis, SNAs bearing G-rich oligonucleotides are found to possess superior 
uptake to SNAs functionalized with poly-T, poly-A, or poly-C DNA, though SNAs of virtually 
any sequence exhibit superior uptake to single-stranded oligonucleotides.71 
 The cellular uptake of spherical nucleic acids makes them very attractive agents in the 
rapidly-evolving toolkit of nanomedicine. Studies have demonstrated excellent biocompatibility 
of SNAs, such as minimal immune response as well as enhanced resistance to nucleases which 
degrade nucleic acids by cleaving the phosphate backbone.75-76 Once inside cells, SNAs are 
capable of behaving as gene regulation agents by binding to and preventing the translation of 
messenger RNA into disease-related proteins, independent of SNA core composition.77-78 Other 
types of nucleic acids have been employed as well, such as locked nucleic acids (LNA),  small 
interfering RNAs (siRNA), peptide nucleic acids (PNA) and catalytically active ribozymes.79-82 
SNAs can also act as immunomodulatory agents by binding toll-like receptors (TLRs) expressed 
on the inner surfaces of endosomal compartments.83  
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Scheme 1.2. Displacement of nanoflares by target messenger RNA restores fluorescence of attached fluorophores.84  
 Perhaps the most successful commercial application of SNA technology is the multi-
component nanosystem referred to as the “nano-flare,” which takes advantage of the polyvalent 
binding of dye-labelled “reporter” oligonucleotides to SNAs.85-86 The reporter oligonucleotides, 
when bound to a AuNP SNA, exhibit low fluorescence due to quenching by the gold core. Once 
the SNA binds to target mRNA, the reporter flares are displaced and the fluorescence of the dye 
is restored, allowing quantitative detection of virtually any mRNA sequence in live cells by 
confocal microcopy and flow cytometry (Scheme 1.2). This elegant technology harnesses both 
the active uptake of SNAs along with their high DNA loading and programmable multivalent 
interactions with complementary oligonucleotides.  
 This dissertation is focused on the design, synthesis, and characterization of novel, 
rationally-designed SNAs with expanded capabilities arising from either modified core 
composition or modified oligonucleotide chemistry compared to the classical DNA-modified 
AuNP SNAs. For in vivo translation, SNAs with biocompatible cores are highly desired due to 
concerns about the possible long-term chronic toxicity of gold nanoparticles and their tendency 
to accumulate in the body.87 Our initial efforts focused on the design of SNAs assembled via 
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metal-ligand coordination bonds, an approach not previously explored for constructing SNA 
nanomaterials. The tailorable and reversible nature of metal coordination bonds provides an 
opportunity to create programmable DNA nanomaterials that respond to variable physiological 
conditions such as pH, ionic strength, and/or presence of endogenous competitive ligands. In 
Chapter 2 we report the synthesis and characterization of Fe3+-crosslinked DNA nanoparticles 
assembled from 3,4-hydroxypyridinone (HOPO)-modified DNA duplexes. We demonstrate that 
Fe3+-HOPO coordination bonds are strong enough to serve as chemically orthogonal cross-links 
between DNA strands, and the iron atoms are site-selectively incorporated at the HOPO ligands 
rather than chelated by the phosphate backbone or nucleobases of DNA. However, the DNA- 
Fe3+ nanoparticles synthesized by this approach did not exhibit appreciable cellular uptake, likely 
due to the random orientation of nucleic acids comprising the nanoparticle. Thus, this study 
highlighted the importance of the DNA packing geometry in determining cellular uptake and the 
same coordination chemistry approach was further adapted to generate bioactive SNAs. 
 In Chapter 3 the synthesis of Fe3+-HOPO infinite coordination polymer (ICP) 
nanoparticles and their subsequent functionalization with DNA is described. Drawing from 
previous lessons, the core material was generated first and then modified with a dense shell of 
oligonucleotides. A rigid, ditopic HOPO ligand with an azide functional handle was synthesized 
and mixed with Fe3+ under dilute aqueous conditions, affording amorphous ICP nanoparticles. 
The azide-bearing ICP particles were subsequently mixed with DNA oligonucleotides containing 
a strained cyclooctyne, enabling DNA functionalization via copper-free click chemistry under 
ambient conditions with no special additives. A particular advantage of the Fe3+-HOPO 
coordination bond is its pH sensitivity. At physiological pH, the tris-Fe(HOPO)3 complex is the 
predominant species, but at lower pH values, particularly endosomal pH (6.0-6.5), the tris 
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complex dissociates to the bis complex, providing a mechanism for disassembly of the core 
material and release of oligonucleotides. The cellular uptake of the DNA-ICP nanoparticles was 
probed in several cell lines and found to be comparable to their AuNP-based counterparts. In 
addition, the DNA-ICP particles were capable of knocking down a disease-related protein in 
ovarian cancer cells in a dose-dependent fashion without the need for transfection agents. 
 Chapter 4 describes an alternate approach to pH-sensitive SNA core construction by 
employing self-assembled DNA-polyester block copolymer micelles. Using poly(caprolactone) 
(PCL) as the hydrophobic block and DNA as the hydrophilic block, self-assembled micelles 
presenting an outer layer of DNA were obtained. Furthermore, appending several DNA strands 
to the terminus of the polycaprolactone block in a brush-like fashion increased the DNA surface 
density on the self-assembled micelles. The PCL core material, being a polyester, also exhibits 
slow pH-dependent hydrolysis in acidic conditions, providing a release mechanism for the 
oligonucleotides. These self-assembled micelle SNAs were capable of cell entry and intracellular 
gene knockdown of green fluorescent protein (GFP). Most importantly, comparison of the 
biophysical properties of the linear and DNA-brush type micelles showed that the higher DNA 
loading on the surface of the micelle led to higher cellular uptake as well as sharper melting 
transitions between cross-linked micelles, lending further credence to the hypothesis that DNA 
density on the surface of SNAs is inextricably linked to their biological properties. 
 Transitioning from cell culture to in vivo studies, Chapter 5 describes the development 
and evaluation of SNA nanoclusters (NCs) as potential agents for imaging of breast cancer in a 
mouse model by positron emission tomography (PET) via a tumor pre-targeting strategy. We 
designed the SNA to function as a reverse “nano-flare” which localizes at the tumor site, and 
subsequently captures and releases circulating 64Cu-labeled oligonucleotides for sensitive and 
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specific imaging of the tumor tissue with minimal uptake in off-target organs. In vitro, we found 
that the nanosystem was extremely efficient at capturing and releasing a target oligonucleotide 
under physiologically relevant conditions, with kinetics several orders of magnitude faster than 
state-of-the-art covalent pre-targeting nanosystems based on irreversible click chemistry 
reactions such as the tetrazine-cyclooctene Diels-Alder cycloaddition. A major advantage of our 
design is its programmability based on the particle-bound and tracer oligonucleotide sequence(s) 
as well as its reversibility. 
 Importantly, the core composition of the SNAs was chosen in a way to enable alloying 
with 64Cu for studying their biodistribution, as well as rapid fabrication of libraries of SNAs with 
varying surface compositions due to the ready availability of thiolated ligands and their simple 
surface functionalization chemistry with gold. As opposed to functionalizing pre-fabricated 
nanoparticle cores with oligonucleotides, the pre-targeting SNA nanoclusters were synthesized 
via a one-pot reaction by mixing thiolated oligonucleotides with Au3+ followed by reduction with 
sodium borohydride to afford ultrasmall AuNC SNAs (~2.5 nm diameter). Inclusion of 64CuCl2 
in the reaction mixture afforded 64CuAuNCs which could be tracked in vivo to determine their 
biodistribution. We discovered that the blood circulation time of DNA-functionalized 
64CuAuNCs was extremely short (<1% remaining in blood after 1 hour) due to their high 
negative charge density, leading to protein corona formation and sequestration in the spleen and 
liver, rendering them unsuitable for pre-targeting studies.88  
 Replacement of the DNA oligonucleotide shell with a mixture of PEG and 
phosphorodiamidate morpholino (PMO) oligonucleotides afforded colloidally stable SNA NCs 
which exhibited greatly improved circulation time (20-30x), enabling in vivo pre-targeting 
studies. Our results indicated that the SNA AuNCs accumulate in tumor tissue after injection and 
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are able to capture circulating 64Cu-labeled oligonucleotides, enabling visualization of tumor 
tissue by PET via a novel SNA-based pre-targeting strategy. Ongoing studies are focused on 
improving the tumor-to-muscle ratio of the PET images, comparing the effectiveness of the pre-
targeting strategy compared to a single radionuclide injection, and optimizing the overall binding 
kinetics of the nanosystem. 
 The studies outlined in Chapter 6 were prompted by the discovery that neutral PMO-
modified SNAs exhibit vastly different pharmacokinetics compared to their charged analogs. The 
final chapter focuses on the basic chemical and biophysical properties of PEG/PMO-modified 
gold nanoparticles. Monodisperse, commercially-available citrate-capped 10 nm gold 
nanoparticles were used as the starting material to generate PMO SNAs, primarily to ensure 
batch-to-batch reproducibility and simplify their purification and characterization due to the 
well-studied chemical and optical properties of AuNPs.  The binding kinetics of PMO SNAs 
with complementary oligonucleotides were studied and found to vastly exceed the rates observed 
with DNA SNAs. Similarly, the hybridization thermodynamics of PMO SNAs with DNA SNAs 
showed much stronger association compared to DNA SNA pairs as measured by thermal 
denaturation experiments. The effect of the co-adsorbed PEG length on the colloidal stability and 
cellular interactions of the PMO SNAs was also studied. Shorter PEG lengths imparted poorer 
colloidal stability but facilitated superior cellular uptake, presumably due to exposure of the 
nucleobases to the cell surface and subsequent recognition by scavenger receptors. Longer PEG 
lengths did not affect the ability of PMO SNAs to capture complementary oligonucleotides but 
negatively affected their cell uptake. Having established the optimal blending ratio of PEG and 
PMOs for both colloidal stability and cellular uptake, the ability of PMO SNAs to engage in 
intracellular gene regulation was evaluated. Our preliminary results indicated that PMO SNAs 
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knocked down disease-related mRNA in ovarian cancer cells without the need for transfection 
agents or ancillary targeting moieties, a property not associated with any PMO-modified 
nanocarrier to date. Ongoing studies are underway to compare the knockdown effect of PMO 
SNAs with previously-validated positive controls such as lipid-transfected DNA. 
 Taken together, the studies presented in this dissertation contribute both to the 
fundamental understanding of SNA behavior in vitro and in vivo as well as the practical synthetic 
considerations for their translation into viable therapeutic and diagnostic agents for 
nanomedicine. The following chapter will begin the discussion of SNAs for gene regulation by 
rational bottom-up design of the SNA core material.  
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Chapter 2 
 
Development of a biocompatible Fe3+ coordination strategy for the synthesis of 
nucleic acid complexes, nanoparticles, and metallogels 
[Portions of this work have been published previously as Chad A. Mirkin, Colin M. Calabrese, 
William Morris. Metal-Ligand Coordination Polymer Nanoparticles and Methods for Making. 
US Patent No. 9,677,075. 2017.] 
 
Abstract 
The synthesis of chemically modified nucleic acids capable of forming 3D networks via metal 
coordination bonds is reported. A novel Fe3+-chelating 3-hydroxy-4-pyridinone phosphoramidite 
was obtained in 3 steps and incorporated onto oligonucleotides using an automated DNA 
synthesizer. The resulting modified oligonucleotides were capable of selectively and 
quantitatively binding Fe3+ in aqueous media. Fe(DNA)3 complexes were formed from single-
stranded DNA, whereas nanoparticles and coordination polymer metallogels were formed from 
double-stranded DNA in aqueous buffer, depending on reaction conditions. This work represents 
a general and practical synthetic strategy for the assembly of biocompatible DNA-metal 
structures for medicine and materials, and demonstrates that biocompatible metal-ligand 
coordination bonds are a selective and stable means for joining nucleic acids together to form 
higher-order structures. 
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Introduction 
Living organisms employ DNA for the storage of genetic information, but its use as a synthetic 
building block in the construction of nanomaterials has expanded rapidly in the last thirty years. 
Advances in automated oligonucleotide synthesis have afforded researchers a simple and reliable 
way to form chemically programmable linkages at the nanoscale via Watson-Crick base pairing 
of complementary DNA strands.89 The predictable, reversible, and hence controllable nature of 
DNA hybridization makes it an extremely valuable structural design element in the 
nanotechnologist’s toolbox. 
 DNA can spontaneously fold into nanostructures by the rational design of nucleobase 
sequences that hybridize into prearranged 2D and 3D shapes.90-91 Native DNA, however, 
possesses few modifiable chemical handles for further synthetic elaboration. To design 
functional materials, oligonucleotides can be covalently bound to a vast library of organic small 
molecules,92-99 polymers,100-105 and nanoparticles.106-107 These nucleic acid conjugates can 
subsequently assemble into rationally-designed supramolecular structures based on the sequence-
specific hybridization of the attached DNA oligonucleotides.108-111 Due to the biological origin of 
DNA, many of these hybrid materials find applications in therapeutics and biosensing. DNA 
nanostructures have shown promise as novel drug carriers,112-117 gene regulation agents,68, 118-120 
and disease biomarker detectors.85, 121-123 Furthermore, engineered macroscopic DNA hydrogels 
have attracted interest for use in tissue engineering,124-125 3D cell culture,126 biomolecule 
detection,127 and controlled drug release.128 
Consequently, researchers have increasingly sought additional methods for the generation 
of DNA nanostructures in a biocompatible and bioorthogonal fashion. Common bioconjugate 
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chemistries include thiol-maleimide, alkyne-azide, and tetrazine-alkene “click” reactions, which 
are popular because the functional groups on DNA and other biomolecules do not interfere with 
the progress of the reaction. However, these approaches involve irreversible covalent 
modifications to DNA, creating unnatural linkages with potentially unknown biological activity. 
An alternative approach is to employ metal coordination bonds to assemble oligonucleotides, 
which offers the advantage of tunable, reversible, and dynamic linkages that can be formed in 
situ from individual DNA components.  
The engineering of metal-DNA assemblies is an emerging field of research. Significant 
efforts have been dedicated to the synthesis of nucleic acids containing artificial metallo-base 
pairs.129-133 Coordination-driven assembly of DNA into larger structures has also been 
investigated by several research groups. Discrete structures, such as DNA-Fe2+ triangles,134 
DNA-decorated coordination cages,135 and cyclic dimers136 have been described. Extended 
coordination polymers of DNA are also known,137-142 though some examples involve DNA 
tethered to a pre-fabricated metal complex.143-146 This topic has also been covered in several 
reviews.147-150 However, most literature examples of metal-binding oligonucleotides involve 
lengthy ligand syntheses on small scales and rely on potentially toxic metal/ligand combinations. 
We sought to prepare macroscopic quantities of modified oligonucleotides so their metal-
complexing behavior could be investigated at high concentrations. Furthermore, no DNA-metal 
coordination polymer structures have been investigated for biological applications. Since these 
materials can be comprised almost entirely of DNA, they are inherently biocompatible if paired 
with a nontoxic metal-ligand combination. Employing DNA as a ligand adds a degree of 
complexity due to its hydrophilicity, high molecular weight, and intrinsic affinity for transition 
metal cations. The system described herein overcomes these challenges, opening the door for a 
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new class of metal coordination-based DNA materials and proving that metal coordination bonds 
comprise a novel and viable self-assembly technique for biocompatible nucleic acid 
nanomaterials. 
Experimental Procuedures 
Materials and methods. Diphenylcarbamoyl chloride was purchased from TCI America 
(Portland, OR). All reagents for oligonucleotide synthesis were purchased from Glen Research 
(Sterling, VA) and used according to manufacturer instructions. 10X phosphate-buffered saline 
was purchased from Invitrogen (Carlsbad, CA). Deuterated solvents were purchased from 
Cambridge Isotope Laboratories Inc. (Andover, MA). All other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO) and used without further purification. NMR spectra were 
recorded on a Bruker Avance 400 MHz NMR spectrometer. 1H NMR spectra were referenced 
internally to residual proton signals in the deuterated solvents. 31P{1H} NMR spectra were 
referenced to an external 85% H3PO4 standard. Electrospray ionization (ESI) mass spectra were 
recorded on an Agilent 6120 LC-TOF instrument in positive ionization mode. UV-Vis spectra 
were collected on an Agilent Cary 5000 UV-Vis spectrometer in quartz cuvettes having a path 
length of 1 cm. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) data 
was collected on a Bruker AutoFlex III MALDI-ToF mass spectrometer (Bruker Daltonics, 
Billerica, MA). 
Crystallography. Single crystals of ligand (1) and two stereoisomers of its iron complex Fe(L)3 
were mounted in inert oil (Infineum V8512). All measurements were made on a CCD area 
detector with graphite monochromated Cu Kα radiation. Data were collected using a Bruker 
APEXII detector and processed using APEX2 from Bruker. Structures were solved using direct 
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methods. The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included 
in idealized positions, but not refined. Their positions and isotropic displacement parameters 
were restrained relative to their parent atoms using the HFIX command in SHELXL-97. 
Oligonucleotide synthesis. Oligonucleotide synthesis was carried out on a BioAutomation 
MM48 DNA synthesizer according to the manufacturer standard trityl-on protocol. The ligand 
phosphoramidite (3) was coupled for an extended period of time (5 minutes). All 
oligonucleotides were synthesized in 1 µmol columns and deprotected by treatment with 30% 
aqueous ammonium hydroxide (55ºC, 17h). Ligand-capped oligonucleotides (AL) and (BL) were 
then directly purified by reverse-phase HPLC. Dimethoxtyrityl-capped oligonucleotide (A) was 
purified by reverse-phase HPLC, then detritylated by treatment with 20% AcOH for 1 hr, 
followed by extraction with ethyl acetate (3x) and lyophilization of the aqueous layer. 
HPLC purification. Oligonucleotides were purified on a Varian ProStar HPLC system fitted 
with a DynaMax Microsorb 300-10 C18 column. The mobile phase consisted of 
triethylammonium acetate buffer (pH 7.0) and acetonitrile. Oligonucleotide (A) was purified 
employing a gradient of 0-75% acetontrile over 45 minutes, with the desired product eluting after 
~25 minutes. Fractions were collected, lyophilized, and detritylation was carried out as described 
above. All other oligonucleotides were eluted employing a gradient of 0-35% acetonitrile over 45 
minutes, with the desired products eluting after ~20 minutes. Fractions were collected, pooled, 
and lyophilized to afford the pure, fully-deprotected oligonucleotides. 
Synthesis of 1-(4’-(2-hydroxyethyl)phenyl)-2-methyl-3-hydroxy-4-pyridinone (1). To a 100 
mL round-bottomed flask with a magnetic stirrer was added maltol (3.00 g, 23.8 mmol), 4-
aminophenethyl alcohol (6.53 g, 47.6 mmol), and 25 mL dilute HCl (0.25N). The mixture was 
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heated and refluxed for 24 hr with stirring, resulting in the precipitation of the desired product. 
Upon cooling to room temperature, the reaction mixture was diluted with H2O and vacuum-
filtered to recover the precipitate. The filter cake was washed with H2O followed by methanol 
and allowed to dry on the filter, yielding 5.19 g (21.2 mmol, 90%) of (1) as a tan, 
microcrystalline powder. Crystals suitable for X-ray diffraction analysis were obtained by 
recrystallization from hot DMF. 1H NMR (400 MHz, DMSO-d6) δ 7.48 (d, J = 7.3 Hz, 1H), 7.37 
(d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 6.16 (d, J = 7.3 Hz, 1H), 3.63 (t, J = 6.8 Hz, 2H), 
2.78 (t, J = 6.8 Hz, 2H), 1.93 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 169.98, 145.45, 141.28, 
140.03, 138.38, 130.46, 129.13, 127.03, 111.24, 62.13, 38.80, 13.81. HRMS-EI (m/z): [M+H]+ 
calculated for C14H16NO3 246.1125, found 246.1130. 
Synthesis of FeL3 complex from ligand (1). To a 50 mL round-bottomed flask with a magnetic 
stirrer was added (1) (0.500 g, 2.04 mmol) and 10 mL absolute EtOH. To the resulting 
suspension was added 0.275 g (0.680 mmol) of ferric nitrate nonahydrate, causing the color to 
change to dark purple. Concentrated aqueous ammonium hydroxide was added dropwise, with 
stirring, until the color of the solution turned red. The mixture was heated overnight at 40° C 
with stirring, then poured into ethyl acetate (100 mL), causing precipitation of the complex. The 
solids were filtered, washed with additional ethyl acetate, and dried in vacuo to afford 0.480 g 
(0.61 mmol, 90%) of complex (1a) as a red powder. Crystals suitable for X-ray diffraction 
analysis were grown by slow diffusion of acetonitrile into a methanol solution of the complex. 
HRMS-EI (m/z): [M+H]+ calculated for C42H43FeN3O9 787.2390, found 787.2392. 
Synthesis of diphenylcarbamoyl-protected pyridinone (2). To a 100 mL round-bottomed flask 
with a magnetic stirrer was added (1) (2.00 g, 8.15 mmol) followed by diphenylcarbamoyl 
chloride (2.08 g, 8.97 mmol) and dry pyridine (25 mL). The resulting suspension was stirred 
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under N2 and N,N-diisopropylethylamine (1.56 mL, 8.97 mmol) was added dropwise via syringe. 
After stirring overnight, the reaction mixture was poured into 200 mL dilute HCl (1M) and the 
resulting suspension vacuum-filtered and dried in vacuo to afford a brown solid. The crude 
product thus obtained was suspended in methylene chloride (10 mL) and shaken vigorously. The 
suspension was suction-filtered and washed with additional methylene chloride to afford 2.59 g 
of (2) as an off-white powder (5.88 mmol, 72%). 1H NMR (400 MHz, DMSO-d6) δ 7.63 (d, J = 
7.6 Hz, 1H), 7.50 – 7.15 (m, 14H), 6.22 (d, J = 7.6 Hz, 1H), 4.67 (s, 1H), 3.62 (t, J = 6.6 Hz, 
2H), 2.76 (t, J = 6.8 Hz, 2H), 1.90 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.48, 151.82, 
150.04, 142.94, 141.65, 141.38, 141.12, 140.04, 139.47, 136.54, 130.63, 129.46, 127.47, 127.11, 
126.82, 124.33, 115.82, 62.09, 38.80, 14.68. HRMS-EI (m/z): [M+H]+ calculated for C27H25N2O4 
441.1809, found 441.1811. 
Diphenylcarbamoyl-protected pyridinone phosphoramidite (3). In an oven-dried 50 mL 
Schlenk flask with a magnetic stirrer was suspended (2) (0.500 g, 1.14 mmol) in 5 mL dry, 
degassed methylene chloride. The mixture was stirred under N2 and N,N-diisopropylethylamine 
(0.59 mL, 3.41 mmol) was added via syringe, followed by O-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (0.51 mL, 2.27 mmol). After 1 hr, methanol (0.1 mL) was 
added and the mixture stirred for an additional 30 min. Solvent was removed by rotary 
evaporation and the crude product purified by column chromatography on silica gel, eluting with 
3:1 acetone/CHCl3 containing 1% triethylamine (v/v). Fractions containing the desired product 
(Rf ~ 0.75) were pooled and evaporated to afford 0.53 g phosphoramidite (3) (0.82 mmol, 73%) 
as a colorless foam. Prior to DNA synthesis, (3) was dissolved in anhydrous acetonitrile at a 
concentration of 0.1M and stored overnight at -20ºC over 3Å molecular sieves. 1H NMR (400 
MHz, CD2Cl2) δ 7.61 – 7.03 (m, 14H), 6.38 (d, J = 7.6 Hz, 1H), 3.99 – 3.83 (m, 2H), 3.83 – 3.70 
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(m, 2H), 3.57 (dtd, J = 13.6, 6.8, 3.3 Hz, 2H), 2.99 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 6.3 Hz, 2H), 
2.00 (s, 3H), 1.14 (dd, J = 16.8, 6.8 Hz, 12H). 31P{1H} NMR (162 MHz, CD2Cl2) δ 147.71. 
HRMS-EI (m/z): [M+H]+ calculated for C36H42N4O5P 614.2901, found 641.2897.  
AFM imaging. AFM imaging was carried out according to established protocols for DNA 
origami structures. Particles were drop-cast onto freshly-cleaved mica sheets pre-treated with 10 
mM MgCl2 to promote DNA adhesion to the surface. The droplet was allowed to stand for 10 
minutes, then the surface was washed repeatedly with distilled H2O and dried under a stream of 
N2. Images were collected by tapping mode in air on a Bruker Dimension Icon atomic force 
microscope equipped with a POINTPROBE-PLUS® Silicon-SPM-Sensor. 
MTT assay procedure. SKOV-3 cells were seeded in a 96-well plate at a population of 5x103 
cells per well.  After 24 h, the cells were treated with 0.1 mL of a solution of compound 1 
(diluted from DMSO stock solution into Opti-MEM) and incubated at 37oC for 24 h.  After 
incubation, the compound was removed from the cells and replaced with 0.1 mL of complete 
McCoy’s 5A medium (supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin).  Cell viability was measured by MTT assay at 48 h and 72 h following 
the addition of compound 1 to the cells. Briefly, cells were incubated with 0.1 mL of complete 
McCoy’s 5A medium. 10 µL of MTT solution (5 mg/mL MTT in 1x PBS; Molecular Probes) 
was added into each well of cells and cells were incubated at 37oC for 2 h.  After incubation, 0.1 
mL of SDS-HCl solution (0.1 g/mL SDS in 0.01 M HCl) was added to each well to solubilize the 
formazan product, and cells were further incubated at 37oC overnight.  After overnight 
incubation, the absorbance of the cell lysate was measured at 570 nm using a Synergy H4 
Multimode Microplate Reader (Biotek).  The relative cell viability was calculated compared to 
vehicle-treated cells.  Reported values represent the mean ± SD of three replicates. 
21 
 
Cellular uptake experiments. All microscopy was performed using an SP5 laser scanning 
confocal microscope exciting at 494 nm. C166 mouse endothelial cells were incubated with 1 
mL of cell culture medium containing the particle mixture at a total DNA concentration of 100 
nM or 1 µM. After 24 hr, the cells were treated with Hoechst 33258 nuclear stain (Life 
Technologies), fixed, washed, and then examined by confocal fluorescence microscopy. Cell 
uptake of fluorescein-labeled DNA was observed, and images collected in Z-stack mode verified 
that the dye was present in the cytosol rather than the exterior of the cell membrane. The 
modified DNA was found to be nontoxic to cells under the conditions tested with no visible loss 
of cell viability after 24 hr. Equivalent methods were used for flow cytometry, however cells 
were not treated with Hoechst and instead were trypsinized for 3 minutes in 0.5% trypsin-EDTA 
(GIBCO), resuspended in Opti-MEM, and analyzed using a Guava Easycyte 8HT (Millipore) 
equipped with a 532nm laser.  
Gene regulation experiments. The gene knockdown capability of the supramolecular DNA-
Fe3+ nanoparticles was evaluated with skmel-28 human melanoma cells. Cells were cultured in 
OptiMEM serum-free buffer, in 48-well plates with a density of 15,000 cells/well. Cells were 
then treated with nanoparticles alone or nanoparticles mixed with Lipofectamine® RNAiMAX 
(Invitrogen) according to manufacturer instructions to give a total DNA concentration of 30 nM. 
The cells were incubated for a total of 48 hours, replacing the media after 16 hours. Cells were 
then harvested and the total survivin mRNA expression was quantitated by RT-qPCR. 
Results and Discussion 
Synthesis of hydroxypyridinone-modified oligonucleotides. We first set out to synthesize a 
Fe3+-specific ligand which could be attached to the 5´ hydroxyl group of an oligonucleotide via 
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automated DNA synthesis. The ligand chosen for this purpose is structurally related to 
deferiprone (Ferriprox®), an FDA-approved iron chelator classified as a 3-hydroxy-4-pyridinone 
(3,4-HOPO).151 The coordination chemistry and pharmacological properties of these compounds 
have been thoroughly investigated.152 3,4-HOPOs exhibit pH-dependent iron-chelating behavior 
in aqueous solution (Figure 2.1), forming the FeL2+ complex at low pH (<4), the FeL2
+ complex 
at intermediate pH (3-7), and the FeL3 complex at physiological pH (≥7.4). The pH dependence 
is due to competition between Fe3+ and H+ at the enolic 3-hydroxy position. The stability 
constant of the deferiprone tris-iron complex is large (log β3 ≈ 1036), making it an attractive 
choice for coordination-driven self-assembly (Table 2.1). Recently, 3,4-HOPO ligands have been 
utilized for the formation of PEG metallogels153 as well as crosslinking whole cells in vitro.154 
An N-aryl-3-hydroxy-4-pyridinone phosphoramidite was synthesized in 3 steps from 
inexpensive, commercially available starting materials (Scheme 2.1). Overnight reflux of maltol 
and 4-aminophenethyl alcohol in dilute hydrochloric acid afforded the free ligand (1), which was 
 
Figure 2.1. Speciation of deferiprone-Fe3+ complexes.152 
 
 
Stability constants (deferiprone) 
log K1 15.10   FeL
2+ 
log K2 11.51   FeL2
+ 
log K3 9.27   FeL3 
Table 2.1 Stability constants for Fe3+/deferiprone.155 
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recrystallized from DMF. Selective carbamoylation of the enolic hydroxyl group followed by 
phosphitylation of the primary alcohol furnished the phosphoramidite (3), which was coupled to 
DNA after purification by column chromatography. To confirm the structure of the iron chelate, 
the red tris-Fe3+ complex of the unprotected ligand was obtained by treatment of (1) with 0.33 
equiv. ferric nitrate and ammonium hydroxide in ethanol followed by precipitation from ethyl 
acetate. Crystals suitable for X-ray diffraction analysis were grown by slow diffusion of 
acetonitrile into a methanol solution of the complex. Both Δ-fac and Λ-mer stereoisomers were 
obtained as separate single crystals (Figure 2.2 and A2.3). Additionally, the cytotoxicity of (1) 
was investigated in C166 mouse endothelial cells using the MTT assay. Over 72 hours, 
negligible loss in cell viability was observed at the highest concentration tested (Figure A2.1).  
 
Scheme 2.1. Synthesis of ligand phosphoramidite. Reagents and 
conditions: a) 4-aminophenethyl alcohol, dilute HCl, reflux 24h; b) 
diphenylcarbamoyl chloride, pyridine, Hünig’s base, RT, 16h; c) 2-
cyanoethyl-N,N-diisopropylchlorophosphite, Hünig’s base, RT, 1h 
 
Figure 2.2 Crystal structure of a Δ-fac-
FeL3 complex (mer isomer not shown) 
The ligand phosphoramidite was coupled to the 5´ terminus of a 20-mer oligonucleotide (AL) 
and its complement (BL) sharing a 15-base overlap. Oligonucleotides having a 20-base overlap, 
(SV1L) and (SV2L), were also synthesized. SV1L is an antisense oligonucleotide sequence 
which targets the mRNA encoding the apoptosis inhibitor protein survivin, which is upregulated 
in many cancer cell lines and promotes resistance to chemotherapeutics and more aggressive 
disease progression.156 DNA synthesis was carried out in 1 µmol columns according to the 
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manufacturer standard trityl-on protocol, followed by cleavage and deprotection in concentrated 
NH4OH. The crude oligonucleotides were purified by reverse-phase HPLC and characterized by 
MALDI-TOF. The desired ligand-capped oligonucleotides eluted after the truncated failure 
sequences due to the slight hydrophobicity of the terminal modification. The control 
oligonucleotide (A) lacking any chemical modifications was likewise synthesized and purified 
by trityl-on protocol. 
Oligo Sequence (5´3´) FW (calc’d) [M-H]- (found) 
A A5-ATC-CTT-ATC-AAT-ATT 6067 6071 
AL Ligand-AAAAA-ATC-CTT-ATC-AAT-ATT 6374 6374 
BL Ligand-AAAAA-AAT-ATT-GAT-AAG-GAT 6511 6512 
SV1L Ligand-CCC-AGC-CTT-CCA-GCT-CCT-TG 6272 6276 
SV2L Ligand-CAA-GGA-GCT-GGA-AGG-CTG-GG 6579 6572 
SV1FL Ligand-CCCAGCCTT*CCAGCTCCTTG 6783 6785 
Table 2.2 Oligonucleotides synthesized for this study with the calculated and found masses (MALDI-TOF). T* = 
fluorescein-deoxythymidine (Glen Research) 
Synthesis and characterization of Fe(DNA)3 complexes. To ensure that iron binds to the 
modified DNA in the expected fashion, we first carried out experiments to synthesize the 
Fe(DNA)3 complex as a proof-of-concept. The tris-Fe
3+ complex of (1) exhibits a ligand-to-
metal charge transfer (LMCT) band in the visible spectrum, with an associated λmax of 460 nm 
and ε460 = 5700 L∙mol/cm-1. The bis and mono complexes absorb at longer wavelengths. Thus, 
UV-Vis may be used to monitor the reaction of the ligand-modified DNA with iron, since DNA 
does not absorb in this region.i As expected, a 100 µM solution of (AL) in phosphate-buffered 
saline (pH 7.4) quantitatively formed the Fe(AL)3 complex after standing overnight in the 
presence of stoichiometric Fe(NO3)3∙9H2O, as measured by UV-Vis (Figure 2.3). No LMCT was 
observed when the unmodified oligonucleotide A was treated with Fe3+ under the same 
conditions (Figure 2.4). 
                                                 
i Extinction coefficients of the ligand (ε260 = 3900 L·mol/cm-1) and the FeL3 complex (ε460 = 5700 L·mol/cm-1) were 
determined by the Beer-Lambert relationship from serial dilution the compounds in PBS buffer. 
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Figure 2.3 Top: 100 µM (AL) in 1X PBS. Bottom: 100 
µM (AL) in 1X PBS treated with 33 µM Fe3+. 
 Figure 2.4 Top: 100 µM (A) in 1X PBS. Bottom: 100 
µM (A) in 1X PBS treated with 33 µM Fe3+. 
Titration of 100 µM (AL) with increasing concentrations of Fe(NO3)3∙9H2O showed a clear 3:1 
binding ratio of DNA:Fe3+ (Figure 2.5-6). These results confirm the site-specific complexation of 
iron by the DNA macroligand. Furthermore, kinetics experiments indicated that complexation of 
iron by the free ligand occurred roughly 10 times faster as compared to the DNA macroligand, 
suggesting a diffusion-limited complexation process due to the much larger molecular weight of 
the macroligand (Figure A2.4). 
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Figure 2.5. Titration of a 100 µM solution of (AL) 
with ferric nitrate in 1X PBS buffer. 
Figure 2.6. UV-Vis spectra corresponding to the titration 
curve shown to the left. 
  
Formation of DNA-Fe3+ metallogel at high concentrations. With the iron-binding DNA in 
hand, we set out to determine its ability to self-assemble into higher order structures when 
hybridized into a duplex. (Scheme 2.2)  
 
Scheme 2.2. Synthesis of extened DNA-Fe3+ coordination networks by a two-step assembly process. 
This could be verified macroscopically by forming duplex DNA (AL·BL) in buffer at 
concentrations sufficient for gel formation, followed by addition of Fe3+. A 0.25 mL solution of 
(AL·BL) was prepared in 1X PBS containing 2 mM of the duplex and 1.33 mM Fe3+. Control 
samples contained either no iron, 2 mM of (AL) alone, or 2 mM of (AL·BL) in the presence of 
1.6 mM deferoxamine B (DFO), a hexadentate iron chelator capable of competitively removing 
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iron from the HOPO-Fe3+ complex (Table 2.3). Only in the first case was gelation observed, with 
the control samples remaining as free-flowing liquids (Figure 2.7). These results indicated that 
higher-order DNA coordination polymer structures are indeed formed from the (AL·BL) duplex. 
At least 1 mM of duplex was required for gelation to occur. In addition, we found the gelation of 
the DNA solution could be reversed by heating above the melting temperature (Tm ≈ 40° C) of 
the duplex,ii affording a liquid which solidified upon cooling to room temperature. This opens up 
the possibility of novel thermo-responsive DNA metallogels with tunable melting temperatures 
depending on the DNA base sequence. 
Figure 2.7. Gelation of duplex DNA in the presence of Fe3+ at 
room temperature (25° C) 
Sample Reagent Metal Gel 
1 (AL·BL) None No 
2 (AL) Fe3+ No 
3 
(AL·BL)  
+ DFO 
Fe3+ No 
4 (AL·BL) Fe3+ Yes 
Table 2.3. Screening of conditions required for 
gelation of DNA/ Fe3+ solutions 
A metallogel was also synthesized from the (SV1·SV2) duplex, which possesses a higher 
melting temperature (Tm ≈ 70° C) due to its greater number of base pairs and higher GC content. 
A 2 mM solution of (SV1·SV2) in 1X PBS, containing 
1.33 mM Fe3+, was prepared. At 55° C, the 
(AL·BL)/Fe3+ solution flowed freely as a liquid 
whereas the (SV1·SV2)/Fe3+ solution remained as a 
gel. At 75° C, both solutions melted completely. 
                                                 
ii Oligonucleotide melting temperatures were calculated using OligoAnalyzer software from Integrated DNA 
Technologies (Skokie, IL) 
T (ºC) (AL·BL) (SV1L·SV2L) 
25 gel gel 
55 liquid gel 
75 liquid liquid 
Table 2.4. Temperature-dependent gelation of 
DNA/Fe3+ solutions 
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(Figure 2.8) Furthermore, decreasing the pH of the medium is also expected to decrease the 
viscosity of the gel as the metal complexes dissociate to bis and mono species due to competition 
with H+. This effect has been demonstrated with similar catechol-based metallogels formed by 
complexation of ferric iron.157  
 
Figure 2.8. Temperature-dependent gelation of DNA metallogels heated to 55° C (left) and 75° C (right) 
Formation of DNA-Fe3+ nanoparticles at lower concentrations. At concentrations lower than 
those required for gelation, the (SV1L·SV2L) duplex forms DNA nanoparticles in the presence 
of Fe3+. The following procedure was developed for their synthesis. First, a 1 mL stock solution 
was prepared containing 50 µM (SV1L) and 50 µM (SV2L) in PBS, affording the 
(SV1L·SV2L) duplex at a total DNA concentration of 100 µM. Stoichiometric Fe(NO3)3∙9H2O 
(33 µM) was then added and the mixture allowed to stand overnight at room temperature. The 
progress of the reaction was monitored by UV-Vis, in combination with dynamic laser light 
scattering (DLS) to verify the formation of higher-order structures. Prior to iron addition, DLS 
shows a single monodisperse peak (dH ≈ 6 nm) corresponding to the (SV1L∙SV2L) duplex. After 
iron addition, self-aggregation occurs, giving rise to a broad size distribution typically ranging 
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from 10-200 nm or higher. Large structures (>10 nm) are not seen when (SV1L) alone is treated 
with Fe3+ (Figure A2.2). 
Precise control of particle size was an initial roadblock. Precipitation of the DNA-iron mixture 
into water-miscible organic solvents (ethanol, THF) yielded very large aggregates (250-1000 
nm) which were unstable upon re-immersion in buffer, potentially due to the denaturing effect of 
the organic solvent. We also investigated altering the ratio of complementary strands, with the 
excess single-stranded DNA acting as a chain stopper, but this approach gave inadequate size 
control. In the end, gel-filtration chromatography (GFC) provided the best results. In a typical 
synthesis, the crude reaction mixture was passed through a short column (3-5 mL) of Sepharose 
CL-4B, a crosslinked agarose matrix. In addition, this technique removes unmetallated DNA and 
residual synthesis impurities. 
Figure 2.9. (Left) DLS size distribution of particles purified by GFC. 
Figure 2.10. (Right) AFM image of particles deposited on mica.  
 
Fractions were collected and analyzed by DLS, showing separation of particles by size. With this 
technique, fractions containing particles with a mean diameter of 20-40 nm were obtained, 
comparable in size to existing DNA-nanoparticle conjugates. To corroborate the DLS data, 
fractions were also imaged by atomic force microscopy (AFM), revealing spherical 
nanostructures with a size distribution analogous to that found with DLS (Figure 2.9-10).  
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Synthesis of fluorescent DNA-Fe3+ nanoparticles and cellular uptake. DNA and RNA 
nanoparticles have attracted interest due to their potential uses as gene regulatory agents. Having 
obtained particles of the ideal size for cell entry,158-159 we then examined the level of cell uptake 
compared to single-stranded DNA. To visualize internalization, it was necessary to incorporate a 
fluorescent dye into the DNA. The sequence of SV1 was modified with a commercially-available 
fluorescein-bearing thymidine base (T*), affording SV1FL (Table 2.1). SV1FL was then 
duplexed with SV2 and particles were synthesized according to the protocol outlined previously. 
Particle size distributions were determined by AFM, due to interference of the fluorescent dye 
with DLS size measurements. Sedimentation of heavier fractions occurred upon prolonged 
standing, likely due to the hydrophobic nature of the fluorescein modification (Figure 2.11). This 
observation suggests that the colloidal stability of the particles is altered by the conjugation of 
hydrophobic compounds. C166 mouse endothelial cells were then incubated with three different 
size fractions of fluorescein-labeled particles at a total DNA concentration of either 1 µM or 100 
nM in Opti-MEM medium, with iron-free SV1FL serving as the control. The treatment period 
was 16 hours. 
 
 
Figure 2.11. (Left) Synthesis of dye-labelled particles and 
fractions obtained from GFC showing settling of heavy 
particles. Figure 2.12. (Right) Uptake in C166 cells 
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Confocal microscopy and flow cytometry indicated that the DNA-iron particles entered cells at 
roughly the same rate compared to the iron-free control DNA (Figure A2.5). This result 
demonstrates that, with the current design, the DNA-iron coordination polymer particles do not 
behave analogously to classical SNAs and are not actively transported into the cell. However, 
preliminary RT-qPCR experiments indicated that the particles are indeed capable of survivin 
mRNA knockdown if transfected into the cell using a Lipofectamine®, a commercially-available 
transfection agent (Figure 2.13). This result suggests that, at the very minimum, the individual 
components comprising the DNA-Fe3+ particles are capable of gene regulation once inside the 
cell, with the barrier to transfection-free gene regulation being the lack of active transport. 
 
Figure 2.13. Survivin expression in skmel-28 melanoma cells, 30 nM total DNA, quantitated by RT-qPCR. 
 
Conclusions 
We have synthesized and characterized complexes and coordination polymers of ligand-modified 
DNA with iron. The 3-hydroxy-4-pyridinone ligand has proven effective for assembling iron(III) 
complexes of single-stranded DNA and coordination polymers of duplex DNA under 
physiological pH and salt concentration. Importantly, we carried out the synthesis of the 
modified DNA on large scales (>20 µmol) following simple, user-friendly synthetic methods. At 
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high concentrations, metallogels are obtained whose properties can be tuned based on the DNA 
base sequence. At lower concentrations, we obtained coordination polymer nanoparticles 
possessing a spherical morphology, consistent with literature reports of metal-free DNA 
assemblies constructed from similar building blocks.160-163 The cellular uptake of DNA-Fe3+ 
nanoparticles was examined but their behavior was not analogous to other spherical nucleic acids 
(SNAs) previously described, most likely to due to random orientation of the DNA strands 
comprising the particle as well as the low density of surface-exposed single-stranded DNA. 
Entry of DNA nanostructures into cells is highly dependent on the geometric conformation of the 
oligonucleotides.164-165 Furthermore, as evidenced by the concentration-dependent degree of 
polymerization of the DNA-Fe3+ polymer, dilution of the nanoparticles for cell culture 
experiments can potentially cause the particles to fragment into smaller oligomers. Nevertheless, 
we believe this work opens the door to novel DNA-based materials for biological applications. 
The DNA metallogels described herein are easy to synthesize, and may be a promising 
biocompatible medium for cell transplant therapy and tissue engineering. The DNA 
nanoparticles described herein also serve as a proof-of-concept study demonstrating that iron 
coordination bonds are an effective means to assemble DNA nanostructures. In Chapter 3 the 
same chemistry is applied to generate SNAs capable of spontaneous cellular uptake, applying the 
lessons learned from the studies in this chapter.  
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Chapter 3 
 
Biocompatible infinite-coordination-polymer nanoparticle-nucleic-acid 
conjugates for antisense gene regulation 
[Portions of this work have been published previously as Chad A. Mirkin, Colin M. Calabrese, 
William E. Briley, Timothy J. Merkel. Biocompatible infinite coordination polymer 
nanoparticle-nucleic acid conjugates for antisense gene regulation. US Patent No. 9,617,451. 
2017; and Calabrese, C. M.; Merkel, T. J.; Briley, W. E.; Randeria, P. S.; Narayan, S. P.; Rouge, 
J. L.; Walker, D. A.; Scott, A. W.; Mirkin, C. A. Biocompatible Infinite Coordination Polymer 
Nanoparticle-Nucleic Acid Conjugates For Antisense Gene Regulation. Angew. Chem. Int. Ed. 
2015, 54, 476-480.] 
Abstract 
Herein, we report the synthesis of DNA-functionalized infinite-coordination-polymer (ICP) 
nanoparticles as biocompatible gene-regulation agents. ICP nanoparticles were synthesized from 
ferric nitrate and a ditopic 3-hydroxy-4-pyridinone (HOPO) ligand bearing a pendant azide. 
Addition of Fe(III) to a solution of the ligand produced nanoparticles, which were colloidally 
unstable in the presence of salts. Conjugation of DNA to the Fe(III)-HOPO ICP particles by 
copper-free click chemistry afforded colloidally stable nucleic-acid nanoconstructs. The DNA-
ICP particles, when cross-linked through sequence-specific hybridization, exhibited narrow, 
highly cooperative melting transitions consistent with dense DNA surface loading. The ability of 
the DNA-ICP particles to enter cells and alter protein expression was also evaluated. Our results 
indicate that these novel particles carry nucleic acids into mammalian cells without the need for 
transfection agents and are capable of efficient gene knockdown. 
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Introduction 
Spherical nucleic acids (SNAs) have emerged as an interesting new class of materials that have 
shown promise in programmable materials synthesis,41, 166 bio-detection,121, 167-168  and 
intracellular gene regulation.68, 169 Such structures are often comprised of a nanoparticle core 
functionalized with a dense layer of oligonucleotides, although hollow, core-free versions have 
been developed.78, 170 The earliest example of SNAs involved gold nanoparticles modified with a 
dense layer of alkylthiol-functionalized DNA,33 but iron oxide,171-172 silver,173-175  semiconductor 
quantum dot,176-177 and organic cores have been explored as well.29, 178-179 Notably, the chemical 
and biological properties of SNAs are markedly different from their linear counterparts.  SNAs 
exhibit cooperative binding and sharp thermal denaturation profiles, enter cells without the need 
for cationic transfection agents, and have the ability to bind to receptors in a polyvalent 
fashion.51 Consequently, they are powerful new entities for manipulating cellular processes 
through gene regulation,80, 180 drug delivery,113, 181 and immunomodulatory pathways.182 The 
active uptake of SNAs occurs via caveolin-mediated endocytosis, triggered by their binding to 
class A scavenger receptors (SR-As).70, 183 Although SNAs made from gold have shown 
commercial promise as medical diagnostic and research tools and have shown no acute toxicity 
in vivo,79 there are concerns about the potential long term toxicity of gold nanoparticles and their 
metabolic fate.184 Consequently, new forms of SNAs with cores made of biocompatible materials 
are highly sought after.  Herein, we report a strategy that employs the use of infinite coordination 
polymer (ICP) nanoparticles made from ferric ions and a rigid ditopic chelating ligand to 
synthesize novel SNA nanoparticle conjugates.  These DNA-ICPs are designed from chemical 
building blocks approved by the FDA for other pharmaceutical uses, exhibit cooperative binding, 
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and can readily cross mammalian cell membranes and inhibit protein expression in a targeted 
fashion. 
 ICP nanoparticles consist of amorphous networks of organic ligands bridged by metal 
nodes.185-186  They are promising materials for SNA construction as the ligand/metal combination 
that defines the ICP structure can be rationally designed to optimize the toxicological and 
pharmacokinetic profiles of the DNA-ICP conjugate. One major limitation of many ICPs 
designed for medicinal applications is their instability in aqueous buffers. Some researchers have 
circumvented this limitation by encapsulating the particle core in silica187-188 or a shell of 
lipids.189 In contrast, we have sought to design ICP particles that could be synthesized, purified, 
and stored indefinitely under aqueous conditions and without specialized equipment or reagents. 
Furthermore, the use of relatively nontoxic metal ions is a crucial requirement for biological 
applications. These goals were accomplished by synthesizing ICP nanoparticles from strongly 
chelating 3-hydroxy-4-pyridinone (3,4-HOPO) ligands in combination with Fe3+, the most 
abundant transition metal in the body. The coordination chemistry and pharmacology of the 3,4-
HOPOs have been thoroughly investigated,152 and the 1,2-dimethyl derivative (deferiprone) is 
FDA-approved for the treatment of iron overload in humans.151 Furthermore, the Fe(HOPO)3 
complex is known to dissociate below physiological pH.190 This provides a potential release 
mechanism for delivering DNA into the cytosol following cell entry, a novel property not 
typically associated with SNAs prepared to date. 
 It is known that ditopic HOPO and catechol ligands, being isoelectronic, can form 
insoluble coordination polymers with oxophilic metal cations such as Fe3+, Cr3+, Ga3+ and others, 
however, such polymers are poorly understood and have not been well-studied in the 
literature.191-193 These ligands have mainly been studied for metal sequestration and chelation as 
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opposed to materials synthesis.  Therefore, we saw an opportunity to construct a novel 
biocompatible nanoparticle scaffold for modification with DNA. 
Experimental Procuedures 
Materials and methods. 3,5-Diaminobenzoic acid was purchased from TCI America (Portland, 
OR). 4-Azido-butan-1-amine was purchased from Synthonix, Inc. (Wake Forest, NC). All 
reagents for oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) and 
used according to manufacturer instructions. Buffer solutions were purchased from Invitrogen 
(Carlsbad, CA). Deuterated solvents were purchased from Cambridge Isotope Laboratories Inc. 
(Andover, MA). Gold nanoparticles were purchased from Ted Pella (Redding, CA). Amicon® 
Ultra centrifugal filter units were purchased from EMD Millipore (Billerica, MA). All other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used without further 
purification. 1H NMR spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer. 
1H NMR spectra were referenced internally to residual proton signals in the deuterated solvents. 
13C NMR spectra for compounds 3 and 4 were collected on an Agilent DD2 500 MHz NMR 
spectrometer operating at an internal temperature of 100° C. Electrospray ionization (ESI) mass 
spectra were recorded on an Agilent 6120 LC-TOF instrument in positive ionization mode. UV-
Vis spectra and thermal denaturation curves were collected on an Agilent Cary 5000 UV-Vis 
spectrometer in quartz cuvettes having a path length of 1 cm. Matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-ToF) data was collected on a Bruker AutoFlex III 
MALDI-ToF mass spectrometer employing 2,5-dihydroxyacetophenone (DHAP) as the matrix 
material. FTIR spectra were collected on a Perkin-Elmer Spectrum 100 FTIR spectrometer. AFM 
images were collected on a Bruker Dimension Icon atomic force microscope in non-contact 
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mode equipped with a POINTPROBE-PLUS® Silicon-SPM-Sensor. TEM images were 
collected on a Hitachi H8100 transmission electron microscope operating at an accelerating 
voltage of 200kV. TEM and EDX data were collected on a Hitachi HD2300 STEM equipped 
with two Thermo Scientific X-ray EDX detectors. Dynamic light scattering (DLS) and zeta 
potential measurements were collected on a Zetasizer Nano ZS (Malvern Instruments Ltd). ICP-
MS data were collected on a Thermo X-series II ICP-MS. Elemental analysis was conducted off-
site by Intertek Pharmaceutical Services (Whitehouse, NJ).  
Synthesis of diaminobenzoic acid mono-hydroxypyridinone (2) To a 100 mL round-bottomed 
flask with a magnetic stirrer was added 3,5-diaminobenzoic acid (5.00 g, 32.86 mmol), maltol 
(8.70 g, 69.00 mmol) and 30 mL of acidic n-propanol (49:1 propanol/12M HCl). The reaction 
vessel was fitted with a water-cooled condenser and the mixture heated to reflux for 16 h. The 
resulting suspension was vacuum-filtered while hot and the solids washed with acetone (200 mL) 
to yield 4.84 g of (1) as a tan powder (18.60 mmol, 57%). Propanol may be substituted with 5:1 
EtOH/H2O affording similar yields. 
1H NMR (400 MHz, DMSO-d6) δ 7.52 (d, J = 7.4 Hz, 1H), 
7.28 – 7.26 (m, 1H), 6.92 (t, J = 1.7 Hz, 1H), 6.67 (t, J = 2.1 Hz, 1H), 6.16 (d, J = 7.3 Hz, 1H), 
5.77 (s, 2H), 1.96 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 169.96, 167.24, 150.62, 145.45, 
142.79, 138.07, 133.21, 129.02, 115.64, 115.35, 114.34, 111.30, 13.61. HRMS-ESI (m/z): 
[M+H]+ calculated for C13H13N2O4 261.0870, found 261.0875. 
Synthesis of diaminobenzoic acid bis-hydroxypyridinone (3) To a 100 mL round-bottomed 
flask with a magnetic stirrer was added (2) (5.90 g, 22.67 mmol), maltol (3.57 g, 28.34 mmol), 
and 30 mL of acidic 2-ethoxyethanol (49:1 ethoxyethanol/12M HCl). The reaction vessel was 
fitted with a water-cooled condenser and the mixture heated to reflux for 64 h. The resulting 
suspension was vacuum-filtered while hot and the solids washed with water (50 mL), followed 
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by acetone (50 mL), to afford the crude product as a fine brown solid. The bis product was 
selectively isolated by precipitation from boiling pyridine (100 mL), filtration, and further 
precipitation from hot dimethylformamide (100 mL) and drying in vacuo to afford 0.98 g of (3) 
(2.66 mmol, 12%) as a grey powder sparingly soluble in methanol, soluble in hot DMSO and 
DMF. 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, J = 2.0 Hz, 2H), 8.00 (t, J = 2.0 Hz, 1H), 7.64 
(d, J = 7.4 Hz, 2H), 6.22 (d, J = 7.4 Hz, 2H), 2.02 (s, 6H). 13C NMR (126 MHz, DMSO-d6) δ 
170.43, 165.59, 145.52, 142.92, 138.79, 138.26, 134.82, 130.74, 130.47, 128.55, 111.45, 111.28, 
13.79, 13.60. HRMS-ESI (m/z): [M+H]+ calculated for C19H17N2O6 369.1081, found 369.1084.  
Synthesis of diiaminobenzoic acid bis-HP azide (4) To a 50 mL round-bottomed flask with a 
magnetic stirrer was added (3) (0.400 g, 1.09 mmol) fully dissolved in anhydrous DMSO (30 
mL). HATU (0.414 g, 1.09 mmol) and diisopropylethylamine (0.48 mL, 2.73 mmol) were 
subsequently added and the reaction vessel was capped with a rubber septum. After 5 minutes, 4-
azidobutan-1-amine (0.187 g, 1.64 mmol) was injected via syringe and the mixture allowed to 
stir for 4 h under N2. The organic phase was diluted with 1 volume of water and allowed to stand 
for 1 h. The resulting grey precipitate was collected by vacuum filtration and washed extensively 
with water (150 mL), followed by acetonitrile (100 mL), and allowed to dry on the filter. The 
obtained azide monomer (4) was used without further purification. (0.283 g, 0.61 mmol, 56%). 
1H NMR (400 MHz, DMSO-d6) δ 8.72 (t, J = 5.7 Hz, 1H), 8.00 (d, J = 2.0 Hz, 2H), 7.91 (t, J = 
1.9 Hz, 1H), 7.63 (d, J = 7.3 Hz, 2H), 6.23 (d, J = 7.4 Hz, 2H), 3.41 – 3.19 (m, 4H), 2.03 (s, 6H), 
1.60 – 1.53 (m, 4H). 13C NMR (126 MHz, DMSO-d6) δ 170.41, 164.21, 145.55, 142.74, 138.81, 
138.27, 137.87, 128.68, 128.54, 126.92, 126.78, 111.39, 111.23, 51.14, 39.56, 26.72, 26.37, 
13.81, 13.62. HRMS-ESI (m/z): [M+H]+ calculated for C23H25N6O5 465.1881, found 465.1881. 
FTIR (KBr): νmax 2093 cm-1 (N=N=N stretch) 
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Synthesis of DABA-bis-HP-N3 ICP particles (ICP-N3 NPs) In a typical experiment, an 
aqueous stock solution of DABA-bis-HP-N3 was prepared consisting of 2.28 mM ligand and 
24.5 mM NaOH. The ligand is freely soluble in water as its disodium salt. A stock solution of 
Fe(NO3)3·9H2O was prepared consisting of 10.80 mM Fe
3+ and 4 mM HCl (as stabilizer). To a 
glass vial was added 877 µL ligand stock solution, followed by 1 mL Milli-Q H2O, followed by 
123 µL Fe(III) stock and the resulting orange-red mixture (2 mL) shaken for 10 minutes. The as-
synthesized particles have a mean diameter ranging from 10-20 nm (DLS). Particles were 
purified by filtration through an Amicon Ultra 15 mL centrifugal filter with a nominal molecular 
weight cutoff (MWCO) of 100 kDa, washing with 3 x 3 mL portions of Milli-Q H2O, spinning at 
5000 rcf for 10 minutes each. The particles were resuspended in 2 mL of H2O to give an 
approximate azide concentration of 1 mM. The particle solution was lyophilized and the 
resulting dark red powder characterized by FTIR (KBr), showing the characteristic azide stretch 
at 2093 cm-1 is retained after the nanoparticle synthesis. 
Characterization of ICP-N3 nanoparticles. To determine the stoichiometry of metal-ligand 
binding, we conducted a titration wherein samples each containing a fixed concentration of 200 
µM DABA-bis-HP-N3 (4) in 1 mL H2O were prepared with increasing amounts of 
Fe(NO3)3·9H2O ranging from 0 to 220 µM. The absorbance at 460 nm was measured for each 
sample. The LMCT band at 460 nm is characteristic of the tris-HOPO-Fe3+ coordination 
complex._ENREF_117 The equivalence point was reached at 133 µM (0.66 equiv.), consistent 
with Fe2L3 stoichiometry (Figure A3.2). Further increase in absorbance is due to the presence of 
uncoordinated iron precursor salt. Additionally, we conducted elemental analysis on a 
lyophilized sample of the particles to assess their composition. Calc'd for C69H66Fe2N18O15: C 
55.28%, H 4.44%, N 16.82%. Found C 49.10%, H 4.18%; N 14.18%. The lower observed 
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organic content may be explained by the porous nature of the ICP particles and their ability to 
entrap polar solvent molecules, e.g. H2O. Lastly, we studied the bare ICPs by energy dispersive 
X-ray spectroscopy (Hitachi H2300-A STEM) (Figure A3.3). 
ICP-MS and UV-Vis were used in tandem to determine the extinction coefficient ε460 of the 
particles in Milli-Q H2O. Briefly, five samples of ICP-N3 particles in H2O were prepared at 
varying dilutions and the absorbance at 460 nm was measured by UV-Vis. Subsequently, the iron 
concentration of each sample was determined by ICP-MS. Each sample was prepared in a matrix 
consisting of 3% HNO3, 5 ppb indium (internal standard), and deionized water. The iron 
concentration was plotted vs. A460, and the data was fit by a simple linear regression model. The 
slope of the line corresponds to ε460 ≈ 2870 L·mol-1 cm-1 arising from the LMCT of the ICP-N3 
particles, allowing for spectroscopic determination of iron concentration. 
The weight of the particles produced by the above procedure is expected to be in the range of 10-
1000 kDa, since a small portion of the as-synthesized particles pass through a 100 kDa cutoff 
filter. Supporting this observation, the predicted degree of polymerization for ditopic 3,4-HOPOs 
is approximately 1000 repeat units under the reaction conditions given above, when estimated 
from literature stability constants of the 3,4-HOPO-Fe(III) complex.155  
Oligonucleotide synthesis. All DNA synthesis was carried out on a BioAutomation MM48 
DNA synthesizer, according to the standard manufacturer trityl-on protocol with an additional 5 
minute coupling time for non-nucleosidic phosphoramidites. Ac-dC and dmf-dG 
phosphoramidites were used to enable room-temperature deprotection of the nucleobases. 
Oligonucleotides were synthesized on 1 µmol scale and deprotected in concentrated NH4OH 
(30%) for 17 hours at room temperature, except for poly(CCT)-Cy5-containing oligonucleotides, 
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which were deprotected for 2 hours at room temperature. The resulting crude oligonucleotides 
were purified on a Varian Prostar HPLC fitted with a DynaMax Microsorb C18 Column, 
employing a gradient of 0-75% acetonitrile in triethylammonium acetate buffer (pH 7.0) over 45 
minutes. The optical absorbance of the eluent was monitored at 254/310 nm for DBCO-
containing oligonucleotides, 254/649 nm for Cy5-containing oligonucleotides, and 254/280 nm 
for all other oligonucleotides. DBCO-terminated oligonucleotides were lyophilized, resuspended 
in H2O, and conjugated immediately to ICP-N3 nanoparticles. Disulfide-terminated 
oligonucleotides were lyophilized, reduced to the free thiol and conjugated to AuNPs as 
described in previous reports.53  
Synthesis of AuNP-DNA conjugates. AuNP-SNAs synthesized in this study were prepared 
according to established protocols.3 For AuNP-SNAs employed in cell uptake experiments, the 
number of oligonucleotides/AuNP were determined by fluorescence measurements. 
Oligonucleotide loading on AuNP-SNAs was quantified using a 5nM solution of Cy5 labeled 
AuNP-SNAs. The Au core was dissolved using 100mM KCN diluted in deionized water. The 
mixture was then incubated at room temperature for 20 minutes, and the resultant fluorescence 
measured against a standard curve. The standard curve consisted of the equivalent 
oligonucleotide sequence at a range of concentrations, dissolved in water, treated with KCN and 
incubated in the same manner as the SNAs. All fluorescence measurements were made using a 
Synergy H4 fluorescent plate reader (BioTek). Loading on the CCT-Cy5-AuNPs used as a 
positive control for cell uptake experiments was 113 strands/particle (CCT-Cy5-AuNP). 
Loading on the Cy5-T20-AuNPs was 157 strands/particle (Cy5-T20-AuNP). Similar values were 
assumed for the non-fluorescent AuNP-SNA (A-AuNP). 
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Synthesis of DNA-ICP conjugates. In a typical procedure, a solution was prepared containing 
100 µM of the desired cyclooctyne-DNA, 0.5M NaCl, and ICP-N3 particles (500 µM in azide) in 
2 mL Milli-Q H2O. The resulting clear, orange solution was shaken for 16 h at 25°C. The 
reaction mixture was purified by ultrafiltration through an Amicon® Ultra 15 mL centrifugal 
filter (100 kDa MWCO), washing with 4 x 3 mL portions of 0.1M Tris buffer (pH 8.0), spinning 
at 5000 rcf for 10 minutes. The particles were resuspended in 1 mL of 0.1M Tris (pH 8.0). DNA-
ICP particles remain colloidally stable at high salt concentrations (up to 1M NaCl), in contrast to 
the bare ICP-N3 particles, which sediment within minutes in 1M NaCl. This observation 
indicates a stabilizing DNA surface layer has been successfully conjugated to the particle. 
Characterization of DNA-ICP conjugates. The size, charge, and DNA-loading of DNA-ICP 
particles were analyzed by DLS, zeta potential, and UV-Vis. The DNA concentration of a 
particle solution was determined by UV-Vis using the ratio (A260/A460). Bare particles in Milli-Q 
H2O possess A260/A460 ≈ 5.4. DNA-decorated particles were synthesized having a ratio A260/A460 
varying from 10.9 to 15.5, indicating the presence of DNA attached to the particles. Extensive 
washing was conducted to ensure no free DNA remained in solution. Loading of Cy5-containing 
DNA was significantly lower, potentially due to the steric bulk of the dye label. Finally, the zeta 
potential of the bare and DNA-loaded ICPs was compared, with all samples prepared at identical 
dilution in 10 mM Tris buffer (pH 8.0) and 0.1M NaCl. (Table A3.1). 
Thermal denaturation studies. DNA-ICP particles bearing complementary sequences with a 17 
base-pair overlap (A-ICP and B-ICP) were mixed at varying salt concentrations in 0.1M Tris 
buffer (pH 8.0) and heated from 20°C to 80°C at a rate of 0.25°C per minute. At room 
temperature, insoluble aggregates formed within 30-60 minutes of mixing the complementary 
DNA-ICPs. Upon heating, a sharp melting transition was observed, consistent with high DNA 
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surface loading of the ICP particles. The same behavior was not observed for a pair of DNA-
ICPs with mismatched sequences (B-ICP and NonTarget-ICP). The free DNA duplex has a 
melting temperature of 54°C in 0.3M NaCl, compared to >60°C for the DNA-ICPs, depending 
on the NaCl concentration. The same experiment was repeated using a gold nanoparticle/DNA-
ICP pair (A-AuNP and B-ICP).  
MTT toxicity assay of ICP ligands. To ensure the parent ligand comprising the particle core did 
not exhibit cellular toxicity, an MTT assay was performed. SKOV-3 cells were seeded in a 96-
well plate at a population of 5x103 cells per well.  After 24 h, the cells were treated with 0.1 mL 
of a solution of compound 3 or 4 (diluted from DMSO stock solution into Opti-MEM) and 
incubated at 37oC for 24 h.  After incubation, the compound was removed from the cells and 
replaced with 0.1 mL of complete McCoy’s 5A medium (supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin).  Cell viability was measured by MTT assay at 48 h and 
72 h following the addition of compound 3 or 4 to the cells. 
Briefly, cells were incubated with 0.1 mL of complete McCoy’s 5A medium. 10 µL of MTT 
solution (5 mg/mL MTT in 1x PBS; Molecular Probes) was added into each well of cells and 
cells were incubated at 37oC for 2 h.  After incubation, 0.1 mL of SDS-HCl solution (0.1 g/mL 
SDS in 0.01 M HCl) was added to each well to solubilize the formazan product, and cells were 
further incubated at 37oC overnight.  After overnight incubation, the absorbance of the cell lysate 
was measured at 570 nm using a Synergy H4 Multimode Microplate Reader (Biotek).  The 
relative cell viability was calculated compared to vehicle-treated cells.  Reported values 
represent the mean ± SD of three replicates. 
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Cell culture and uptake studies. For visualizing cell uptake by confocal microscopy, ovarian 
cancer (SKOV-3), cervical cancer (HeLa) and C166 mouse endothelial cells were cultured in 
DMEM supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals) and 1% 
Penicillin/streptomycin (Life Technologies).  
All microscopy was performed using an SP5 laser scanning confocal microscope. Cellular 
images were obtained by culturing HeLa cells in supplemented Dulbecco’s Modified Eagle 
Medium (DMEM, Life Technologies) at approximately 30% confluency in Nunc Lab-Tek II 
borosilicate-bottom chamber slides (Thermo Scientific). Cells were allowed to attach for 24 
hours, after which they were washed once with PBS and resuspended in OptiMEM. Cells were 
then treated with either linear DNA, AuNP-SNAs, or DNA-ICPs at a concentration of 100 nM 
(DNA basis). After 24 hours the cells were washed once with OptiMEM, and resuspended in 
DMEM containing Hoechst 33258 (Life Technologies). All images are of live cells. Equivalent 
methods were used for flow cytometry, however cells were not treated with Hoechst and instead 
were trypsinized for 3 minutes in 05% trypsin-EDTA (GIBCO), resuspended in Opti-MEM, and 
analyzed using a Guava Easycyte 8HT (Millipore) equipped with a 633nm laser.  
For naked-eye visualization of cell uptake, MCF-7 and SKOV-3 cells were plated in 6 well 
plates (~100,000 cells/well). After incubating the cells for 24 hours in DMEM + 10% FBS 
containing medium, the cell media was changed to Opti-MEM and the following concentrations 
of DNA-ICPs were added to individual wells (DNA basis): 0.0, 0.1, 0.5, 1.0, 2, and 5 µM. The 
particles were incubated in cells for 24 hours, after which the cells were washed thrice in PBS, 
cells were replenished with fresh media, and the cells were incubated for an additional 48 hours. 
Thereafter, cells were rigorously washed to remove any extracellular ICP particles, trypsinized, 
and immediately transferred to 1.5 ml Eppendorf tubes containing PBS. The cells were then 
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centrifuged at 1100 RPM for 5 minutes to form cellular pellets. Pictures of the cell pellet were 
taken against a white background to show a concentration dependent increase in ICP uptake.  
Western blot and gene knockdown analysis. SKOV3 cells were obtained from American 
Tissue Culture Collection (ATCC).  The cells were incubated in 5% CO2 at 37˚C in McCoy’s 5A 
medium supplemented with 10% heat-inactivated FBS. Cells were cultured in 6 well cell culture 
plates (BD Biosciences) with 100,000 cells per well seeded 24 hours before treatment with ICPs.  
Medium was replaced with Opti-MEM (Life technologies) immediately prior to treatment with 
ICPs or Lipofectamine RNAimax (Life technologies) DNA.  Lipofectamine transfection was 
performed according to manufacturer’s instructions to deliver 25 pmole of DNA.  After 12 hours, 
the medium was replaced with fresh media (McCoy’s 5A with 10% FBS) and the cells incubated 
for another 48 hours. The cells were then washed three times with PBS, trypsinized and the pellet 
was resuspended in 100 μL of mammalian cell lysis buffer (Cell Signalling) containing protease 
and phosphatase inhibitor (Thermo Scientific).  The whole cell lysates were then purified and 
collected by centrifugation and frozen at -80 ˚C. Protein concentrations were determined using 
the BCA Protein Assay Kit (Pierce).  Equal amounts of protein samples (25 μg) were 
fractionated by 4-20% precast gradient gel (Bio-Rad) and transferred to nitrocellulose 
membranes (Thermo Scientific).  Membranes were dried overnight, rehydrated in PBS, then 
blocked for 1 hour at room temperature in blocking buffer (LI-COR Biosciences).  Proteins were 
detected with rabbit primary antibodies against HER2 (1000:1) (Cell Signaling), mouse antibody 
against beta-tubulin (1000:1) (Thermo Scientific) and anti-rabbit or anti-mouse IgG-dye 
conjugated secondary antibodies (10,000:1) (LI-COR Biosciences).  The fluorescence signal was 
recorded and quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences) and 
quantified using Image Studio software (LI-COR Biosciences).   
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Agarose gel analysis of DNA-ICP degradation. To visualize the amount of nucleic acids 
released from DNA-ICP particles under acidic conditions, an agarose gel experiment was carried 
out. Briefly, five aliquots of DNA-ICPs (B-ICP) containing 12.2 µM total DNA were diluted 1:1 
with the following buffer solutions (100 mM each): KHP buffer, pH 4.0; HEPES buffer, pH 5.5; 
MES buffer, pH 6.0, PBS buffer, pH 7.4, or Tris buffer, pH 8.0. As a control, a sample was 
prepared with the single-stranded oligonucleotide (B-DBCO) containing the same total amount 
of DNA in deionized H2O. The solutions were allowed to stand at RT for 48 h, then were 
subsequently diluted again 1:1 with 0.5x TAE buffer. The samples were then analyzed in 1% 
agarose gel run at 90V for 1 hour in 0.5x TAE buffer.  Agarose gels were imaged on a Fujifilm 
FLA-5100 gel imager and 1X SYBR® Gold stain was used to visualize oligonucleotides.  
Results and Discussion 
Synthesis of infinite coordination polymer particles. For the purpose of polymerizing Fe3+ into 
coordination polymer nanoparticles, we synthesized a new ditopic ligand DABA-bis-HP-N3 (4), 
which deliberately employs the inexpensive building blocks maltol and 3,5-diaminobenzoic acid 
(DABA, 1) (Scheme 3.1a). Two sequential acid-catalyzed condensations of maltol with DABA 
(1 to 2; 2 to 3) followed by HATU-mediated amidation of the carboxylic acid afforded the azide-
bearing ditopic ligand 4. Importantly, the carboxylic acid in 3 may be amidated with a wide 
variety of amine building blocks, affording ICP particles with tailorable post-synthetic chemistry 
dictated by the pendant functional groups. 
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Scheme 3.1. Synthesis and assembly of ICP particles and their cellular uptake. a) Synthetic scheme for bis-3,4-
HOPO azide (4). b) Assembly of ICP particles from Fe(NO3)3 and  compound 4, followed by conjugation with DNA 
via a Cu free ‘Click’ reaction. c) Scheme depicting the cellular uptake of ICP-DNA conjugates. Reaction conditions: 
i) maltol, n-propanol, reflux, 16 h. ii) maltol, ethoxyethanol, 64 h, reflux. iii) 4-azido-butan-1-amine, HATU, 
diisopropylethylamine, DMSO, RT, 4 h. iv) Fe(NO3)3·9H2O, NaOH (aq.), RT, 10 min. v) Dibenzocyclooctyne-
DNA, 0.5M NaCl, RT, 16 h 
To synthesize ICP nanoparticles from ligand 4, we prepared a dilute NaOH solution of ligand 4 
(1.07 mM ligand, 1877 µL) and injected a solution of ferric nitrate (10.8 mM, 123 µL) into it 
(Scheme 3.1b). Particle formation occurs instantaneously and the color of the solution turns from 
clear to red due to the ligand-metal charge transfer band (LMCT) of the tris-HOPO-Fe3+ 
complex (λmax ≈ 460 nm).194 The resulting ICP-N3 nanoparticles were colloidally unstable in the 
presence of low concentrations of salts (NaCl, Tris·HCl), leading to gradual precipitation of a 
red, insoluble material. (Figure 3.1).  
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Figure 3.1. Bare colloidal ICP-N3 nanoparticles stored overnight at varying concentrations of NaCl. From left to 
right: 0 M, 0.1 M, 0.5 M, 1.0 M 
The crude ICP-N3 particles were purified by centrifugal filtration (100 kDa molecular weight 
cut-off) and re-suspended in H2O. The particles were retained on the filter, as they were too large 
to pass through. Minimal loss of material through the filter indicated a colloidal dispersion of 
high molecular weight species was obtained. In deionized H2O, the as-synthesized particles were 
stable, with a mean hydrodynamic diameter of 10-20 nm, determined by dynamic light scattering 
(DLS) (Figure 3.2). TEM and AFM imaging revealed aggregates of small nanoparticles, with 
some degree of fusion occurring upon drying (Figure A3.4). Furthermore, the composition of the 
ICP-N3 particles was probed spectroscopically. Aliquots containing a fixed concentration of 
DABA-bis-HP-N3 ligand in H2O were prepared and treated with increasing amounts of iron 
ranging from 0 to 1.1 equivalents. The absorbance at 460 nm increased until 0.66 equivalents of 
FeIII were added, consistent with a metal-ligand stoichiometry of Fe2L3 (Figure A3.2).  
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Figure 3.2. Characterization of DNA-ICP particles. AFM image of (a) Bare ICP particles drop-cast and dried on 
mica. b) DNA-functionalized ICP particles drop-cast and dried on mica. c) DLS histograms comparing size 
distributions of bare and DNA-functionalized ICPs. d) Cooperative melting of ICP-DNA aggregates. 
Conjugation of oligonucleotides to ICP particles. For conjugation to bare ICP-N3 particles, all 
oligonucleotides were made on an automated DNA synthesizer, purified by reverse-phase HPLC, 
and characterized by MALDI-ToF. Dibenzocyclooctyne (DBCO) phosphoramidites are 
commercially available and easily incorporated onto the 5´ termini of the oligonucleotides. DNA 
strands modified with a Cyanine 5 (Cy5) dye were used for intracellular imaging studies. DNA 
strands modified with a 5´ alkylthiol were used to construct AuNP-SNAs for comparison with 
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DNA-ICP particles (Table 3.1). DBCO-bearing oligonucleotides were conjugated to ICP-N3 
particles by simply mixing the two reactants in aqueous NaCl (0.5M) followed by repeated 
filtration to remove unreacted DNA. Importantly, gradual addition of salt was not necessary to 
prevent aggregation of the nanoparticles, unlike their gold counterparts. The resulting DNA-ICP 
particles were suspended in Tris·HCl buffer (100 mM, pH 8.0) and remained colloidally stable 
when stored at 5°C or when heated up to 80 °C over the course of a melting analysis. 
Oligo Name Sequence (5´3´) FW (Calc’d)  [M-H]- (Found) 
A-DBCO DBCO-TEG-A4-AATCCTTATCAATATTT 6942 6951 
B-DBCO DBCO-TEG-A4-AAATATTGATAAGGATT 7080 7082 
A-SH HS-(CH2)6-A4-AATCCTTATCAATATTT 6699 6689 
HER2-DBCO DBCO-TEG-CTC-CAT-GGT-GCT-CAC 5075 5070 
NONT-DBCO DBCO-TEG-GAG-CTG-CAC-GCT-GCC-GTC-A 6360 6369 
Cy5-DBCO DBCO-TEG-CCTCCTCCT-Cy5-CCTCCTCCT 6337 6341 
CCT-Cy5-SH HS-(CH2)6-CCTCCTCCT-Cy5-CCTCCTCCT 6094 6098 
Cy5-T20-SH* Cy5-TTTTTTTTTTTTTTTTTTTT-(CH2)3-SH 7084 7084 
Table 3.1. All oligonucleotides synthesized for conjugation to ICP-NPs and AuNPs with mass determined by 
MALDI-ToF. *Purchased from TriLink BioTechnologies (San Diego, CA) 
Characterization of DNA-ICP SNAs. In addition to increasing colloidal stability, the 
conjugation of DNA to the surface of ICP-N3 particles resulted in changes to particle size, 
surface charge, and morphology (Figure 3.2). DLS and zeta potential measurements showed a 
consistent increase in hydrodynamic diameter and surface charge, respectively. Particles were 
imaged by AFM to visualize changes in size and morphology. UV-Vis spectroscopy was used to 
calculate the relative contribution of DNA to the absorbance at 260 nm, and hence the DNA 
concentration was determined. Inductively-coupled plasma mass spectrometry (ICP-MS) was 
used to calculate directly the extinction coefficient ε460 of the ICP particles (Figure 3.4a). Lastly, 
incubation of DNA-ICP particles in aqueous buffers ranging from physiological pH (7.4) to low 
lysosomal pH (4.0) showed a clear red-shift in the LMCT λmax, indicating partial dissociation of 
the tris-coordinated Fe3+ nodes comprising the particle (Figure 3.4b). Likewise, agarose gel 
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analysis of DNA-ICP particles incubated in buffers of various pH showed significant shedding of 
DNA from the particle core at pH values below physiological pH. (Figure 3.3) Other 
coordination polymers based on HOPOs and catechols exhibit similar pH dependence.153, 195-196 
 
Figure 3.3. Agarose gel analysis of ICP degradation after 48 hours. Note that the DNA released from the ICP is 
slightly retarded in the gel due to its higher molecular weight after reaction with the ligand (4). 
 
Figure 3.4. UV-Vis analysis of DNA-ICP particles. a) Comparison of bare ICP particles with DNA-ICP particles 
showing the DNA absorbance at 260 nm. Inset: determination of LMCT ε460. b) pH dependence of LMCT 
absorbance. The red-shift of λmax with decreasing pH is indicative of complex dissociation (see inset). 
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Thermal denaturation studies. In order to probe the surface density of oligonucleotides on the 
DNA-ICP particles, thermal denaturation experiments were carried out wherein ICPs with 
complementary sequences (A-ICP and B-ICP) were mixed, allowed to hybridize, and then 
heated above the melting transition of the duplex. The free double-stranded DNA duplex 
possesses a 17 base-pair overlap with Tm = 54.0°C in 0.3M NaCl. In contrast, the same 
complementary strands form duplexes with a Tm = 66.9°C when conjugated to ICP-N3 particles, 
an increase of nearly 13°C. The melting transition of the DNA-ICP particle aggregates is 
extremely narrow, an indication of cooperativity; the full width at half-maximum of the melting 
curve is typically <2°C, compared to 10-20°C for free double-stranded DNA (Figure 3.2d). A-
ICP particles alone exhibited no aggregation or melting under the experimental conditions, nor 
did A-ICP particles mixed with non-complementary particles (NonTarget-ICP). We also 
studied the interaction of DNA-ICP particles with conventional AuNP-SNAs (A-AuNP) that 
were prepared and purified according to established protocols. Similar aggregation and melting 
behavior was observed between A-AuNP and B-ICP particles mixed in a 1:1 ratio (Figure 
A3.5). Overall, these studies suggest high DNA surface loading on the ICP-N3 particles.  
Cellular uptake studies. Due to the high apparent oligonucleotide density on the DNA-ICP 
surface, we hypothesized that they would function as efficient gene delivery agents, much like 
their gold predecessors. To test this assumption, ICP-N3 particles were functionalized with the 
poly(CCT) oligonucleotide Cy5-DBCO bearing an internal fluorophore-label to afford Cy5-ICP 
particles. Likewise, gold nanoparticles (15 nm) were functionalized with the analogous Cy5-SH 
oligonucleotide to afford Cy5-AuNP particles having a loading of approximately 113 
strands/AuNP, as determined by fluorescence. To test our hypothesis, uptake was examined in 
HeLa cervical cancer cells (Figure 3.5). The DNA-ICP particles were found to cross cell  
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Figure 3.5. Cellular uptake and gene knockdown. Confocal microscopy image of HeLa cells treated with (a) Cy5-
ssDNA and (b) DNA-ICP particles (100 nM DNA in each case). Hoechst stain denotes the nucleus in blue while the 
Cy5 dye attached to the DNA is red. c) Fluorescence intensity of Cy5 dye quantified by flow cytometry. d) Naked-
eye visualization of DNA-ICPs taken up in pelleted SKOV-3 ovarian cancer cells e) Expression of HER2 protein in 
SKOV-3 cells treated with non-targeting DNA-ICPs, HER2 targeting ssDNA + Lipofectamine (25 nM DNA basis), 
and HER2 targeting DNA-ICPS. Starred bars (**) indicate knockdown was significant (p<0.05) as determined by 
unpaired student's T test.  
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membranes more efficiently than the free DNA strands, and exhibited comparable uptake to 
AuNP-SNA nanoparticles bearing the same sequence. 
 These results suggest that DNA-ICP nanoparticles have the potential to transport large 
amounts of DNA to the cytosol. A dose-dependent increase in iron concentration was found after 
incubation of DNA-ICPs in SKOV-3 ovarian cancer and MCF-7 breast cancer cells for 24 hours. 
The color of the iron complex could be seen by the naked eye in pelleted cells treated with DNA-
ICPs. Confocal microscopy experiments with SKOV-3 and C166 cells confirmed that DNA-ICPs 
enter such cell lines, demonstrating that these structures exhibit comparable uptake 
characteristics to AuNP-SNAs (Figures A3.6-A3.8). 
Gene knockdown studies. Having demonstrated the ability of DNA-ICP conjugates to enter 
cells in a manner analogous to AuNP-SNAs, we probed their ability to alter protein expression 
by targeting a known cancer-related mRNA transcript. SKOV-3 ovarian cancer cells were 
chosen as they over-express human epithelial growth factor receptor 2 (HER2), which is 
involved in signal transduction pathways leading to malignant cell growth and differentiation.197 
We performed a series of gene knockdown experiments utilizing anti-HER2 DNA-ICPS. SKOV-
3 cells were incubated with different concentrations of antisense DNA-ICPS (HER2-ICP) or 
non-targeting DNA-ICPS (NonTarget-ICP), with free anti-HER2 DNA complexed with 
Lipofectamine® (Life Technologies) as a positive control. After 3 days, cells were harvested and 
HER2 expression was determined by Western blot analysis (Figure 3.5e). Treatment with anti-
HER2 DNA-ICPs reduced HER2 expression by up to 81%, in a dose dependent fashion. This is 
comparable to results achieved with commercial transfection kits, and with no change in HER2 
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expression observed with non-targeting DNA-ICPs. Lastly, no toxic effects or cell death resulted 
from treatment with DNA-ICPs, as predicted by MTT assays (Figure A2.1 and A3.1). 
Conclusions. We have reported a facile method to synthesize biocompatible, DNA-decorated 
infinite coordination polymer nanoparticles that are capable of cell entry and gene regulation 
without transfection agents. Iron(III)-based ICP nanoparticles, synthesized in water, can be 
conjugated directly to oligonucleotides and carry them across cell membranes. By confocal 
microscopy, we observed punctate fluorescence when cells were treated with dye-labelled ICP 
particles, which is also seen with classical AuNP SNAs, suggesting they share a similar 
endocytotic uptake pathway. Furthermore, the core is comprised of benign building blocks that 
are not expected to pose significant health hazards. This work represents a major step towards 
the construction of clinically viable gene regulation constructs for in vivo applications in the 
treatment of cancer and other genetic diseases. 
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Chapter 4 
 
Biodegradable DNA-brush block copolymer spherical nucleic acids enable 
transfection agent-free intracellular gene regulation 
[Portions of this work have been published previously as Zhang, C.*; Hao, L. L.*; Calabrese, C. 
M.*; Zhou, Y.; Choi, C. H. J.; Xing, H.; Mirkin, C. A., Biodegradable DNA-Brush Block 
Copolymer Spherical Nucleic Acids Enable Transfection Agent-Free Intracellular Gene 
Regulation. Small 2015, 11, 5360-5368.] 
*These authors contributed equally to this work. C. M. Calabrese carried out the chemical 
synthesis and characterization of DNA-block copolymers described herein and was responsible 
for conducting the additional experiments requested by peer reviewers prior to publication. 
Abstract 
 A new strategy for synthesizing spherical nucleic acid (SNA) nanostructures from 
biodegradable DNA block copolymers is reported. Multiple DNA strands are grafted to one end 
of a polyester chain (poly-caprolactone) to generate an amphiphilic DNA brush block copolymer 
(DBBC) structure capable of assembling into spherical micelles in aqueous solution. These novel 
DBBC-based micelle-SNAs exhibit a higher surface density of nucleic acids compared to micelle 
structures assembled from an analogous linear DNA block copolymer (DBC), which endows 
them with the ability to more efficiently enter cells without the need for transfection agents. 
Importantly, the new SNAs show effective gene regulation without observable cellular toxicity 
in mammalian cell culture. 
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Introduction 
 Spherical nucleic acids (SNAs) are an emerging class of nanostructure, typically 
consisting of a nanoparticle core densely functionalized with a nucleic acid shell.33, 51 These 
structures exhibit a wide variety of novel properties that are substantively different from their 
linear nucleic acid counterparts, making them especially attractive for intracellular 
applications.68, 79, 169 Specifically, they are recognized by Class A scavenger receptors and 
naturally internalized by many cell types via caveolin-mediated endocytosis.70 They have been 
used as novel probes for measuring intracellular genetic content and as potent gene regulation 
agents.198-199 They are especially attractive as gene regulation materials since they do not need 
ancillary transfection agents such as viruses, peptides, lipids or cationic polymers to cross the 
cell membrane.73 Thus far, SNAs have been made with a variety of core materials, including 
many inorganic compositions63, 171 and several polymer compositions,29, 80, 100, 178, 200-208 and there 
are now a few examples of hollow SNA structures that are held together by cross-linked DNA or 
silica shells.78, 170 Although the nanoparticle core typically plays little role in determining the 
general chemical and biological properties of the corresponding SNAs, it can be a major concern 
when such structures are being considered as therapeutic candidates.209-210 Indeed, a significant 
synthetic challenge for the chemistry community is to design totally biocompatible and 
biodegradable SNAs that exhibit the hallmark properties of conventional SNAs with inorganic 
cores. One approach has been to use liposomal architectures as cores,77 but an alternative 
approach that may provide even greater tailorability is the use of polymer micelle architectures. 
Although a variety of nucleic acid polymer micelle architectures have been reported, 124-133 none 
have been developed and optimized with regard to general SNA features and intracellular 
biological activity.  Indeed, a few studies involving polymer micelle structures for intracellular 
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gene regulation have been undertaken, but they either required a cationic transfection agent (e.g. 
polyethyleneimine) for transfection or were constructed using non-degradable polymers.80, 211 To 
date, there are no biodegradable DNA block copolymer (DBC) based micelle structures that have 
been shown to exhibit the natural cellular uptake properties of SNAs, and therefore the use of 
such structures with respect to intracellular and therapeutic applications has been limited. 
Importantly, SNA-like properties are directly related to the orientation and high density of 
nucleic acids on the nanoparticle surface.69 
 
Scheme 4.1. Schematic showing the synthesis of DNA grafted block copolymer-based micelle SNAs. (a) The 
synthesis of the linear DNA-b-PEO-b-PCL block copolymer and the corresponding formation of micelle-SNAs 
(LDBC-SNAs). (b) The synthesis of the brush DNA-g-PCL-b-PCL block copolymer and the formation of micelle 
SNAs (DBBC-SNAs) with a higher surface density of nucleic acids. 
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To overcome the problem of low cell internalization associated with DNA block copolymer 
micelle structures, we identified the need to synthesize micelle SNAs with a dense layer of 
nucleic acids on the polymer core surface. Herein, we describe a strategy for preparing DBC 
micelle-SNAs with a biodegradable core and a dense layer of highly oriented oligonucleotides 
projecting from the surface of the aforementioned core. Traditionally, approaches to synthesizing 
DBC micelle architectures have involved the linear coupling of nucleic acids to hydrophobic 
polymer blocks (Scheme 4.1a).100 We have found this approach does not reliably yield structures 
with a nucleic acid density high enough and suitable for optimal SNA cellular transfection 
capabilities (vide infra). Therefore, our synthetic approach relies on the generation of a DNA-
brush block copolymer (DBBC) based micelle structure (Scheme 4.1b), which was pioneered by 
Gianneschi et al. in the context of non-degradable constructs for materials assembly purposes.212  
In our synthetic approach, the key components of the DBBC micelle structures are prepared by 
grafting multiple DNA strands onto the terminal segment of a diblock copolymer consisting of 
polycaprolactone (PCL; a component in FDA-approved therapeutics213) and azide-modified PCL 
via copper-free click chemistry to form a DBBC macromolecule. Then, when transferred from an 
organic solvent mixture consisting of 1:1 DMSO/DMF into an aqueous solution, the as-
synthesized amphiphilic DNA-brush block copolymers assemble into ~ 40 nm diameter spherical 
micelles (Scheme 4.1b). For comparative purposes, we also prepared a similarly sized micelle 
structure from a linear DBC component (Scheme 4.1a). 
Experimental Procuedures 
Materials and Methods. All DNA synthesis was carried out on a BioAutomation MM48 DNA 
synthesizer according to the standard manufacturer trityl-on protocol. All reagents for 
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oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) and used following 
the manufacturer’s instructions. Ac-dC and dmf-dG phosphoramidites were used to enable room-
temperature deprotection of the nucleobases. α-Chlorocyclohexanone, sodium azide, N,N-
dimethylformamide (DMF), tin(II) octanoate, caprolactone (CL), and all other solvents were 
purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. M-
chloroperoxybenzoic acid (mCPBA) was purchased from Fluka (Buchs, Switzerland).  
Oligonucleotide synthesis. Oligonucleotides were synthesized on 1 µmol scale and deprotected 
in concentrated NH4OH (30%) for 17 hours at room temperature. The resulting crude 
oligonucleotides were purified on a Varian Prostar HPLC fitted with a DynaMax Microsorb C18 
Column, employing a gradient of 0-75% acetonitrile in triethylammonium acetate buffer (pH 
7.0) over 45 minutes. The optical absorbance of the eluent was monitored at 254/310 nm for 
DBCO-containing oligonucleotides, 254/494 nm for fluorescein-containing oligonucleotides, and 
254/280 nm for all other oligonucleotides. Fractions were collected, lyophilized, and the DNA 
concentration quantified by UV-Vis. 
Synthesis of α-chloro-ɛ-caprolactone. To a solution of 10 g (75 mmol) of 2-
chlorocyclohexanone in 100 mL dichloromethane was added 20 g (81 mmol) of mCPBA (70%). 
The reaction mixture was stirred for 3 days at room temperature, then the reaction vessel was 
cooled to -20 °C to precipitate mCPBA. After vacuum filtration, the filtrate was washed with 
saturated aqueous NaHSO3 (3x), followed by saturated aqueous NaHCO3 (3x), and finally with 
H2O. After drying over MgSO4, the organic phase was vacuum-filtered, and the solvent was 
removed under reduced pressure to yield the crude product (yield not quantitated) which was 
used immediately in the next step.   
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Synthesis of Diblock Copolymer Poly(α-N3-εCL-b-εCL). The monomer α-chloro-ɛ-
caprolactone was prepared by the Baeyer-Villager oxidation of α-chlorocyclohexanone using 
excess mCPBA. After isolation, 0.5 g monomer (3.36 mmol) was mixed with 3.0 g commercially 
available polycaprolactone (MW = ~ 14 kDa, as macro-initiator) in dry toluene (10 mL). The 
mixture was dried by repeated (3×) azeotropic distillation with toluene. Then, the solution was 
heated to 130 °C in a preheated oil bath and stirred under N2. The reaction mixture was stirred 
for 5 min at 130 °C and then one drop of tin(II) octanoate was added via syringe. The 
temperature was maintained at 130 °C for another 3 hours. The resulting viscous mixture was 
rapidly cooled, upon which it solidified. The crude polymer was purified by repeated dissolution 
in dichloromethane and heptane precipitation (3×), resulting in a white solid after drying. Then 
the pendant chlorides of the as-synthesized poly(α-Cl-εCL-b-εCL) were converted into azides by 
treatment with sodium azide in DMF overnight at room temperature. After removal of DMF in 
vacuo, 15 mL of toluene was added, and the remaining NaN3 was removed by centrifugation 
(4000 rpm at 25 °C for 20 min). The diblock copolymer was recovered by precipitation in 
heptane. After washing with heptane multiple times, the solid precipitate was collected by 
vacuum filtration and dried under reduced pressure to afford 2.2 g (73% yield, PCL basis) of 
azide-modified copolymer. 
Synthesis of Azide-terminated PEO-PCL Diblock Copolymer. Azide-terminated 
oligo(ethylene oxide) with 4 PEG units (C8H16O4N3, 109 mg, 0.5 mmol) was weighed into a dry 
flask and ε-caprolactone (8.5 g with M/I ratio of ~ 150:1) was subsequently added. The synthesis 
and purification of single azide-terminated PEO-PCL diblock copolymer follow the same 
procedures for poly(α-Cl-εCL-b-εCL) as mentioned above with similar isolated yield of the 
desired product after precipitation into heptane. 
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DNA Conjugation. For each azide-containing polymer, the same procedure was followed. First, 
the polymer was dissolved in a 1:1 DMSO/DMF solution, and then a large excess of DBCO-
DNA dissolved in DMSO was added to the polymer solution and incubated at 40 °C overnight. 
After conjugation, the resulting linear and brush DBC samples were used immediately for 
micelle formation. 
Formation and Purification of Micelle-SNAs. Briefly, DBCs dissolved in an organic solvent 
(DMSO/DMF, 1:1) were loaded in a dialysis bag with a 50 kDa MW cutoff membrane and the 
solution was dialyzed against deionized water for 12 hours. After removal of large aggregates by 
filtration through a 0.2 μm syringe filter, the micelle-SNA conjugates were purified using an 
Amicon Ultra-15 ultrafiltration device (Millipore, MWCO 50 kDa) to remove excess free DNA. 
Characterization. 1H NMR spectra were recorded on a Bruker Avance 400 MHz NMR 
spectrometer and referenced internally to residual proton signals in the denatured solvents. FTIR 
spectra were collected on a Perkin-Elmer Spectrum 100 FTIR spectrometer using disposable KBr 
plates. Gel permeation chromatography (GPC) was carried out in THF at 32 °C at 1 mL/min with 
a Viscotek TDAmax liquid chromatograph (Malvern Instruments, UK) equipped with a 
programmable autosampler and refractive index detector. AFM images were obtained with a 
Bruker Dimension Icon atomic force microscope in a tapping mode under ambient conditions. 
DLS hydrodynamic size and zeta potential measurements were collected on a Malvern Zetasizer 
Nano-ZS (Malvern Instruments, UK) with a laser wavelength of 633 nm. Cryogenic TEM 
images were collected on a JEM 1230 microscope (JEOL) at an accelerating voltage of 80 kV. 
NTA measurements were performed with a NanoSight LM10 (NanoSight, Amesbury, UK) 
equipped with a sample chamber with a 638 nm laser and a Viton fluoroelastomer O-ring. 
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Confocal fluorescence images of the cells treated with micelle-SNAs were collected with a Zeiss 
LSM 510 inverted confocal scanning microscope. 
Cell Culture, Flow Cytometry, and Western Blotting. Cells were cultured at 37 °C and 5% 
CO2 in DMEM supplemented with 10% FBS and 1% streptomycin/penicillin. For cellular uptake 
study, HeLa cells were seeded in a 6-well plate 24 h prior to treatment and incubated with 
micelle-SNAs derived from linear or brush block copolymer structures, respectively. Right 
before flow cytometry analysis, cells were trypsinized, washed, suspended in 0.5 ml 1× 
phosphate-buffered saline (PBS) and fixed by addition of 0.5 ml of 3.7% formaldehyde in PBS. 
The fluorescence intensity from fluorescein (excitation wavelength at 488 nm, emission 
wavelength at 520 nm) of 10,000 cells was collected using a BD LSR II flow cytometer. For 
western blotting, C166 cells over-expressing EGFP were transfected with micelle-SNAs (with 
0.5, 1, and 2 µM of total DNA in OptiMEM) overnight and further incubate for another 2 days 
after medium change. Protein lysate with equal amount of total protein were fractionated by 4-
20% Precast gradient gel (Bio-Rad). The intact gel was then transferred to a nitrocellulose 
membrane (Thermo Scientific) and blocked in odyssey blocking buffer (LI-COR Biosciences). 
Proteins were detected with primary antibodies against actin (1:500) (Santa Cruz 
Biotechnology), EGFP (1:1000) (Clontech Laboratories Inc) followed by IRDye 680 secondary 
antibodies (1: 10,000) (LI-COR Biosciences) diluted in PBST containing 5% non-fat milk. The 
desired bands were visualized using the Odyssey® CLx Infrared Imaging System (LI-COR 
Biosciences). 
Thermal denaturation studies. In binary (2-component) nanoparticle systems, two different 
sets of SNAs were prepared with different linkers (Type A and Type B) presenting 
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complementary sticky ends (5´-TTCCTT-3´ and 5´-AAGGAA-3´). In a typical experiment, the 
DNA linkers were first hybridized to the appropriate particles by combining the linkers and 
either micelle-SNAs or 15 nm AuNP-SNAs in 0.5 M phosphate buffered saline (PBS) solution, 
heating the solution to 40 °C for approximately 30 minutes, then slowly cooling to room 
temperature. This was done to ensure that the maximum number of DNA linkers were hybridized 
to each particle. The micelle-SNA and AuNP-SNA solutions containing complementary linkers 
were then combined in the appropriate ratio, resulting in the formation of visible aggregates 
within minutes. To determine the melting temperature of each aggregate, approximately 1 mL of 
the suspension was placed into a quartz absorbance cuvette (Hellma) equipped with a magnetic 
stirrer and loaded into a Cary 5000 UV/Vis spectrophotometer (Agilent). The melting transitions 
were determined by monitoring the absorbance increase at 260 nm, which occurs upon DNA 
sticky end dehybridization resulting in aggregate dissociation.  
Confocal Microscopy and Immunofluorescence. Cells were seeded in a 35 mm FluoroDish 
and incubated with fluorescein-labelled DBBC-SNAs (with total DNA 1 μmol) in complete 
DMEM for different time points. Cells were rinsed with PBS, fixed in 3.7% PFA in PBS for 15 
min, and imaged under a Zeiss LSM 510 inverted confocal scanning microscope. The excitation 
wavelength of fluorescein-labelled DBBC-SNAs was 488 nm, and the corresponding emission 
filter was 500-550 nm. To track the colocalization of SNAs with intracellular proteins, after 
incubation with fluorescein-labelled DBBC-SNAs (with total [DNA] = 1 μM) for different time 
points, cells were rinsed with PBS, fixed with 3.7% PFA in PBS, and permeated with 0.1% 
Triton X-100 for 3min. After blocking with 5% BSA in PBS for 1 h, cells were stained with a 
primary antibody against the protein marker of interest at 5 μg/mL (1% BSA in PBS) overnight 
at 4 °C. After rinses with 0.05% Tween-20 in PBS, cells were stained with an Alexa Fluor 633-
65 
 
labeled secondary antibody (Invitrogen Alexa Fluor 633 Goat Anti-Rabbit or mouse IgG (H+L) 
at 1 μg/mL (1% BSA in PBS) for 1 hour at RT. The excitation wavelength of the secondary 
antibody was 633 nm, and the corresponding emission filter was 660 - 710 nm. The primary 
antibodies include rabbit against Rab9 (Abcam ab179815), and mouse against LAMP1 (Santa 
Cruz sc-20011).  
Cytotoxicity analysis. The cytotoxicity of the micelle-SNAs was evaluated with a Vybrant® 
MTT Cell Proliferation Kit (Molecular Probes) following the protocol provided by the 
manufacturer. Briefly, HeLa cells were seeded in a 96-well plate in 100 μL of media and 
incubated for 24 h. The cells were then treated with micelle-SNAs (2 μM, total DNA 
concentration) and the same concentration of single-stranded DNA. Cells without any treatment 
were used as a control group. At varying lengths of time (1, 2, 3 and 4 days), the media was 
removed, the cells were washed with PBS buffer (3×) and then incubated with 100 μL fresh 
culture medium and 10 μL of freshly-made 12 mM MTT solution at 37°C in 5% CO2 for 4 h. 
After this step, 100 μL lysis buffer (1 g of SDS in 10 mL of 0.01 M HCl) per well was added. 
Cells were further incubated overnight and the absorbance was measured at 570 nm using a 
Multiskan® Spectrum (Thermo Scientific). Each set of conditions was repeated in three 
independent experiments and the results averaged. 
Gel electrophoresis. Agarose gel electrophoresis was used to check the formation of micelle-
SNAs either by linear DBC or DNA grafted DBBC. Gels containing 1% agarose (w/w) were run 
on an FB-SB-710 electrophoresis unit (FisherBiotech) at room temperature in 1×Tris-Borate 
EDTA (TBE) buffer (50 V, constant voltage). The gels were directly imaged if the DNA was 
labeled with fluorescein; otherwise, imaging was carried out by ethidium bromide staining and 
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UV illumination (302 nm). Denaturing PAGE analysis for DBBC conjugates was performed in a 
gel containing 15% acrylamide (19:1, acrylamide/bisacrylamide), 8 M urea, and 1×TBE buffer. 
The sample solutions were heated up to 95 °C for 10 minutes for denaturing. Then, the samples 
were loaded into the gel and run on a SE600 cooled vertical electrophoresis unit (Hoefer, 300 V, 
constant voltage) with 1×TBE buffer. After electrophoresis, the gels were stained with ethidium 
bromide and imaged in a gel reader (Alpha Innotech). Under denaturing conditions, the DBBC 
based micelle-SNAs could not run into the gel and remained in the loading well after 
electrophoresis (Figure A4.5), indicating that the as-synthesized micelle-SNAs were quite stable 
in aqueous solution. To demonstrate the DBBC macromolecules contain multiple DNA strands 
on each polycaprolactone chain, we synthesized DBBC macromolecules with only a few DNA 
brushes loaded on the polymer chain. By reducing the ratio of DNA/PCL to ~ 3 during the click 
conjugation reaction, the as-prepared DNA-brush block copolymer was analyzed by denaturing 
PAGE again. In Figure A4.5, a series of bands can be seen on the gel, which can be attributed to 
DNA-PCL conjugates with a different number of DNA strands on each polycaprolactone chain. 
Again, the major product consisted of large micelle structures that accumulated at the bottom of 
the loading well.  
Degradation of DBBC-SNAs.  To visualize the amount of nucleic acids released from DBBC-
SNAs under different pH conditions an agarose gel experiment was carried out. Briefly, 
fluorescein-labeled DBBC-SNAs containing 10 µM total DNA were diluted 1:1 with the 
following buffer solutions (100 mM each): HEPES buffer, pH 5.5; MES buffer, pH 6.0, PBS 
buffer, pH 7.4. As a control, a sample was prepared with the AuNP functionalized with the same 
oligonucleotides (anti-EGFP antisense DNA) diluted 1:1 with the buffers described above, 
respectively. The solutions were allowed to stand at RT for 18, 24, 48, and 72 hours, then 
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analyzed by agarose gel electrophoresis (1% agarose). The agarose gels were imaged on a 
Fujifilm FLA-5100 gel imager with a 473 nm laser to visualize the fluorescein-labeled DNA.   
 
Results and Discussion 
In a typical DBBC micelle-SNA synthesis (Figure A4.1), α-chloro-ε-caprolactone (α-Cl-
εCL) prepared by the Baeyer-Villager oxidation of α-chlorocyclohexanone214 was employed 
as a monomer for polymerization. The diblock copolymer poly(α-Cl-εCL-b-εCL) was 
synthesized from the monomer, α-Cl-εCL, and commercially available polycaprolactone (MW 
= ~ 14 kDa) as the macro-initiator. The pendant chlorides of the as-synthesized poly(α-Cl-ε
CL-b-εCL) were converted into azides by treatment with sodium azide in DMF overnight at 
room temperature.215 1H NMR spectroscopy was used to characterize the product, and the 
spectrum suggested the as-synthesized diblock copolymer contained on average 15 N3 groups, as 
determined by integration (peak A and G in Figure A4.2). In addition, FT-IR spectroscopy of the 
azide-containing PCL diblock copolymer showed the characteristic azide band at 2106 cm-1 
(N=N=N stretch, Figure A4.3).216 Gel permeation chromatography (GPC) analysis was also 
consistent with block copolymer formation as evidenced by an increase in molecular weight 
from ~ 14 to ~ 16 kDa (Figure A4.4). When substituted with azide groups, the poly(α-N3-εCL-
b-εCL) exhibited a slightly shorter retention time than that of poly(α-Cl-εCL-b-εCL) in the 
GPC column. Finally, poly(α-N3-εCL-b-εCL) and an excess of cyclooctyne-terminated DNA 
strands were added to an organic solvent mixture (1:1 DMSO:DMF) to initiate the copper-free 
click reaction of DNA strands with the azide-modified block, resulting in the formation of the 
DNA-g-PCL-b-PCL macromolecule. For comparative purposes, a linear DBC was also 
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synthesized. Instead of using 14 kDa PCL as the macro-initiator, an azide-terminated 
poly(ethylene oxide) with 4 ethylene glycol units was employed to initiate the caprolactone 
polymerization to synthesize a PEO-b-PCL block copolymer with a comparable molecular 
weight (~18 kDa based on 1H NMR integration). Again, click chemistry was used to conjugate 
DNA to the as-synthesized PEO-b-PCL block copolymer and generate the linear DNA-b-PEO-b-
PCL block copolymer. After the DNA conjugation reaction, both the DNA brush block 
copolymer micelle-SNAs (DBBC-SNAs) and the linear DNA block copolymer micelle-SNAs 
(LDBC-SNAs) were prepared and purified according to literature protocols used for analogous 
linear non-biodegradable structures.29 In this process, excess DNA was removed by an 
ultrafiltration device with a MWCO of 50 kDa membrane. The amount of DNA conjugated to 
the polymer was determined by measuring the absorbance of the micelle-SNA solutions at 260 
nm. Based on the total amount of polymer used for conjugation, it was determined that an 
average of 10 DNA strands were successfully conjugated onto each polymer chain. Moreover, 
polyacrylamide gel electrophoresis, under denaturing conditions, was used to analyze the 
resulting DNA-g-PCL-b-PCL macromolecules. The bands representing DBBC conjugates 
containing multiple DNA strands can be clearly identified on the gel when excess DNA was used 
for the conjugation (Figure A4.5). 
SNA Sequence (5’  3’) 
Micelle-SNA:EGFP DBCO-(EG)4-(spacer 18)x- CGGACACGCTGAACTTGTGG 
Scrambled antisense DNA DBCO-(EG)4-(spacer 18)x- CGGATACGCTGATCTTGTGG 
Fluorescein-SNA DBCO-(EG)4-(spacer 18)x- CGGACACGCTGAACTTGTGG-Fl 
AuNP-SNA Propylthiol-(spacer 18)5- ACA TCC ACG TAG TCT TAG  
Linker Strand-1 
 (hybridized with AuNP-SNA) 
AAGGAA T CTA AGA CTA CGT GGA TGT 
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Linker Strand-2 
 (hybridized with micelle-SNA) 
TTCCTT T CCA CAA GTT CAG CGT GTC CG 
Table 4.1. Oligonucleotide sequences used in this study. Fl = fluorescein; DBCO = dibenzocyclooctyne; EG = 
ethylene glycol.  “Spacer 18" denotes a phospodiester followed by 6 ethlyene glycol units in the DNA backbone. 
x=0 when the DNA was used in the formation of linear DNA-b-PEO-b-PCL, x=1 when the DNA was used in the 
formation of DNA-g-PCL-b-PCL. 
 
 
Figure 4.1. Characterization of as-synthesized polycaprolactone-based micelle-SNAs. (a) 1% agarose gel 
electrophoresis; nucleic acids were stained with ethidium bromide; (b) A typical DLS measurement of micelle-
SNAs derived from (top) linear and (bottom) brush block copolymer structures; (c) Melting transition behaviour for 
micelle-SNAs hybridized to complementary 15 nm AuNP-SNAs; (black trace) micelle-SNAs made from linear 
structures and (red trace) micelles made from the brush architecture; (d) Cryogenic TEM images of micelle-SNAs 
derived from brush block copolymer. Both DBBC-SNA and LDBC-SNA nanoparticles remain intact under 
cryogenic conditions and are relatively uniform in size with diameters ~ 30-50 nm. 
With purified samples, multiple techniques were employed to characterize these two 
polycaprolactone-based SNAs (Figure 4.1). Gel electrophoresis (1% agarose gel, Figure 1a) 
showed a single major band for each sample on the gel image, indicating the micelle-SNAs have 
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a narrow size distribution. Compared to unmodified DNA of the same sequence, the 
electrophoretic mobilities of the micelle-SNAs are greatly decreased, consistent with the 
significant difference in size and overall charge. Notably, the electrophoretic mobility of SNA 
made from the brush architecture is slightly lower than that of one made from the linear 
structure, indicating that the former SNA is slightly larger. The size distributions of the micelle-
SNAs were also probed by dynamic light scattering (DLS), which indicated an average 
hydrodynamic diameter of 44 nm for the SNAs derived from the brush architecture and 40 nm 
for ones derived from the linear architecture (Figure 4.1b), consistent with the gel analysis. 
Meanwhile, zeta potential analysis gave values of -48.5 ± 3.7 mV and -27.9 ± 3.2 mV, 
respectively (Figure A4.6), consistent with the micelle derived from the brush architecture 
having a higher density of DNA. Furthermore, the micelle-SNAs were cast on mica and imaged 
by atomic force microscopy in dry form (Figures A4.7); in both cases, spherical structures were 
readily apparent. To visualize the morphology of the micelle-SNAs in an environment closer to 
the one in which they are prepared, cryogenic transmission electron microscopy (Cryo-TEM) 
was used (Figure 4.1d). In this method, a very thin layer of micelle-SNA-containing solution was 
quickly frozen and directly imaged. Cryo-TEM imaging avoids dehydration-induced artifacts, 
allowing the fully intact nanoparticles to be visualized. Indeed, round 30-50 nm diameter 
particles of both DBBC-SNAs and LDBC-SNAs were observed, which are consistent with the 
DLS size data.  
Since the density of DNA on the particle surface is a key factor that leads to its SNA-like 
properties, it is important to determine nucleic acid surface coverage. In contrast with 
conventional AuNP-SNAs, where particle concentration can be easily determined by measuring 
the plasmon resonance peak associated with AuNPs, it is difficult to directly determine the 
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micelle particle concentration using spectrophotometric methods. Alternatively, we used 
nanoparticle tracking analysis (NTA)217-218 to determine the particle concentrations for micelle-
SNAs (see details in Appendix, Figure A4.8 and Table A4.1). Importantly, the DNA loading for 
the brush block copolymer based micelle-SNAs (302 strands/particle; 22.2 pmol/cm2) was 
significantly higher than the linear block copolymer based micelle-SNA (190 strands/particle; 
15.6 pmol/cm2), which is comparable to AuNP-based SNAs of similar sizes (300 strands/particle 
for 30 nm AuNP cores; corresponding to a DNA density of 17.6 pmol/cm2).53 Another important 
feature of SNA structures is their cooperative hybridization properties, arising from the 
association of multiple DNA strands between each particle. This results in a sharp melting 
transition during the thermal denaturation of hybridized complementary particles.29, 51  Generally, 
higher DNA loading results in higher melting temperatures and sharper transitions under 
comparable conditions. The thermal denaturation of micelle-SNAs was carried out by 
hybridizing both brush and linear block copolymer based micelle-SNAs with AuNP-SNAs 
containing complementary sticky ends, respectively, and then monitoring the absorbance change 
at 260 nm with gradual heating (Figure 4.1c and Figure A4.9). Around the melting temperature, 
extinction dramatically increased due to the hyperchromic effect of cooperative DNA 
dehybridization. As shown in Figure 1c, the melting curves for both types of micelle-SNAs when 
hybridized with AuNP-SNAs were sharp and elevated, with the Tm of the DBBC-based micelle-
SNA (39.5 ˚C) being almost 3 degrees higher than the linear DBC-based micelle-SNA (36.9 ˚C). 
The higher melting temperature for the DBBC-based micelle-SNA is consistent with a structure 
with a higher surface density of nucleic acids.219 
With well-characterized micelle-SNAs in hand, we evaluated their biological function with in 
vitro cell uptake studies. Both micelle-SNAs exhibit the ability to enter cells without the 
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assistance of cationic transfection reagents, but with different efficiencies. Confocal microscopy 
revealed that fluorescein-labelled micelle-SNAs (1 µM total DNA) enter HeLa cells after 16 h of 
incubation. Notably, the green fluorescence from micelle-SNAs consisting of brush block 
copolymers was significantly more intense than that of the linear block copolymer based micelle-
SNAs (Figure 4.2d,e), indicating more efficient uptake of the former as opposed to the latter. 
This result was also confirmed by quantifying the fluorescence intensity of the cell population 
using flow cytometry.  
 
Figure 4.2. Cellular uptake of micelle-SNAs. (a-e) Fluorescence micrograph of HeLa cells incubated with different 
forms of nucleic acids at a total DNA concentration of 1 µM for 16 h. DNA strands were labelled at the 5’-end with 
fluorescein and the dye molecules are located at the outside terminus of the micelle-SNA structure. a) negative 
control, cells without DNA incubation; b) single stranded fluorescein-labelled DNA (Fluo-DNA); c) positive 
control, single stranded Fluo-DNA transfected with Lipofectamine® 2000; d) micelle-SNAs derived from linear 
block copolymer structures; e) micelle-SNAs derived from brush block copolymer structures. In the fluorescence 
images, micelle-SNAs assembled from the brush block copolymer show significantly higher uptake compared to 
those derived from the linear analog or component single stranded DNA; (f) Fluorescence-activated cell sorting 
(FACS) analysis of the cells when incubated with different forms of nucleic acids. FACS data also confirm the brush 
block copolymer based micelle-SNA has higher cell uptake efficiency than that of the linear block copolymer based 
micelle-SNA. Single stranded DNA and DNA transfected by conventional Lipofectamine® 2000 were used as 
controls.  
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Although incubated with equal amounts of total DNA, the mean fluorescence intensity of 
cells treated with brush block copolymer based micelle-SNAs was almost twice that of linear 
block copolymer based micelle-SNAs (Figure 2f), presumably due to their higher surface density 
of nucleic acids. Compared to the positive control which utilized Lipofectamine® 2000 as the 
transfection agent, DBBC-SNAs show slightly lower but comparable transfection efficiency 
without any co-carrier. We further studied the intracellular location of DBBC-SNAs as a 
function of incubation time under conditions where HeLa cells were continuously incubated with 
fluorescein-labelled micelle-SNAs (1 µM total DNA). AuNP SNAs traffic through the endocytic 
pathway into late endosomes and reside there without accumulating in lysosomes.210 We 
hypothesized that the DBBC-SNAs follow the same route upon cellular entry due to their similar 
architecture. In these experiments, the DBBC-SNAs carry a green fluorophore (fluorescein), and 
the cells are stained with a complementary Alexa dye-labeled marker of interest (red). As shown 
in Figure 4.3, strong colocalization of SNAs with Rab9 (a protein which preferentially localizes 
in late endosomes) was observed after 6 h of incubation, and colocalization persisted 24 h post-
incubation. Importantly, we did not observe appreciable colocalization between the fluorescent 
signals of DBBC-SNAs and markers for lysosomes (LAMP-1) over a 24 h period of time. From 
these data, we conclude that SNAs primarily remain inside late endosomes and do not migrate 
beyond this point to the lysosome. These observations confirm that within a typical cell doubling 
time (23-24 h for HeLa cells), the micelle-SNAs likely employ the same intracellular trafficking 
pathway as AuNP-based SNAs. 
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Figure 4.3. Confocal microscopy of fluorescein-labelled DBBC-SNA and immunofluorescence staining of organelle 
markers (red, labelled by Alexa Fluor 663). Biomarkers are Rab9 (for late endosomes) and LAMP-1 (for 
lysosomes). Note that most DBBC-SNAs colocalize with late endosomes during the incubation in HeLa cells. There 
is no significant colocalization of DBBC-SNAs with lysosomes, which is consistent with the behaviour of AuNP-
SNAs.  
We further tested the intracellular gene regulation capacity of the DBBC-based micelle-
SNAs in specialty C166 mouse endothelial cells over-expressing enhanced Green Fluorescent 
Protein (eGFP). The DNA strands on the micelle-SNAs were synthesized with an antisense 
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sequence against the eGFP mRNA. After transfection and further incubation for 48 h, eGFP 
knockdown was readily apparent by fluorescence microscopy (Figure 4.4a,b). Importantly, the 
quantification of eGFP protein expression via western blot shows a concomitant ~ 52% reduction 
in eGFP expression (Figure 4.4c), demonstrating that the micelle-SNA can effectively bind the 
cytosolic mRNA target and alter the expression of its associated protein. Compared to LDBC-
SNAs under the same conditions, DBBC-SNAs are more effective at regulating gene expression 
via the antisense mechanism (Figure 4.4d).  
 
Figure 4.4. Gene regulation by DBBC-based micelle-SNAs. (a) Fluorescence micrograph of C166 mouse 
endothelial cells that highly express the EGFP protein before DBBC-based micelle-SNA treatment. (b) Fluorescence 
micrograph of C166 mouse endothelial cells after DBBC-SNA treatment. The green fluorescence was significantly 
suppressed due to the EGFP gene knockdown. The micelle-SNAs were equipped with anti-EGFP sequence and the 
cells were cultured for another 2 days after SNA transfection. (c) Western blotting of EGFP expression in C166 cells 
after treatment with anti-EGFP DBBC-based micelle-SNAs and single stranded DNA samples under various total 
DNA concentrations. (d) Western blotting of EGFP expression in C166 cells after treatment with anti-EGFP DBBC-
SNAs and control samples under total DNA concentrations of 2 μM. The positive control sample was antisense 
DNA transfected by conventional Lipofectamine® 2000.   Actin was used as an internal reference.  
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When the DBBC-based micelle-SNAs are modified with a scrambled DNA sequence, EGFP 
expression does not change at all concentrations tested (0.5-2 µM of total DNA), indicating the 
gene knockdown effect is sequence-specific (Figure A4.10). To further validate that our new 
constructs may have significant potential for biomedical applications, we tested the 
biodegradation and cellular toxicity of DBBC-SNAs. During the transfection and intracellular 
trafficking process, SNAs will encounter quite different chemical environments, such as varied 
pH values and ionic strength in serum, endosomes, and lysosomes. This may cause the PCL core 
of the micelle particles to degrade at a different rate depending on their location.  
 
Figure 4.5. The pH-dependent degradation of DBBC-based micelle-SNAs. Samples were incubated in 50 mM 
MES buffer (pH 5.5), 50 mM HEPES buffer (pH 6.0), or 1X PBS (pH 7.4). Agarose gel electrophoresis was used to 
monitor the degradation process. a) Degradation of DBBC-based micelle-SNAs after 24 hour incubation under 
different pH buffer conditions. Note that a significant amount of single stranded DNA can be observed in the gel 
image; b) the mobility and shape of the DBBC-based SNA bands over incubation time under different buffer 
conditions. In the first 24 hours, the SNA bands look relatively sharp.  However, as the incubation time increases, 
the bands become smeared and diffuse, indicating the gradual degradation of the entire micellar structures. Note that 
the micelles held at lower pH (5.5) suffer considerably more degradation after 72 hours.  
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To evaluate their biodegradability, we incubated the DBBC-SNAs in buffers of varied pH values 
to mimic different intracellular environments. As shown by agarose gel electrophoresis, 
component single-stranded DNA appeared after 24 h incubation, indicating the degradation of 
micelle-SNAs and shedding of DNA oligonucleotides (Figure 4.5a). Meanwhile, gel bands 
representing the DBBC-SNAs became smeared and diffused with increased incubation time 
(Figure 4.5b). Notably, micelle-SNAs degraded faster in lower pH buffer conditions, pointing to 
the possibility of their faster degradation when trafficking through intracellular vesicles with low 
pH, such as the endosomes.210 The cellular toxicity of DBBC-based micelle-SNAs was analyzed 
using the standard MTT assay (Figure 4.6).220  
 
Figure 4.6. Cellular toxicity of DBBC-based micelle-SNAs analyzed by a standard MTT assay. Cells treated with 
DBBC-SNAs (red), LDBC-SNAs (blue), and single stranded DNA (black) at the same total DNA concentration (2 
μM). Viable cells with active metabolism convert MTT into a purple colored formazan product with an absorbance 
maximum near 570 nm, and cell viability was quantified by normalization of the absorbance at 570 nm to non-
treated cells. Error bars represent the standard deviation of absorbance at 570 nm from 3 independent wells of cells 
in a 96-well plate. 
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Even with an incubation time of up to 4 days, we found that cell viability remained essentially 
unchanged. This confirms that the as-synthesized micelle-SNAs with biocompatible and 
biodegradable polycaprolactone cores do not have measurable cellular toxicity under these 
conditions. 
Conclusions. We have developed a novel strategy to construct a DNA-brush block copolymer 
based micelle-SNA with increased DNA surface density, which endows the new construct with 
properties similar to existing AuNP SNAs. Compared to the micelle-SNAs constructed from 
linear block copolymers, the DBBC-based micelle-SNAs exhibit a higher surface density of 
nucleic acids, a more negatively charged surface, a higher melting temperature, a more 
cooperative thermal denaturation profile, and more effective transfection agent-free cellular 
uptake. Importantly, the micelle-SNAs derived from the DNA-brush block copolymer show 
effective target gene knockdown in vitro.  
It is worthwhile to note that since the polymer core can gradually degrade under 
physiological conditions due to acid-catalyzed or esterase-catalyzed cleavage of the ester 
backbone bonds,221 these constructs open new avenues towards the controllable, continuous 
release of nucleic acids as regulatory agents for intracellular biological processes. Generally, in 
addition to PCL, a wide variety of polyesters, such as PLA222 and PLGA223 can be employed to 
initiate polymerization and then form DBBC-based SNAs consisting of different types of 
polyester cores. As such, the rate of particle degradation and nucleic acid release may be tuned 
by judicious monomer selection. We anticipate that this synthetic approach can be extended to a 
wide variety of polyesters to generate a new class of nanostructured materials with highly 
tailorable properties for various nucleic-acid based therapeutic approaches. In addition, this study 
further demonstrates that high surface density of nucleic acids on SNAs is directly correlated 
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with their cooperative binding behavior and cellular uptake, and that the self-assembled micelle 
SNAs undergo the same endocytotic intracellular trafficking pathway as classical AuNP SNAs. 
These results point to a shared recognition and uptake mechanism among all SNAs regardless of 
core composition.  
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Chapter 5 
 
CCR5 pre-targeted nanosystem for breast cancer imaging and therapy based 
on in vivo nucleic acid hybridization of spherical nucleic acid nanoclusters 
Abstract 
 Positron emission tomography (PET) probes for the sensitive and specific imaging of 
tumor tissue, relying on nucleic acid hybridization-based pre-targeting, were synthesized and 
evaluated in a mouse breast cancer model. Ultrasmall gold nanoclusters (< 3 nm) functionalized 
with a dense shell of phosphorodiamidate morpholino (PMO) oligonucleotides and targeting 
peptides were fabricated and their biodistribution was studied by alloying the gold core with 
64Cu. We hypothesized that the polyvalent nature of the spherical nucleic acid nanoclusters 
(AuNC SNAs) would enable faster and more specific pre-targeting than linear nucleic acid 
hybridization. The ability of these nanoclusters to capture and release a target oligonucleotide 
was evaluated in vitro and the kinetics of the target capture were determined. Injection of rodents 
with the AuNC SNAs followed by a complementary 64Cu-radiolabeled target oligonucleotide 
demonstrated specific localization of the probe at the tumor site after accumulation of the 
nanoclusters. The sequence-specificity of the capture process was also investigated. Studies are 
ongoing to assess the relative tumor accumulation of hybridized 64Cu-oligo compared to direct-
targeted 64CuAuNC SNAs and their targeting efficiency. 
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Introduction 
Imaging probes for sensitive and specific detection of biomarkers specifically expressed 
during breast cancer (BC) progression to determine the tumor burden, rate of progression, and 
metastatic sites are extremely important in clinical oncology.224-226 More importantly, the 
accurate determination of these biomarkers may help to design targeted therapeutic intervention 
to improve the treatment outcome of patients. Of the probes developed for BC imaging, positron 
emission tomography (PET) probes, especially PET radionuclide-labeled nanoparticles have 
been widely used for both pre-clinical and clinical investigations due to their enhanced targeting 
specificity, imaging sensitivity, and optimal target-to-background (T/B) contrast ratio.227-231 
However, non-specific tumor retention of nanoprobes may interfere with accurate quantitative 
measurements of the targets for precise diagnosis and specific treatment, especially for early 
stage tumors and metastases. 
Recently, the Liu laboratory developed an ultra-small gold nanocluster alloyed with 64Cu 
(64CuAuNC) for PET imaging of BC that shows low non-specific tumor retention and significant 
clearance from non-target tissues in vivo.232 This is a critical advance given the capability of 
these 64CuAuNCs to afford extended blood retention, radiolabel stability, and multivalency for 
improved targeting efficiency. Of the targets assessed as prognostic markers for BC, the 
chemokine receptor CCR5, is of interest due to the important role of CCL5/CCR5 axis in 
promoting tumor progression and metastases and the overexpression of CCR5 in tumors 
compared to normal breast tissue.233-241 For accurate detection of biomarkers expressed in 
tumors, the pre-targeting strategy is a promising method to improve detection efficiency and T/B 
contrast ratio compared to the direct targeting strategy. Pre-targeting involves the delivery of two 
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components: a non-radioactive tumor-seeking antibody, peptide, or particle, and subsequent late 
binding radiolabeled molecules that specifically interact with the pre-targeting moiety associated 
with the tumor.242-244 Of the pre-targeted systems, the nucleic acid hybridization strategy is 
attractive due to the fast hybridization kinetics, duplex stability, programmability, and 
reversibility.245 Gold was chosen as the core material for the initial development of this system 
due to the ease of rapidly prototyping different nanocluster designs using commercially-available 
thiolated oligonucleotides, polymers, and heterobifunctional linkers. 
 Numerous pre-targeting systems for in vivo PET imaging have been described based on 
both irreversible bioorthogonal “click” reactions as well as hybridization of nucleic acids. 
Irreversible pre-targeting reactions demonstrated to work in vivo include strained cyclooctyne-
azide cycloaddition and inverse electron-demand Diels-Alder cycloaddition.246-247 Nucleic acid 
hybridization strategies have been investigated employing linear DNA, locked nucleic acid 
(LNA), peptide nucleic acid (PNA), PMOs, and PMO dendrimers.248-252 We hypothesized the 
efficiency and specificity of the pre-targeting approach could be increased by introducing the 
pre-targeted oligonucleotides in the form of polyvalent spherical nucleic acid (SNA) 
nanoclusters. SNAs hybridize with target oligonucleotides much more rapidly than their linear 
counterparts and form more thermodynamically stable duplexes.253-254 In addition, presentation 
of a tumor-targeting ligand on the SNA surface allows for multivalent interaction with the 
disease-related receptor.255 
Herein, we report a CCR5 pre-targeted nanosystem using nonradioactive spherical 
nucleic acid nanoclusters (AuNC SNAs) with multiple copies of PEG-DAPTA and 
phosphorodiamidate morpholino (PMO) oligonucleotides conjugated to the surface (DAPTA-
PMO SNAs). PMO oligonucleotides were found to be far superior to conventional DNA 
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oligonucleotides for surface functionalization of the SNAs due to their enhanced blood 
circulation time. After the clearance of non-specifically retained AuNC SNAs, the SNAs bound 
on the surface of tumor cells can be illuminated following the administration of a complementary 
oligo radiolabeled with 64Cu through in vivo nucleic acid hybridization. We investigate the in 
vitro capture and release kinetics of this nanosystem and demonstrate the feasibility of this 
approach under physiological conditions. Further, we report the imaging of tumor tissue in a 
mouse breast cancer model with this pre-targeted nanosystem. While the focus of this research is 
on BC, this strategy potentially has wide applicability across a variety of diseases and will enable 
not only imaging, but tumor treatment with either cytotoxic drugs or therapeutic radionuclides. 
We further demonstrate the sequence-specificity of in vivo nucleic acid hybridization. 
Experimental Procuedures 
Materials and methods. DBCO-Cy5 was purchased from AAT Bioquest (Sunnyvale, CA). All 
reagents for oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) or 
ChemGenes (Wilmington, MA) and used according to manufacturer instructions. Custom 
phosphorodiamidate morpholino oligonucleotides were synthesized by Gene Tools (Philomath, 
OR). 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-NHS ester was 
purchased from Macrocyclics (Plano, TX). 64CuCl2 was produced on-site at the the Mallinckrodt 
Institute of Radiology (MIR) cyclotron facility and received as a stock solution in 0.1N HCl. 
Thiolated poly(ethylene glycol) derivatives were purchased from Creative PEGWorks (Chapel 
Hill, NC). Thiol-PEG5K-NHS ester was purchased from Nanocs (Boston, MA). Buffer solutions 
and cell culture media were purchased from Gibco (Gaithersburg, MD). D-Ala-Peptide-T-amide 
was custom-synthesized by CPC Scientific (Sunnyvale, CA). All other reagents were purchased 
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from Sigma-Aldrich (St. Louis, MO) and used as received. UV-Vis spectra were collected on a 
Cary 60 spectrometer in quartz cuvettes with a path length of 1 cm. TEM images were collected 
on a JEOL JEM-1400Plus transmission electron microscope. Dynamic light scattering (DLS) and 
zeta potential measurements were collected on a Zetasizer Nano ZS (Malvern Instruments Ltd). 
MALDI spectra were collected on an Applied Biosystems Voyager-DE STR MALDI-TOF 
spectrometer.  
Synthesis of DNA and RNA conjugates. DNA and 2´-OMe-RNA oligonucleotides were 
synthesized on a MerMade MM12 automated oligonucleotide synthesizer according to standard 
manufacturer protocols. OMe-RNA oligonucleotides were modified at the 5´ terminus with 
commercial monomethoxytrityl (MMT)-protected alkylamino, cyanine dye (Cy5), and PEG 
modifiers from Glen Research following manufacturer instructions. The OMe-RNA 
oligonucleotides were purified by reverse-phase HPLC on C18-coated silica with 
triethylammonium acetate buffer (0.03M, pH 7.0) and acetonitrile as the mobile phase ramping 
from 0-75% acetonitrile over 45 minutes. Fractions were pooled, lyophilized, and deprotected by 
treatment with 20% acetic acid for 1 hour at room temperature. The aqueous layer was washed 
3x with ethyl acetate, lyophilized again, and the resulting dried RNA characterized by UV-Vis 
and MALDI-TOF. Amino-modified OMe-RNA was reacted with an excess of DOTA-NHS ester 
in a mixture of 9:1 DMSO/4-methylmorpholine for 16 hours at room temperature. The reaction 
mixture was diluted with water and the crude product purified by ultrafiltration (3 kDa MWCO 
Amicon Ultra-4, Millipore) spinning at 7500 x g for 30 minutes. The retained OMe-RNA was 
suspended in 0.5 mL PBS buffer and purified once more by eluting through a NAP-5 desalting 
column (GE Life Sciences). Fractions were collected and pooled and the resulting DOTA-
modified OMe-RNA characterized by MALDI-TOF spectroscopy. 
85 
 
Synthesis of Cy5-PMO-OPSS. 5´-azide and 3´-ortho-pyridyl disulfide (OPSS) modified PMO 
oligonucleotide was purchased from Gene Tools. A stock solution of 1 mg DBCO-Cy5 in 1 mL 
anhydrous DMSO was prepared (~825 nmole/mL), and 80 µL of DBCO-Cy5 stock solution was 
mixed with 50 µL of PMO stock solution (1 mM in H2O). The mixture was shaken at 37° C 
overnight and diluted to 0.5 mL with 1X PBS. The crude reaction mixture was purified by size 
exclusion chromatography (NAP-5 column equilibrated in 1X PBS) to remove excess Cy5 and 
fractions collected and analyzed for purity by UV-Vis and MALDI-TOF.  
Radiolabeling of OMe-RNA-DOTA conjugates. In a typical experiment, 1 nanomole of OMe-
RNA-DOTA conjugate was mixed with 0.5-1 mCi of 64CuCl2 buffered with 0.1M NH4OAc (pH 
5.5) for 45 minutes at 45° C. The mixture was purified by repeated ultrafiltration (3 kDa 
MWCO) to remove unbound 64CuCl2 and a small portion of the retentate (3 µL) analyzed by 
radio-iTLC on silica gel with 1:1 10% NH4OAc buffer (pH 5.5) and methanol as the mobile 
phase. Radiochemical purity was assessed by integration of the TLC trace and the radiochemical 
yield and specific activity determined by the relative activity in the retentate vs the filtrate post-
purification.  
Synthesis of Thiol-PEG5K-DAPTA. To a 1.5 mL centrifuge tube was added 0.1 mL anhydrous 
DMSO, 19.3 mg of thiol-PEG5K-NHS (.004 mmol, 1 equiv.) and 10 mg of D-Ala-Peptide-T-
amide (DAPTA) (0.006 mmol, 1.5 equiv.) and the mixture shaken overnight at 37° C. 
Afterwards, the reaction mixture was diluted to 0.5 mL in 1X PBS and purified by gel filtration 
through a NAP-5 column (GE Healthcare Life Sciences) equilibrated with 1X PBS to remove 
excess DAPTA. Fractions were collected and pooled and the presence of conjugated DAPTA 
was established by UV-Vis (λmax ≈ 280 nm). The starting material and product were both 
analyzed by MALDI-TOF to confirm conjugation of DAPTA. The molecular weight distribution 
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of the starting material showed a maximum at 4830 Da, whereas the MW distribution of the 
product showed a maximum at 5776 Da, an overall shift consistent with the molecular weight of 
DAPTA appended to the polymer (MW = 856.9 g/mol).  
Synthesis of 64CuAuNC PMO SNAs. To a 20 mL glass vial with a magnetic stirrer was added 2 
mL of Milli-Q H2O, 8.6 µL of HAuCl4 stock solution (58 mM), 20 µL of IGEPAL CA-630 
solution (1% w/v in H2O), 50 µL PMO- OPSS stock solution (1 mM in H2O) and an equal 
amount of PEG5K-thiol stock solution (1 mM in H2O). Finally, 1 mCi of 
64CuCl buffered in 
0.1M NH4OAc (pH 5.5, 10 µCi/µL) was added and the reactants equilibrated with stirring for 30 
min at room temperature. For the synthesis of non-radioactive SNAs, the 64CuCl addition step 
was omitted. Next, 0.4 mL of sodium borohydride solution (40 mM in H2O) was added, causing 
the reaction mixture to turn a deep maroon color. The reaction mixture was stirred overnight 
followed by the addition of a second portion of sodium borohydride after 16 hours to ensure 
complete incorporation of 64Cu.  The particles were purified by ultrafiltration (Amicon Ultra-15 
30 kDa MWCO) with 3 x 4 mL washes of Milli-Q H2O spinning at 5000 x g. The retained 
particles were suspended in 1 mL H2O and radiochemical purity was assessed by radio-iTLC on 
silica gel with 1:1 10% NH4OAc (pH 5.5) and methanol as eluent and subsequent integration of 
the region(s) of interest. (Figure A5.2) For synthesis of 64CuAuNC DNA SNAs, the same 
procedure was followed as described for PMO SNAs, but instead, 3´-thiolated DNA was 
employed and the reaction mixture treated with 10 × 20 µL portions of 5M NaCl over ~ 12 h. 
Oligonucleotide capture studies. Non-radioactive PMO AuNC SNAs were synthesized as 
described above with a 1:1 ratio of PMO/PEG5K. For each batch of SNA, the extinction 
coefficient of the clusters at 520 nm was determined by UV-Vis and ICP-MS (Figure A5.3). 
Estimation of cluster core size by TEM was used to calculate the average number of Au atoms 
87 
 
per cluster according to the equation: atoms/cluster = (rcluster/ratom)
3. The calculated gold 
concentration in a sample of AuNCs was divided by the calculated number of gold atoms per 
cluster to give the concentration of clusters. In a typical synthesis, the number of gold atoms per 
cluster was approximately 700-800. Binding rates were determined using fluorescence 
measurements collected on an ISS K2 spectrometer with an excitation wavelength of 633 nm and 
an emission wavelength of 670 nm. For each binding curve, a solution of 500 pM Cy5-labeled 
antisense 2´-OMe-RNA in 1 mL 1X PBS was prepared in a polymethacrylate cuvette and 
allowed to warm to 37° C using the internal temperature controller. Then, the OMe-RNA 
solution was mixed with AuNCs and the change in fluorescence over time was measured in 2 
second increments. Bimolecular rate constants were derived by curve-fitting the acquired data 
for each nanocluster concentration tested (1, 2.5, 5, 10 and 25 nM) in triplicate. 
Cellular uptake and surface association studies. 4T1-Luc breast cancer cells (ATCC, 
Manassas, VA) were suspended in 1.5 mL microcentrifuge tubes containing Gibco DMEM 
phenol red-free media supplemented with 10% fetal bovine serum at a density of 5.0·105 
cells/tube. Cells were treated in triplicate with Cy5-labeled AuNC s at a total AuNC 
concentration of 4 nM per group and incubated for 24 hours. The media was removed and the 
cell pellets were washed with 3 × 1 mL portions of 1X PBS, resuspended in PBS by vigorous 
pipetting, then transferred to polystyrene tubes cooled in an ice bath for flow cytometry analysis. 
The relative fluorescence intensity of each group of cells was measured exciting at a wavelength 
of 633 nm on a BD FACSCalibur flow cytometer and the mean fluorescence intensity was 
calculated in triplicate. For cellular surface association studies, the same treatment protocol was 
followed, but the washed cell pellets were instead incubated with NaCN (10 mM in 1 mL PBS) 
for 30 minutes to allow dissolution of surface-associated AuNCs and subsequent release of 
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fluorophore labels. The fluorescence of the supernatants was measured on an ISS K2 
spectrometer with an excitation wavelength of 633 nm and an emission wavelength of670 nm. 
The relative fluorescence intensity was calculated in triplicate for each group of cells. 
Animal biodistribution studies. All animal studies were performed in compliance with 
guidelines set forth by the NIH Office of Laboratory Animal Welfare and approved by the 
Washington University Animal Studies Committee. Normal female C57BL/6 mice (Charles 
River Laboratory, Wilmington, MA) were used for the biodistribution studies. About 10 µCi of 
64Cu radiotracer in 100 μL saline (APP Pharmaceuticals, Schaumburg, IL) was injected via the 
tail vein. The mice were anesthetized with inhaled isoflurane and re-anesthetized before 
euthanizing them by cervical dislocation at each time point (1 h, 4 h, and 24 h post injection, n = 
3 per group). Organs of interest were collected, weighed, and counted in a well Beckman 8000 
gamma counter (Beckman, Fullerton, CA). Standards were prepared and measured along with 
the samples to calculate the percentage of the injected dose per gram of tissue (%ID/gram) and 
the and the percentage of injected dose per organ (%ID/organ). 
Micro-PET/CT imaging. The human breast cancer 4T1 cell line (ATCC, Manassas, VA) was 
cultured in RPMI 1640 medium supplemented with 10% FCS, 50 units mL−1 sodium penicillin, 
50 units mL−1 streptomycin sulfate, and 2 mM L-glutamine at 37 °C with 5% CO2. Female 
Balb/c mice at 6 weeks age (Charles River Laboratory, Wilmington, MA) were subcutaneously 
implanted with 3 × 106 4T1 cells into the right flank. The tumors were allowed to grow for 1 
week to reach a size of approximately 0.5–0.8 g before the mice were used for the PET/CT 
imaging studies. Mice were anesthetized with isoflurane and injected with 60-70 µCi of 64Cu 
radiotracer in 100 μL of saline via the tail vein. MicroPET scans were performed on either 
microPET Focus 220 (Siemens, Malvern, PA) or the Inveon PET/CT system (Siemens, Malvern, 
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PA) at 1 hour (20 min frame), 4 hours (30 min frame), and 24 hours post-injection (60 min 
frame). The microPET images were corrected for attenuation, scatter, normalization, and camera 
dead time and co-registered with microCT images. All of the PET scanners were cross-calibrated 
periodically. The microPET images were reconstructed with the maximum a posteriori (MAP) 
algorithm and analyzed using Inveon Research Workplace. The tumor uptake of 64Cu radiotracer 
was calculated in terms of the percent injected dose per gram (%ID g−1) of tumor tissue in three-
dimensional regions of interest (ROI) without the correction for partial volume effect. 
Results and Discussion 
Design of pre-targeting system. Our initial design for the catch-and-release pre-targeting 
nanosystem relied on SNA nanoclusters functionalized on their surface with a “sense” DNA 
sequence, and complementary 2´-OMe-RNA “antisense” and “comptetitor” strands to deliver the 
radionuclide cargo and subsequently release it, respectively.  (Table 5.1).  
Oligo Sequence (5´3´) FW 
(calc’d) 
[M-H]- 
(found) 
Sense* CCC AGC CTT CCA GCT CCT TGA-OPSS 7328 7329 
DOTA Antisense‡ DOTA-C12-UCA AGG AGC UGG AAG 5738 5764 
Cy5 Antisense‡ Cy5-UCA AGG AGC UGG AAG 5622 5607 
DOTA Scr Antisense‡ DOTA-C6-GGC GAA UAU GAC GGA 5654 5661 
Competitor‡ UCA AGG AGC UGG AAG GCU GGG 7165 7143 
Competitor* TCA AGG AGC TGG AAG GCT GGG 7274 7277 
Sense-Cy5* Cy5-CCC AGC CTT CCA GCT CCT TGA-OPSS 8641 8642 
Sense-PEG6† PEG6-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH 7211 7201 
Sense-PEG2000† PEG2K-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH 8867 8831 
Sense-DAPTA† DAPTA-C12-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH 7956 8012 
Table 5.1. Oligonucleotide sequences employed in this study with molecular weights determined by MALDI-TOF 
in negative ionization mode. Oligos denoted with a (*) = PMO, (†) = DNA, (‡) = 2´-OMe-RNA 
The sequence design was based on previously-reported studies with SNAs probing the kinetics 
of complementary strand displacement from duplexes bound to the SNA surface.256 We 
anticipated this approach would offer kinetics suitable for in vivo for pre-targeting experiments, 
as well as synthetic modularity, allowing the attachment of targeting moieties to the 5´ terminus 
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of the sense strand as well as varied cargoes to the 5´ terminus of the antisense strand. (Scheme 
5.1). 2´OMe-RNA was chosen for antisense and competitor oligonucleotides due to its enhanced 
nuclease resistance and the higher thermodynamic stability of DNA-RNA duplexes relative to 
DNA-DNA duplexes.257 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was 
selected as the chelating moiety for 64Cu due to its high association constant with Cu2+ ions,258 
commercial availability of functionalized derivatives (e.g. DOTA-NHS ester), and FDA approval 
for in vivo use in human clinical trials of radiopharmaceuticals.259 
 
Scheme 5.1. Proposed pre-targeting nanosystem based on in vivo SNA hybridization. 
Synthesis, characterization and biodistribution of SNAs. Radiosynthesis of 64Cu-alloyed 
AuNC SNAs was carried out via a one-pot sodium borohydride reduction of HAuCl4 in the 
presence of thiolated oligonucleotides adapted from previously reported methods (see 
Experimental Procedures).232 In vivo biodistribution experiments revealed that 64Cu-labeled 
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DNA-SNA nanoclusters exhibited very short circulation time in mice, with less than 1% of the 
injected dose remaining in the blood after one hour. Various lengths of PEG modification as well 
as the hydrophobic CCR5-targeting peptide (D-Ala-peptide T-amide) were presented on the 
surface of the SNA nanoclusters but none achieved blood circulation greater than 1% ID/gram 
after one hour. Our findings were consistent with the previously-reported in vivo biodistribution 
of 13 nm AuNP siRNA SNAs as determined by ICP-MS in non-tumor-bearing mice.79   
 
Figure 5.1. Blood circulation of AuNC SNAs 1 hour post-injection in female C57 mice.  Inset: structural 
comparison of PMO (left) and DNA oligos is shown (right) 
 None of the terminal DNA modifications tested ameliorated the rapid sequestration of the 
SNAs in the liver and spleen, suggesting that the negative charge of DNA is not effectively 
screened by conjugation of neutral molecules (PEG, peptides) to the 5´ DNA terminus. These 
results demonstrated that a DNA SNA-based pre-targeting strategy is hampered by the 
pharmacokinetics of the DNA-SNA nanoconstruct, including virtually any other in vivo 
application requiring delivery to specific tissues. We saw this as an opportunity to expand the 
versatility of the SNA platform for in vivo biomedical use, and our findings prompted us to alter 
the chemical composition of the oligonucleotides on the surface of the SNA nanoclusters.
 Switching the particle-bound nucleic acids from DNA to PMO oligonucleotides 
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dramatically improved the blood circulation time, but also required the inclusion of thiol-PEG in 
the reaction mixture to coadsorb on the surface of the nanoclusters, rendering them colloidally 
stable. PMO-only nanoclusters irreversibly aggregated upon attempted purification. A ratio of 
1:1 PEG (average Mn = 5000) to PMO oligonucleotide was found to provide the longest blood 
circulation time, sufficient for in vivo pre-targeting studies (Figure 5.1 and Figure A5.1).  
 Blood circulation of the 1:1 PEG5K/PMO SNAs was 19.0 ± 1.9 %ID/gram at 1 hour 
post-injection, compared to 0.62 ± 0.05% ID/gram for PEG6-capped DNA SNAs. The blood 
circulation of the PMO SNA remained high at 4 hours (12.0 ± 0.22% ID/gram) and 24 hours (5.5 
± 1.2% ID/gram). After one hour, the majority of the DNA SNA ended up in the liver (38.3 ± 
1.2% ID/gram) and spleen (29.5 ± 4.1% ID/gram), compared to the PMO SNA which exhibited 
much lower liver and spleen accumulation (17.0 ± 1.8 and 4.7 ± 0.3% ID/gram, respectively).   
 
Figure 5.2. Core size, hydrodynamic diameter, and zeta potential characterization of AuNC PMO SNAs.  
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 The PEG/PMO-decorated AuNC SNAs were characterized by DLS, TEM, and zeta 
potential measurements (Figure 5.2). The loading of PMO oligonucleotides and PEG on the 
surface of the clusters was determined to be 22 ± 2 PMOs/cluster and 19 ± 1 PEG/cluster. The 
gold core was dissolved with sodium cyanide, and the released ligands were isolated by size-
exclusion chromatography and quantified by UV-Vis spectroscopy. The loading is higher than 
the reported values for DNA SNAs of similar size (~5 oligonucleotides per 2 nm cluster), 
presumably due to the absence of electrostatic repulsion between the surface ligands.260   
 
Figure 5.3. Biodistribution of 64Cu-OMe-RNA radiotracer (top) and PMO SNA nanocluster (bottom) in female C57 
mice 1 hour post-injection. Biodistribution of nanoclusters at longer time points is shown in Figure A5.1. 
The biodistribution of the antisense 64Cu-DOTA-2´-OMe-RNA strand was also studied. In a 
typical experiment, the free DOTA-RNA was incubated with 64CuCl2 for 45 minutes at 45° C 
and purified by ultrafiltration, with a radiochemical yield of 87-88% and radiochemical purity 
>99%. On average, the  measured specific activity of 64Cu-DOTA-RNA was between 0.5-1 
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mCi/nmol depending on the amount of 64Cu added to the reaction mixture, consistent with 
literature reports.261 The pharmacokinetics of the 64Cu-DOTA-2´-OMe-RNA were consistent 
with the behavior of similar short 2´-modified oligonucleotides, exhibiting rapid excretion with 
most of the tracer residing in the kidneys (21.1 ± 2.6 %ID/gram) after one hour (Figure 5.3).262  
Binding kinetics measurements. With both the pre-targeting SNAs and the cargo in hand, we 
then set out to determine the kinetics of the antisense strand capture in vitro at physiologically 
relevant concentrations via fluorescence quenching experiments. AuNC SNA concentrations 
ranging from 1 to 25 nM were examined for their ability to capture 500 pM of antisense Cy5-
2´OMe-RNA in 1X PBS at 37° C, relying on the quenching of the dye label upon hybridization 
to the nanocluster to monitor the rate of the reaction. The change in fluorescence over time was 
measured and kobs for each binding curve was determined by fitting the data to the simple 
association kinetics equation: 
([𝐓𝐚𝐫𝐠𝐞𝐭 𝐁𝐨𝐮𝐧𝐝] =  [𝐓𝐚𝐫𝐠𝐞𝐭 𝐁𝐨𝐮𝐧𝐝]𝐦𝐚𝐱 ·  𝒆𝒌𝒐𝒃𝒔  ·  𝐭𝐢𝐦𝐞)  
  
Figure 5.4. Binding kinetics measurements. Left: Representative linear fit to determine kon (slope) and koff 
(intercept). Right: Binding curves of antisense Cy5-OMe-RNA to AuNCs at different AuNC concentrations. 
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Both kon and koff were determined using a linear fit (kon = (kobs - koff) / [SNAs]). From our 
measurements, the bimolecular rate constant for capture of the antisense strand kon by the PMO 
SNA nanoclusters was 3,360,000 ± 234,000 M-1 s-1, several orders of magnitude faster than 
previously described DNA-SNA systems as well as commercially-available bioorthogonal click 
reaction pairs such as the tetrazine-cyclooctene Diels-Alder cycloaddition (Figure 5.4).263 The 
dissociation constant Kd of the hybridized OMe-RNA was 1.70 ± 0.12 nM, indicating that 
hybridization would indeed be achievable under physiological conditions. 
 Further, the ability of the competitor to release the hybridized antisense strand was 
studied. While introduction of an excess (10 µM) of 2´-OMe-RNA competitor strand resulted in 
the displacement of ~50% of the bound antisense strand from the SNA surface, addition of the 
same amount of PMO competitor strand possessing an identical sequence released 100% of the 
bound antisense strand, likely due to the lack of charge repulsion experienced by the incoming 
competitor strands. (Figure 5.5).  
 
Figure 5.5. Representative capture-and-release curves of PMO AuNC SNAs. At t=0 s, 10 nM of nanocluster is 
added to a solution of 500 pM antisense Cy5-OMe-RNA. At t=300 s, various concentrations of competitor 
oligonucleotide are added and the fluorescence is restored as the OMe-RNA is displaced from the nanocluster. 
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 Taken together, our results indicated that the pre-targeting nanosystem would be effective 
under in vivo conditions due to both the favorable biodistribution of the key components (SNA 
and tracer) as well as their rapid binding kinetics under dilute conditions.  
Cellular uptake experiments. Internalization of the SNAs into the tumor cells poses a potential 
issue as they would be rendered unavailable to bind the circulating antisense strand in vivo. DNA 
SNAs are well-known for their ability to rapidly cross cell membranes without transfection 
agents, thus, this phenomenon would have to be avoided in the case of PMO SNAs, since linear 
oligonucleotides do not cross cell membranes readily.68  
 
Figure 5.6. Uptake of PMO and DNA AuNCs with varying surface ligand coating in 4T1 breast cancer cells. 
To test whether internalization would prohibit effective in vivo hybridization, 4T1 breast cancer 
cells were treated in suspension with several variants of fluorescent cyanine dye-labeled 
nanoclusters to deconvolute the relative contribution of the oligonucleotides as well as the 
targeting ligand DAPTA to their degree of internalization. Nanoclusters were prepared with 
surfaces bearing the sense sequence DNA-Cy5, PMO-Cy5/PEG5K (1:1), or PMO-Cy5/PEG5K-
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DAPTA (1:1) and incubated for 24 hours with 4T1 cells at a nanocluster concentration of 4 nM. 
The cells were subsequently washed and then analyzed by flow cytometry. The DNA SNAs, as 
expected, exhibited the highest degree of internalization followed by PMO SNAs (Figure 5.6). In 
addition, to probe the surface association of the various nanocluster types with 4T1 cells, the 
same experiment was repeated, but after 24 hours, the cells were gently washed with PBS and 
the suspended cell pellet treated with 10 mM NaCN for 30 minutes to dissolve any surface-
associated gold nanoclusters, releasing the Cy5 label into solution. The results of this experiment 
indicated that the DAPTA-functionalized nanoclusters had the highest surface association with 
the cells (Figure 5.7), as expected due to the role of DAPTA as an antagonist of the CCR5 
receptor.264 These results suggested that the majority of PMO SNAs would not be trapped inside 
cellular compartments and would be available for hybridization at the tumor site.  
 
Figure 5.7. 4T1 cell surface association of DNA and PMO AuNCs with varying surface ligand coating after NaCN 
treatment of cell pellet. 
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Optimization of pre-targeting schedule. Successful PET imaging of tumor tissue by in vivo 
pre-targeting is highly dependent on the wait time (pretargeting interval) between the injection of 
the non-radioactive targeting capture moiety and the radioactive cargo. Our initial in vivo pre-
targeting experiment was designed to determine the optimal time between introduction of the 
SNA and the radioactive cargo to allow hybridization of 64Cu-OMe-RNA at the tumor site. 4T1 
tumors were implanted in the mammary fat pads of female BALB/c mice and SNA nanoclusters 
functionalized with 1:1 PMO/PEG5K-DAPTA were injected one week post-implant. The total 
dosage of SNA delivered per animal was 11.4 µg (Au basis) or roughly 72.5 pmol (SNA basis). 
Then, mice were injected with 60-70 µCi of 64Cu-OMe-RNA tracer (specific activity = 577 
µCi/nmol) either 4 hours, 24 hours, or 48 hours post-injection of SNA (n=3 mice in each group). 
Mice were imaged by PET/CT 4 hours post-injection of the 64Cu-OMe-RNA tracer and the 
tumor uptake quantitated for each injection delay timepoint. Activity of the 64Cu-OMe-RNA 
tracer in the tumor increased from 0.39 ± .05% ID/gram at 4 hours to 1.85 ± 0.32% ID/gram at 
24 hours and remained constant at 1.98 ± 0.45% ID/gram after 48 hours (Figure 5.7). This initial 
result was promising as it suggested that tumor accumulation of the 64Cu-OMe-RNA tracer was 
indeed dependent on presence of SNA at the tumor site. The rapid elimination of 64Cu-OMe-
RNA would preclude its nonspecific tumor accumulation in the absence of SNA pre-treatment. 
 Likewise, the tumor-to-muscle ratio more than doubled from approximately 2.5 in the 4 
hour group to ~6.6 in the 48 hour group, demonstrating increased tumor imaging sensitivity with 
an increased pre-targeting interval. Consistent with previous studies with 64CuAuNCs in a 
different tumor model, we observed low non-specific tumor retention of the tracer by the 
enhanced permeability and retention (EPR) effect (<3% ID/gram).232  
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Figure 5.8. Left: Representative axial PET images of tumor-bearing mice at different pretargeting intervals. Right: 
coronal image of mouse in 4-hour group showing tumor localization.  
 
Figure 5.9. Accumulation of 64Cu-OMe-RNA tracer in tumor tissue at different pretargeting intervals. 
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To expand on this preliminary study, we conducted a repeat experiment to confirm the sequence-
specificity of the tumor accumulation of the tracer. Two groups of 4T1 tumor-bearing mice (n=3 
each) were pre-treated with injections of SNA nanoclusters functionalized with 1:1 
PMO/PEG5K-DAPTA (52.6 µg injected per animal, Au basis).  
 
 
 
 
Figure 5.10. Tumor uptake of active vs. scrambled 64Cu-OMe-RNA tracer in 4T1 tumor mice. Top: Representative 
PET images of mice receiving either scrambled or active tracer. Left: Quantification via PET/CT imaging. Right: 
Quantification via post-PET biodistribution. Starred bars (**) indicate statistical significance (p < 0.05). 
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24 hours later, the mice were injected with 60-70 µCi of 64Cu-OMe-RNA tracer, with 3 mice 
receiving the complementary antisense OMe-RNA sequence and 3 mice receiving the scrambled 
sequence. Mice were imaged by PET/CT 4 hours post-injection of the 64Cu-OMe-RNA tracer 
and the tumor uptake quantitated for each animal. Subsequently, the animals were sacrificed, 
tumors were excised, and the activity of 64Cu-OMe-RNA in the tumors and other organs of 
interest was determined by gamma counting (Figure 5.10-5.11). Finally, the tumors were 
sectioned and imaged by autoradiography to visualize the relative tumor uptake of the antisense 
and scrambled tracers (Figure 5.12). 
 
 
 
Figure 5.11. Post-PET biodistribution quantification of 64Cu-OMe-RNA tumor uptake. Left: Percent injected dose 
per organ (tumor). Right: Tumor-to-muscle ratio calculated by post-PET biodistribution. Starred bars (**) indicate 
statistical significance (p < 0.05). 
The results of this study indicated that the complementary 64Cu-OMe-RNA tracer exhibits 
increased tumor uptake relative to the scrambled tracer, confirming that the pre-targeting effect is 
sequence-specific. The PET image quantification, post-PET biodistribution, and autoradiography 
results suggest a 1.5 to 2-fold increase in tumor accumulation of the complementary tracer 
compared to the scrambled tracer. Post-PET biodistribution indicated that the complementary 
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tracer exhibited %ID/tumor nearly double than that of the scrambled tracer. The tumor-to-muscle 
ratio was slightly higher for the complementary tracer, but not significant. (Figure 5.11). 
 
Figure 5.12. Representative images of tumor sections and their activity visualized by autoradiography. 
 Due to the stability of the PMO/OMe-RNA duplex, we believe the tumor-to-muscle ratio 
can increased by extending the imaging time post-injection of the 64Cu-OMe-RNA, permitting 
further clearance of non-specifically bound oligonucleotides.  
 Studies are ongoing to evaluate direct-targeted PMO SNAs alloyed with 64Cu (and no 
subsequent oligonucleotide tracer) co-functionalized with PEG5K or PEG5K-DAPTA in 
comparison to the pre-targeting system. An additional control group consists of 64Cu-OMe-RNA 
tracer with no prior SNA injection. We hypothesized that the PET signal arising from direct-
targeted 64CuAuNC SNAs would be less intense than that of pre-targeted SNAs hybridized with 
the radiotracer OMe-RNA, since the alloying of 64Cu in the core of the nanocluster typically only 
results in trace 64Cu incorporation (roughly one 64Cu atom per 105 atoms of gold, with a typical 
cluster comprising fewer than 1000 atoms).232 In contrast, each PMO-functionalized SNA has 
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over 20 potential binding sites for a complementary radiolabeled oligonucleotide. Therefore, the 
pre-targeting strategy has the potential to deliver significantly more 64Cu atoms per nanoparticle 
to the tumor site. At the time of writing. these experiments are ongoing in tumor-bearing mice 
using the 4T1 BC model. 
Conclusions. We have developed a novel nanocluster SNA-based pre-targeting nanosystem 
aimed at sensitive and specific imaging of tumor tissue via in vivo nucleic acid hybridization in a 
mouse breast cancer model. Ultrasmall nanoclusters bearing neutral PMO oligonucleotides were 
synthesized and characterized, and their pharmacokinetics far outperformed analogous 
nanoclusters with conventional charged DNA oligonucleotides. To our knowledge, this is the 
first example of SNAs exhibiting extended blood retention time in vivo, enabling a variety of 
new applications not limited to PET imaging. The in vitro kinetics of the capture process 
between the pre-targeted AuNC SNAs and the complementary 2´-OMe-RNA oligonucleotide 
were investigated. The rate constant for the hybridization between the SNA and the target RNA 
was superior to existing covalent pretargeting reactions, with single-digit nanomolar binding 
affinity between the SNA and its complementary oligonucleotide. Effective release of the cargo 
was also demonstrated by introduction of a longer competitor oligonucleotide. Cell culture 
studies indicated that the AuNC PMO SNAs did not exhibit significant internalization in the 
targeted cancer cell line and the presence of the targeting peptide DAPTA on the nanocluster 
increased cell surface association, suggesting the nanoclusters would be available to capture 
complementary oligonucleotides circulating in the blood. Lastly, preliminary in vivo PET 
imaging studies indicated that injection of AuNC SNAs followed by complementary 64Cu-
labeled OMe-RNA resulted in increased PET signal in the tumor tissue as the time interval 
between SNA injection and radiolabel injection was increased, and this effect was sequence-
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specific, though the tumor-to-muscle ratios were not statistically different. Studies are ongoing to 
confirm that the pre-targeting system results in a stronger PET signal and higher tumor-to-
background ratio relative to direct-targeted 64CuAuNC SNAs, and that DAPTA-functionalized 
SNAs exhibit superior tumor localization compared to non-targeting SNAs. Future directions 
will focus on further improving the kinetics of hybridization by employing an all-PMO 
nanosystem (nanocluster, tracer, and competitor) as well as studying PEGylation of the tracer to 
improve circulation time and subsequent tumor accumulation. In addition, the tracer cargo may 
be altered to instead deliver treatment in the form of a cytotoxic drug or a therapeutic 
radionuclide. 
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Chapter 6 
 
Synthesis, characterization, and biological properties of neutral 
phosphorodiamidate morpholino (PMO) spherical nucleic acids 
Abstract 
 Herein, we describe the synthesis, characterization, and biological properties of spherical 
nucleic acids (SNAs) constructed from neutral phosphorodiamidate morpholino (PMO) 
oligonucleotides and Au nanoparticles (AuNPs).  Commercially available, monodisperse AuNPs 
were chosen as the core material to ensure reproducibility and uniformity of the synthesized 
nanoconstructs. The surfaces of AuNPs (10 nm diameter) were densely modified with a mixture 
of thiolated PMOs and poly(ethylene glycol), resulting in colloidally stable SNAs resistant to 
aggregation at high salt concentrations (up to 0.5M NaCl). The PMO SNAs, as compared with 
conventional SNAs, exhibit the ability to more rapidly capture complementary RNA 
oligonucleotides, a consequence of their neutral charge. PMO SNAs, when hybridized with 
complementary SNAs, exhibit cooperative thermal denaturation transitions, consistent with 
dense PMO loading. Finally, PMO SNAs were found to undergo cell uptake without transfection 
agents in a manner analogous to their DNA counterparts, affording a novel nanosystem for PMO 
delivery without the use of potentially toxic cationic polymers or cell penetrating peptides. Their 
ability to engage in intracellular gene regulation is also examined. 
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Introduction 
 Spherical nucleic acids (SNAs) have emerged as a powerful new class of functional 
nanomaterials that have shown promise in supramolecular assembly,265-267 disease biomarker 
detection, 268-269 and antisense gene regulation.270 The classical SNA structure is comprised of a 
gold nanoparticle core functionalized with a dense layer of deoxyribonucleic acid (DNA) 
oligonucleotides.51 A wide range of core materials have been explored including transition 
metals,174-175, 271 metal oxides,272-275 organic materials,276-277 metal-organic frameworks,278 and 
self-assembling micellar structures.279 The high negative surface charge arising from the 
phosphate backbone of the nucleic acid shell imparts colloidal stability due to electrostatic 
repulsion between particles. In solution, SNAs behave much differently from linear nucleic 
acids. SNAs exhibit cooperative binding and narrow thermal melting transitions when hybridized 
with complementary particles or oligonucleotides. They are also able to cross cell membranes 
without the need for ancillary transfection agents despite their high negative charge density. 
Consequently, they are valuable tools for manipulating cellular processes through gene 
regulation,280 drug delivery,281 and immunomodulation.282  For the cell types studied thus far, the 
active uptake of SNAs occurs via endocytosis, triggered by their binding to class A scavenger 
receptors (SR-As) expressed on the surface of mammalian cells.183, 283  Although SNAs made 
from naturally-occurring oligonucleotides (DNA, RNA) have shown commercial promise as 
diagnostic, therapeutic, and research tools, their biodistribution in vivo suffers from low blood 
circulation due to their high surface charge, resultant protein corona accumulation, and 
susceptibility to nuclease degradation.284-285 Therefore, for therapeutic purposes, SNA research 
has focused heavily on topical or local uses (e.g. the skin, immunomodulation)286-287 and on the 
development of new strategies for improving blood circulation and nuclease resistance.288-289  
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Consequently, we decided to explore and develop a new form of SNA, based upon neutral PMO 
oligonucleotides. PMOs have shown promise as intracellular gene regulation agents due to their 
extremely high binding affinity for target mRNA.290 They can be synthesized using 
straightforward phosphoramidite chemistry.291 The higher binding affinity of morpholino 
oligonucleotides for complementary oligonucleotides, which is reflected in a higher duplex 
melting temperature, is due to the lower charge repulsion between the hybridized strands.292 
However, linear PMOs, like linear DNA and RNA oligonucleotides, do not readily enter cells 
without the aid of cationic transfection agents,293-294 electroporation,295 or cell-penetrating 
peptides296-297 and therefore alone are not suitable for regulating intracellular processes, 
including gene knockdown.  Gold nanoparticle-PMO conjugates have been described, with one 
example requiring both a targeting protein for cellular uptake and subsequent localized 
photocleavage to release PMOs into the cytosol.298 Other examples of AuNP-PMO conjugates 
have been described for the purpose of detecting target oligonucleotides in colorimetric assays, 
but such particles are not stable in solutions of high ionic strength and require a potentially toxic 
fluorosurfactant during the synthesis procedure.299-300 Herein we describe methods for the one-
step synthesis of the first PMO SNAs stable under physiological conditions, their hybridization 
behavior with complementary oligonucleotides and SNAs, their unusual ability to cross cell 
membranes without the need for ancillary transfection agents, and their intracellular gene 
regulation behavior.  
Experimental Procedures 
Materials and methods. Citrate-capped gold nanoparticles were purchased from Ted Pella 
(Redding, CA). PMO oligonucleotides were purchased from Gene Tools (Philomath, OR). 
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Uranyl acetate solution was purchased from Electron Microscopy Sciences (Hatfield, PA). DNA 
and RNA synthesis reagents were purchased from ChemGenes (Wilmington, MA) and Glen 
Research (Sterling, VA). Buffer solutions and cell culture media were purchased from Gibco 
(Gaithersburg, MD). Thiolated poly(ethylene glycol) derivatives were purchased from Creative 
PEGWorks (Chapel Hill, NC) and Nanocs (Boston, MA). DBCO-Cy5 was purchased from AAT 
Bioquest (Sunnyvale, CA). All other reagents were purchased from Sigma-Aldrich (St. Louis, 
MO) and used as received. UV-Vis spectra and thermal denaturation curves were collected on an 
Agilent Cary 5000 UV-Vis spectrometer in quartz cuvettes having a path length of 1 cm. 
Dynamic light scattering (DLS) and zeta potential measurements were collected on a Zetasizer 
Nano ZS (Malvern Instruments Ltd). TEM images were collected on a JEOL JEM-1400Plus 
transmission electron microscope and samples were negative-stained with 2% uranyl acetate 
solution for 30 seconds prior to imaging. 
Synthesis of PMO SNAs. To a 15 mL centrifuge tube was added 20 µL 1 mM PMO-ortho-
pyridyl disulfide (OPSS) solution, 2.0 mL Ted Pella 10 nm gold colloid (~9 nM stock solution), 
20 µL IGEPAL CA-630 1% solution,100 µL 0.1M phosphate buffer (pH 7.4), and the mixture 
shaken for 30 minutes at room temperature to allow adsorption of the PMO oligonucleotides by 
spontaneous dissociation of the ortho-pyridyl disulfide bond to release 2-thiopyridone. Then, 20 
µL of 1 mM thiolated PEG solution (Mn = 1000, 3000 or 5000 Da) was added and shaking 
continued overnight at room temperature. The particles were purified by ultrafiltration using an 
Amicon Ultra-15 100kDa MWCO filter with 3 x 4 mL washes of Milli-Q H2O spinning at 5000 
x g. The particles were resuspended in 1.0 mL Milli-Q H2O and the concentration was calculated 
by UV-Vis by measuring the absorbance at 520 nm and dividing by the known extinction 
coefficient for 10 nm AuNPs (9.6·107 L·mol-1·cm-1). DNA-functionalized SNAs were 
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synthesized according to established protocols employing gradual NaCl addition to increase the 
loading density of oligonucleotides.53 
Synthesis of Cy5-PMO-OPSS. 5´-azide and 3´-ortho-pyridyl disulfide (OPSS) modified PMO 
oligonucleotide was purchased from Gene Tools. A stock solution of 1 mg DBCO-Cy5 in 1 mL 
anhydrous DMSO was prepared (~825 nmole/mL), and 80 µL of DBCO-Cy5 stock solution was 
mixed with 50 µL of PMO stock solution (1 mM in H2O). The mixture was shaken at 37° C 
overnight and diluted to 0.5 mL with 1X PBS. The crude reaction mixture was purified by size 
exclusion chromatography (NAP-5 column equilibrated in 1X PBS) and fractions collected and 
analyzed for purity by UV-Vis and MALDI-TOF.  
Synthesis of DNA and 2´-OMe-RNA oligonucleotides. DNA and 2´-OMe-RNA 
oligonucleotides were synthesized on a MerMade MM12 automated oligonucleotide synthesizer 
according to standard manufacturer protocols. OMe-RNA oligonucleotides were modified at the 
5´ terminus with a commercial cyanine dye (Cy5) modifier from Glen Research following 
manufacturer instructions. DNA oligonucleotides were prepared using a 3´ disulfide-bearing 
linker attached to the solid support and modified at the 5´ terminus with a single hexaethylene 
glycol (Spacer 18) linker from Glen Research. The oligonucleotides were purified by reverse-
phase HPLC on C18-coated silica with triethylammonium acetate buffer (0.03M, pH 7.0) and 
acetonitrile as the mobile phase ramping from 0-75% acetonitrile over 45 minutes. Fractions 
were pooled, lyophilized, and deprotected by treatment with 20% acetic acid for 1 hour at room 
temperature. The aqueous layer was washed 3x with ethyl acetate, lyophilized again, and the 
resulting dried nucleic acids resuspended in Milli-Q H2O and the oligonucleotide concentration 
quantified by UV-Vis.  
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Oligonucleotide capture studies. Binding rates were determined using fluorescence 
measurements collected on an ISS K2 spectrometer with an excitation wavelength of 633 nm and 
an emission wavelength of670 nm. For each binding curve, a solution of 100 pM Cy5-labeled 
antisense 2´OMe-RNA in 1 mL 1X PBS was prepared in a polymethacrylate cuvette and allowed 
to warm to 37° C using the internal temperature controller. Then, the RNA solution was mixed 
with PMO SNAs and the change in fluorescence over time was measured in 1 second 
increments. Bimolecular rate constants were derived by curve-fitting the acquired data for each 
SNA concentration tested (50, 100, 200, 400 and 800 pM) in triplicate. For comparison purposes, 
DNA SNAs were likewise tested at concentrations of 100, 200, 400, and 800 pM. 
Cellular uptake studies. All microscopy was performed using an Nikon A1Rsi laser scanning 
confocal microscope exciting at 640 nm. KB human carcinoma cells were plated on glass bottom 
dishes coated with polylysine (MatTek Corporation, glass no. 1.5), and allowed to grow 
overnight. Attached cells were treated with 300 µL of cell culture medium containing either Cy5-
PMO labeled SNAs at a total concentration of 2.5 nM or single-stranded PMO oligonucleotides 
at 250 nM. After 2 and 24 hr intervals, Hoechst 33258 nuclear stain (10 µM, Life Technologies) 
was added and further incubated for 15 min, washed, and then imaged by confocal fluorescence 
microscopy (exciting at 405 and 640 nm). Images were collected in both normal and Z-stack 
mode to verify that particles were present in the cytosol rather than the exterior of the cell 
membrane. Images were analyzed using Nikon NIS-Elements software. For flow cytometry, 
SKOV3 ovarian cancer cells (ATCC) were plated in a 24-well plate at 20,000 cells per well in 
DMEM media (Gibco) containing 10% fetal bovine serum (Hyclone) and 1% penicillin-
steptomycin (ThermoFisher).  Twelve-hours later, cells were treated in triplicate with either Cy5-
labeled SNAs at a total SNA concentration of 2.5 nM or Cy5-labeled single-stranded PMO 
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oligonucleotide at a concentration of 250 nM and incubated for 24 hours. The media was then 
removed, the cells were washed with 3 × 1 mL portions of 1X PBS, trypsinized to remove from 
the plate, and pelleted by centrifugation at 350 x g for 5 minutes.  The cells were then fixed in 
4% paraformaldehyde for 30 minutes at 4 degrees Celsius, washed with 1X PBS, then transferred 
to polypropylene tubes for flow cytometry analysis. The relative fluorescence intensity of each 
group of cells was measured exciting at a wavelength of 633 nm on a BD LSR II flow cytometer 
and the mean fluorescence intensity was calculated in triplicate. 
Gene knockdown studies. SKOV3 ovarian cancer cells (ATCC) were plated in a 24-well 
plate at 100,000 cells per well in DMEM media (Gibco) containing 10% fetal bovine serum 
(Hyclone) and 1% penicillin-steptomycin (ThermoFisher).  Twelve-hours later, cells were 
washed and treated in triplicate with SNAs (SNA1, SNA2, or non-targeting SNA) at a total SNA 
concentration of 2.5 nM in Optimem.  A positive control of an antisense DNA targeting 
HER2 was used by treating cells with 250 nM DNA in lipofectamine 2000.  Twenty-four hours 
later, Optimem was removed and fresh growth media (DMEM, 10% FBS, 1% PenStrep) was 
added for another 48 hours.  The total treatment time was 72 hours from the initial 
transfection.  The media was then removed, the cells were washed with 3 × 1 mL portions of ice 
cold 1X PBS, then the cells were lysed with 100 uL of RIPA lysing buffer.  Lysates were 
collected and total protein concentration was measured with the BCA Protein Assay Kit.  Equal 
amounts of protein (10 ug) were fractionated by a 4-20% precast SDS-polyacrylamide gel (Bio 
Rad) and transferred to a nitrocellulose membrane (Thermo Fisher).  The membranes were then 
immediately blocked with 1%BSA in PBST for 1 hour at room temperature.  Primary rabbit 
antibodies against HER2 and GAPDH (1000:1, Cell Signaling) and flourescently tagged anti-
rabbit IgG secondary antibodies (20000:1, LI-CORE) were used to detect proteins.  The 
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membranes were imaged using a 800 nm laser on the Odyssey Infrared Imaging System (LI-
Core) and quantified using ImageJ. 
Results and Discussion 
 DNA SNAs remain colloidally stable without the need for co-adsorption of poly(ethylene 
glycol) (PEG) or other stabilizing polymers on the gold surface. The charge density of the DNA 
alone is sufficient to render the DNA SNAs colloidally stable due to their strong interparticle 
repulsion in solution.53 In contrast, we found that SNAs synthesized with a surface layer 
consisting of 100% PMO oligonucleotides led to irreversible aggregation upon purification, 
irrespective of the oligonucleotide sequence or length. Thus, we experimented with co-
adsorption of thiolated PEGs along with ortho-pyridyl disulfide (OPSS)-modified PMOs. We 
discovered that PEG-thiol (Mn = 5000), mixed 1:1 with 21-mer PMO oligonucleotides in the 
presence of citrate-capped gold nanoparticles, afforded colloidally-stable PEG/PMO SNAs 
capable of hybridizing with complementary oligonucleotides and SNAs. (Table 6.1)  
Oligo Sequence (5´3´) 
Sense (PMO) CCC AGC CTT CCA GCT CCT TGA-OPSS 
Sense (DNA) PEG6-CCC AGC CTT CCA GCT CCT TGA-PEG6-Thiol 
Sense-Cy5 (PMO, DNA) Cy5-CCC AGC CTT CCA GCT CCT TGA-Thiol 
Antisense (2´-OMe-RNA) Cy5-UCA AGG AGC UGG AAG 
MeltA (PMO, DNA) TTA TAA CTA TTC CTA AAAAA-Thiol 
MeltB (PMO, DNA) TAG GAA TAG TTA TAA AAAAA-Thiol 
HER2-Target1 (PMO) CAT GGT GCT CAC TGC GGC TCC GGC-OPSS 
HER2-Target2 (PMO) AGG GAG CCG CAG CTT CAT GTC TGT G-OPSS 
NonTarget (PMO) CCT CTT ACC TCA GTT ACA ATT TAT A-OPSS 
HER2-Target (DNA) CTC CAT GGT GCT CAC 
Table 6.1. Oligonucleotide sequences employed in this study. PEG6 = 6 ethylene glycol unit spacer 
The as-synthesized PEG/PMO SNAs had a mean hydrodynamic radius of 25.0 ± 6.0 nm 
(compared to 8.6 ± 2.3 nm for citrate-capped AuNPs) and a surface zeta potential of -6.9 ± 4.9 
mV (compared to -22 ± 5.6 mV for citrate-capped AuNPs), consistent with their neutral overall 
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charge. To test their colloidal stability, the PEG/PMO SNAs were stored at increasing salt 
concentrations (up to 0.5M NaCl) and examined for signs of aggregation by dynamic light 
scattering (DLS). After three months, no aggregation or sedimentation was observed (Figure 6.1, 
A6.1). The observed hydrodynamic radii of the SNAs was consistent with TEM images 
produced by negative staining with 2% uranyl acetate (Figure 6.2). 
 
Figure 6.1. Hydrodynamic radius of PMO SNAs vs NaCl concentration. No statistically significant change in dH 
was observed, indicating a lack of salt-induced aggregation. 
 
Figure 6.2. TEM image of PEG5K/PMO SNAs stained with uranyl acetate. 
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PEGs of lower molecular weights (3000 and 1000 Da) were also examined for their ability to 
stabilize PMO SNAs. The PEG/PMO SNAs exhibited similar stability with 3 kDa PEG-thiol 
mixed in a 1:1 ratio, but a 1:1 ratio of 1 kDa PEG-thiol was insufficient to stabilize PMO SNAs 
against aggregation when centrifuged at 20,000 x g for 90 minutes (Figure 6.3). This issue was 
remedied by increasing the molar ratio of PEG to PMO to 2:1. Most importantly, we found that 1 
kDa-PEG modified PMO SNAs were capable of spontaneous cell uptake, whereas 5 kDa-PEG 
modified PMO SNAs showed no apparent uptake by confocal microscopy (vide supra). 
Therefore, both the colloidal stability and cellular interaction of PMO SNAs is dependent on the 
length and quantity of co-adsorbed PEG molecules. 
 
Figure 6.3. 1:1 PEG/PMO SNAs after centrifugation and resuspension in water. PEG molecular weight from left to 
right: 1000 Da, 3000 Da, 5000 Da 
For the 1:1 PEG5K/PMO SNAs employed for biophysical studies, the average loading of PMO 
oligonucleotides and PEG molecules was determined by co-adsorbing PEG5K-fluorescein and 
21-mer morpholino oligonucleotides on 10 nm citrate-capped AuNPs. Three separate batches 
were prepared by the same protocol and 0.5 mL aliquots of each were subsequently dissolved by 
sodium cyanide, the gold salts removed by gel filtration, and the relative amounts of each surface 
ligand determined by UV-Vis spectroscopy. The average loading of PMOs per 10 nm AuNP was 
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103 ± 7 molecules, whereas the average loading of PEG5K per AuNP was 72 ± 15 molecules, 
indicating a roughly equal surface absorption ratio.  
 Kinetics experiments to determine the rate of capture of complementary charged 
olignucleotide (15-mer 2´-OMe-RNA) by uncharged PMO SNAs under physiologically relevant 
conditions were carried out. Briefly, a solution of 100 pM target oligonucleotide (OMe-RNA 
labeled with Cy5 at the 5´ terminus) was prepared in 1X PBS and allowed to equilibrate to 37° 
C. The fluorescence intensity of the solution was monitored after an aliquot of 21-mer 
PEG5K/PMO SNAs was added to the solution, resulting in quenching of the Cy5 fluorescence 
by the AuNP core as the OMe-RNA molecules hybridized to the particles. The experiment was 
repeated at varying concentrations of SNAs (from 50 pM to 800 pM) to determine the rate 
constant kon for the capture process. (Figure 6.4). In all cases, the number of morpholino strands 
was in excess relative to the concentration of the target OMe-RNA, since each AuNP bears 
approximately 100 strands of PMO oligonucleotides. 
 
 
Figure 6.4. Binding kinetics measurements. Left: Dependence of kobs on concentration of SNAs. Slope of line = kon, 
intercept = koff. Each data point represents the average of three kinetics experiments. Right: Representative binding 
curves of Cy5-antisense OMe-RNA to PMO SNAs at different SNA concentrations. 
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We determined that PMO SNA captures the target with a bimolecular rate constant kon of 
approximately 78,300,000 ± 1,040,000 M-1s-1, with a dissociation constant (Kd) of 52.6 ± 5.6 pM, 
which is many orders of magnitude higher than state-of-the-art in vivo click reactions such as the 
tetrazine-cyclooctene Diels-Alder cycloaddition and potentially one of the most rapid 
bioorthogonal conjugation methods discovered to date.301 PMO SNAs also capture target 
oligonucleotides far more rapidly than DNA SNAs at similar concentrations, on the order of 
seconds rather than minutes.254 A DNA SNA loaded with the same oligonucleotide sequence 
(113 ± 17 DNA/AuNP) captured the complementary OMe-RNA at a rate of 2,250,000 ± 230,000 
M-1s-1, over 30 times slower under identical conditions (Figure A6.2). The associated Kd for the 
OMe-RNA hybridized to the DNA SNA was 61.3 ± 2.3 nM.  
SNA Kd kon (M-1 s-1) Surface 
Area 
Oligo density PEG density 
AuNP PMO 
SNA (10 nm) 
 
52.6 pM 78,300,000 1257 nm2 13.6 pmol/cm2 9.5 pmol/cm2 
AuNC PMO 
SNA (2.5 nm) 
1.7 nM 3,360,000 79 nm2 46.3 pmol/cm2 40.0 pmol/cm2 
DNA SNA  
(10 nm) 
61.3 nM 2,250,000 1257 nm2 14.9 pmol/cm2 - 
Table 6.2. Rate constants, dissociation constants, and surface coverage of SNAs discussed in Chapters 5 & 6. 
 Comparison of the rate constants and association constants for the SNAs discussed in this 
chapter and the previous chapter reveals that the Kd value for the smaller (<3 nm) PMO-based 
nanocluster falls in the middle ground between the 10 nm PMO SNA and the 10 nm DNA SNA 
(Table 6.2). There is less correlation in terms of the bimolecular rate constant kon. Due to the 
higher radius of curvature of the smaller nanoclusters, their surface coverage of oligonucleotides 
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is significantly higher than that of the 10 nm particles.302 Other authors investigating the 
hybridization kinetics of surface-bound PMOs found that lower surface coverage led to faster 
hybridization rates, which implies that the steric crowding on the smaller nanoclusters inhibits 
the capture of incoming antisense strands.303 
 It is worth noting that the calculated rate constant for the 10 nm PMO SNA system 
approaches the maximum experimentally observed rates associated with diffusion-limited 
reactions (109 M-1 s-1) and the capture of oligonucleotides seemingly occurs faster than the rate at 
which the nanoparticle can diffuse through solution.304 Pinhiero et. al. describe a similar 
oligonucleotide capture system with DNA nanoparticles.305 The authors describe nucleation as 
"the rate-limiting step of hybridization at low DNA concentrations (nano- to micromolar range), 
relying on efficient collisions between the interacting strands. The subsequent strand realignment 
and fully complementary base-pairing are expected to proceed at a much faster rate." In our 
system, the fluorescence quenching of the reporter dye occurs only after the antisense strand has 
fully hybridized to the SNA. Consequently, hybridization of the antisense strand to the 
nanoparticle can be simplified to a bimolecular process with an overall rate constant of kon. A 
large excess of capture strands on the gold nanoparticles further simplifies the kinetics and 
allows application of a pseudo-first-order kinetic model. Consistent with pseudo-first-order 
behavior, the reaction was carried out at several different SNA concentrations with a constant 
antisense strand concentration. The linear dependence of the rate constant as a function of the 
SNA concentration confirms that a pseudo-first order kinetic model is valid.  
 Typical bimolecular rate constants for hybridization of unmodified DNA duplexes are on 
the order of 106 M-1 s-1.306 We observed a similar kon rate for a corresponding DNA SNA.  In 
contrast, the hybridization of neutral oligos such as PNA with complementary DNA have been 
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shown to be accelerated by as much as 500-fold compared to DNA-DNA duplexes.307-308 
Therefore, our observation that a PMO SNA captures a complementary oligonucleotide with 
kinetics over 1 order of magnitude higher than a DNA SNA agrees with literature reports of 
hybridization rates between DNA and neutral oligonucleotides in solution. An additional factor 
to consider is the polyvalent nature of the PMO SNAs. From the perspective of the incoming 
antisense oligonucleotide, it encounters an extremely high local concentration of its 
complementary strand when colliding with a PMO SNA, leading to enhanced kinetics due to the 
increased likelihood of a successful hybridization event. The same rate enhancement effect is 
often observed when nanoparticles are functionalized with multiple copies of enzymes, despite 
the slower diffusion of the NP-enzyme nanoconstruct.309 Therefore, we believe the dramatic 
enhancement in kinetics calculated for the PMO SNA target capture are consistent with 
phenomena already observed by other authors. 
 Since DNA hybridization typically exhibits anti-Arrhenius behavior resulting in small or 
negative activation energies,310-311 we calculated the activation energy of capture of a 
complementary 2´OMe-RNA strand by a PMO SNA. The bimolecular rate constant for OMe-
RNA hybridization was measured at 10°C and the activation energy (Ea) for hybridization was 
estimated using the Arrhenius equation. We calculated Ea to be roughly 3.7 kcal/mol, which is 
below the activation energy for the diffusion of liquid water (~4.2 kcal/mol),312 indicating that 
the hybridization process on the SNA is indeed diffusion-controlled (See Chapter 6 Supporting 
Information). 
 Having compared the kinetics of PMO SNA hybridization with complementary 
oligonucleotides to DNA SNAs, we then examined their hybridization behavior with 
complementary SNAs. DNA SNAs and PMO SNAs were synthesized bearing 20-mer sequences 
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with a complementary 15-base-pair overlap. The thermal denaturation behavior of the DNA-
DNA SNA pairs and PMO-DNA SNA pairs were compared. Briefly, the SNAs were mixed in 
the presence of salt (0.5M NaCl) and allowed to aggregate. Then, the mixture was gradually 
heated and monitored by UV-Vis to determine the melting temperature (Tm) of the nanoparticle 
aggregates. As a control, DNA and PMO SNAs with identical sequences were also mixed to 
eliminate the possibility of non-specific aggregation. The resulting thermal denaturation curves 
demonstrate that the morpholino SNA and DNA SNA pair, compared to DNA-DNA SNA pair, 
exhibits a dramatically increased melting temperature (>20° C) as well as a sharper melting 
transition. In contrast, the non-complementary pairs did not interact (Figure 6.5). At the same salt 
concentration (0.5M NaCl), the single-stranded DNA-DNA and DNA-PMO duplexes exhibited 
broad melting transitions. Interestingly, the melting temperature of the free DNA-DNA duplex 
exceeded that of the DNA-PMO duplex at 0.5M NaCl, since the Tm of DNA-PMO duplexes 
remains constant irrespective of salt concentration, whereas the Tm of DNA-DNA duplexes 
increases nearly linearly with salt concentration. In comparison, the DNA-DNA duplex had a 
lower Tm than the DNA-PMO duplex in 1X PBS. (Figure 6.6).
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Figure 6.5. Melting behavior of DNA and PMO SNAs bearing complementary or non-complementary sequences. 
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Figure 6.6. Melting behavior of single-stranded DNA-DNA and DNA-PMO pairs at either physiological salt 
concentration (1X PBS) or elevated salt concentration (0.5M NaCl) 
 Cellular uptake experiments by flow cytometry and confocal microscopy in ovarian 
cancer cells (SKOV-3) and human cervix carcinoma (KB) cells demonstrated high uptake of 
PEG1K/PMO SNAs compared to single-stranded PMOs. The SNAs for cellular uptake were 
prepared with a 2:1 ratio of PEG1K to PMO oligonucleotides, and consequently their colloidal 
stability was enhanced. Typically, cationic peptides or polyamines must be appended to 
morpholinos to aid their passage across the cell membrane. Here, we demonstrate that their dense 
loading onto a gold nanoparticle is sufficient for transfection to occur. In SKOV-3 cells, uptake 
of Cy5-labeled PEG/PMO SNAs (2.5 nM) was approximately two orders of magnitude higher 
than the free Cy5-labeled single-stranded morpholino (250 nM) (Figure 6.7). This same trend is 
observed when comparing the cellular uptake of single-stranded DNA to DNA-SNAs. Cellular 
uptake in KB cells was monitored by confocal microscopy at 2 hours and 24 hours, showing low 
uptake of PMO SNAs at the 2-hour time point but significant punctate perinuclear fluorescence 
at the 24-hour time point, suggesting their uptake occurs via an endocytotic pathway (Figure 
6.8).314 We hypothesize that the shorter PEG is necessary to expose the nucleobases so that they 
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can  be recognized by cell surface receptor(s), as the outer nucleobase presentation on analogous 
DNA SNAs has been shown to strongly influence their rate of endocytosis.71 
 
Figure 6.7. Uptake of PMO SNAs in SKOV-3 ovarian cancer cells after 24 h compared to single-stranded PMO 
oligonucleotides. Note that the y-axis is represented on a logarithmic scale for clarity. 
 
Figure 6.8. Confocal microscope images of cellular uptake in KB cells. Treatments: 250 nM single-stranded Cy5-
PMO after a) 2 hours and b) 24 hours, or PMO SNA (2. nM) after c) 2 hours and d) 24 hours, or DNA SNA after e) 
2 hours and f) 24 hours. Bright-field images are omitted for clarity. 
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Figure 6.9. Comparison of uptake of PEG5K/PMO and PEG1K/PMO SNAs. a) Uptake in KB cells of 
PEG5K/PMO SNA after 24 hours. b) Uptake in KB cells of PEG1K/PMO SNA after 24 hours. 
Having demonstrated the ability of morpholino-SNAs to enter cells without the need for special 
transfection agents or chemical modification of the oligonucleotides, we then turned our 
attention to the ability of the SNA to deliver antisense morpholinos to the cytosol to knock down 
disease-related mRNA. In contrast to other commonly employed antisense oligonucleotides such 
as siRNA, which trigger mRNA degradation by RNAse H, morpholino oligonucleotides exert 
their gene knockdown effect by tightly binding to the target mRNA and physically blocking 
movement of the ribosome to prevent transcription. For this purpose, we chose two previously-
validated morpholino sequences targeting human epithelial growth factor 2 (HER2).315 HER2 is 
upregulated in a variety of cancer cell lines and is involved in signal transduction pathways 
leading to malignant cell growth.197  
 PMO SNAs were synthesized by modifying citrate-capped gold nanoparticles with a 2:1 
ratio of 1000 Da PEG-thiol and PMO-OPSS oligonucleotides. Active HER2-targeting SNAs 
(Target1-SNA, Target2-SNA) along with SNAs bearing an inactive PMO sequence (NonTarget-
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SNA) were synthesized and purified (Table 6.1). As a positive control, a validated DNA 
sequence for antisense HER2 knockdown was also synthesized for delivery with the commercial 
transfection agent Lipofectamine®. SKOV-3 cells were treated for 24 hours with 2.5 nM of 
either Target1-SNA, Target2-SNA, or NonTarget-SNA. The cells treated with Lipofectamine 
and DNA were dosed according to manufacturer instructions (25 nM DNA).  
Analysis of HER2 protein expression by Western blot revealed high knockdown efficiency 
(>50%) for both targeted PMO SNAs (Figure 6.10), with some non-specific knockdown by the 
non-targeting SNA. However, the positive control failed to produce any knockdown effect. At 
the time of this writing, studies are currently underway to test other positive controls such as 
cationic morpholinos or morpholinos co-delivered with Endo-Porter, a novel peptide developed 
by Gene Tools that facilitates endosomal escape of PMOs and other bioactive macromolecules. 
 
Figure 6.10. Analysis of HER2 expression in SKOV-3 cells by Western Blot. Lighter bands correspond to higher 
knockdown. Numerical values represent % inhibition of gene expression.  
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Conclusions. In conclusion, we have described a method for the synthesis of stable 
phosphorodiamidate morpholino oligonucleotide (PMO)-functionalized gold nanoparticles that 
exhibit the hallmark properties of spherical nucleic acids traditionally made from charged 
oligonucleotides (DNA, RNA) as opposed to neutral oligonucleotides. Co-functionalization of 
the gold surface with PEG enhances the colloidal stability of the nanoparticles and renders them 
resistant to salt-induced aggregation. Crucially, the PEG does not interfere with the ability of the 
PMO SNAs to capture target oligonucleotides or hybridize with complementary SNAs. We 
discovered that the cellular uptake of the PMO SNAs depends on the length of the co-adsorbed 
PEG, with shorter PEG lengths permitting cellular uptake.  The uptake of PMO SNAs was nearly 
two orders of magnitude higher than their single-stranded PMO counterparts, an effect also 
observed with DNA SNAs compared to their corresponding linear DNA oligonucleotides. The 
cellular internalization of PMO SNAs could be visualized by flow cytometry and confocal 
microscopy in two different mammalian cell lines. Lastly, we examined the ability of the PMO 
SNAs to engage in gene knockdown without the use of any ancillary transfection agents. Our 
preliminary data suggests that PMO SNAs, once internalized, can interact with cytosolic mRNA 
to engage in intracellular gene regulation. Studies are ongoing to validate useful positive controls 
for quantitative comparison of knockdown efficiency with previously-described antisense 
therapies, and further improve the knockdown effect with more careful tailoring of the PMO 
SNA surface composition and the mRNA targeting sequences. 
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Chapter 7 
 
Conclusions 
 This dissertation has focused on the development of nucleic acid-based nanoconstructs 
for cancer therapy and imaging, specifically those fabricated with a dense shell of 
oligonucleotides arranged around a spherical core (SNAs). The first part of the dissertation 
(Chapters 2 and 3) emphasizes the use of metal coordination bonds as a chemically orthogonal 
strategy to assemble oligonucleotides into nanoparticles, and the behavior of coordination 
polymer-DNA based nanoconstructs in cell culture, specifically their cellular uptake and gene 
knockdown capability. A metal-ligand pair based on FDA-approved materials was identified 
comprising Fe3+ and 3,4-hydroxypyridinones (3,4-HOPOs) with excellent stability and 
biocompatibility. Direct crosslinking of DNA strands via Fe3+-mediated assembly afforded 
nanoparticles and/or metallogels depending on the reaction conditions. The nanoparticles 
assembled in this fashion did not exhibit spontaneous cellular uptake, demonstrating the 
importance of controlled oligonucleotide geometric orientation in the nanoparticle fabrication 
process. However, direct cationic lipid transfection of the particles indicated they were capable 
of intracellular gene regulation, indicating that the metal-ligand modification of DNA did not 
affect its binding with mRNA. Thus, a new bioorthogonal assembly strategy for DNA 
nanomaterials was discovered for further elaboration. 
 The coordination chemistry developed in Chapter 2 was further adapted to create Fe3+ 
infinite coordination polymer (ICP) nanoparticles which could be subsequently functionalized 
with oligonucleotides. In Chapter 3, synthesis of colloidal nanoscale ICPs was achieved by 
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mixing a rigid azide-modified bis-hydroxypyridinone ligand with Fe3+ under dilute aqueous 
conditions, leading to the spontaneous formation of “clickable” azide-bearing nanoparticles. The 
N3-ICP particles were converted into SNAs in a single step by the addition of NaCl and 
cyclooctyne-functionalized DNA. The resulting DNA-ICP particles exhibited all the typical 
properties of conventional AuNP-based SNAs, including cooperative thermal denaturation 
curves with complementary particles, active cellular uptake, and intracellular gene knockdown. 
Furthermore, the pH-sensitive nature of the Fe3+ coordination bonds employed in the particle 
core afforded a novel means for biodegradation of the nanoparticles once internalized into cells. 
In summary, the studies in Chapters 2 and 3 established a new bioorthogonal and biocompatible 
metal-mediated assembly method for nucleic acids. We also expect this research to lead to 
development of other therapeutic and diagnostic agents; for example, the Fe3+ ICPs described in 
Chapter 3 could also function as magnetic resonance imaging (MRI) contrast agents.316 Due to 
the propensity of the ditopic HOPO ligand to precipitate metal ions out of solution, such 
molecules may also find applications in heavy metal sequestration and waste remediation.317-318 
 Chapter 4 also explores the fabrication of biocompatible cores for SNAs, this time relying 
on self-assembly of micelle-type structures to present a dense orientation of oligonucleotides on 
the particle surface. A rational design approach was also employed in this case, relying on FDA-
approved polycaprolactone (PCL) as the core material due to its biocompatibility and pH-
dependent hydrolysis in aqueous media. Two separate versions of the micelle SNA were 
synthesized to study the effect of DNA density on the particle surface: a linear block copolymer 
of PCL and DNA as well as a brush-type block copolymer comprising PCL bearing multiple 
DNA strands at the terminus. In agreement with the previous studies, it was found that the DNA-
brush block copolymer (DBBC) had enhanced polyvalent behavior compared to the linear DNA 
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block copolymer (DBC) owing to the higher DNA surface density. Specifically, the Tm of the 
DBBC SNA with complementary SNAs was enhanced compared to its linear counterpart, as well 
as the degree of cellular internalization and target mRNA knockdown. The studies in Chapters 3 
and 4 add further evidence to the central hypothesis that the properties of SNAs are largely core-
independent and instead rely on the spherical orientation of nucleic acids on the surface as well 
as the density of their packing. Visualization of the cellular uptake of coordination polymer and 
micelle-cored SNAs by confocal microscopy strongly suggested that they are recognized and 
endocytosed in the same manner as traditional AuNP SNAs. Although recognition by a receptor 
other than SR-A cannot be ruled out, the polyvalent nature of the particles and their 3D 
geometric orientation of DNA is clearly responsible for their cellular uptake.  
 Chapters 5 and 6 see a return to the use of gold as the core material for SNAs, as the 
primary interest was in the functionality of their attached oligonucleotides and the need for rapid 
prototyping and synthesis of modified particles using established gold-thiol chemistry. The work 
in Chapter 5 was motivated by an idea to develop an in vivo pretargeting system for PET 
imaging based on SNAs, because of their polyvalency and rapid hybridization kinetics. This 
work led to the serendipitous discovery that replacement of charged nucleic acids (RNA, DNA) 
on the SNA surface with neutral phosphorodiamidate morpholino oligonucleotides (PMOs) 
markedly affects their biophysical properties while still retaining the key behaviors normally 
associated with SNAs such as cooperative hybridization and spontaneous cell entry, as further 
investigated in Chapter 6. Chapter 5 focuses on the use of ultrasmall (<3 nm) SNA gold 
nanoclusters (AuNCs) as in vivo PET imaging agents via a pre-targeting strategy. Gold was 
chosen since it can be alloyed with radionuclides for PET imaging and biodistribution studies, as 
well as the ease of surface functionalization with a variety of commercially available thiolated 
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ligands. Our initial design of the system relied on tumor-targeted sub-3 nm DNA SNA AuNCs 
designed to capture and release a radiolabeled oligonucleotide in vivo, allowing for sensitive and 
specific detection of tumor tissue. Specifically, our interest was in targeting the CCR5 receptor 
which is over-expressed in triple-negative breast cancer. Alloying of the gold core with 64Cu 
enabled tracking of the biodistribution of the SNAs by PET. Though the DNA AuNC SNAs 
demonstrated acceptable capture kinetics in vitro, their pharmacokinetic behavior was hampered 
by extremely short blood circulation time and high accumulation in the liver and spleen. Trial-
and-error led to the replacement of DNA with PMO oligonucleotides, dramatically enhancing the 
blood circulation time of the 64CuAuNCs. This discovery alone could have a major impact on the 
use of SNAs as therapeutic agents, as current human and animal trials rely on charged SNAs of 
which only a small fraction may end up in the desired organ(s).  
 With PMO AuNCs in hand, we carried out kinetics experiments to determine the rate of 
capture of a complementary RNA strand. Under physiological conditions, the bimolecular rate 
constant for hybridization of the target RNA far exceeded our expectations, outperforming 
covalent bioorthogonal click reactions employed in other pretargeting systems. We also studied 
the cellular interactions of PMO AuNCs, specifically to determine whether they would be 
internalized like their DNA counterparts or remain on the cell surface to facilitate hybridization 
with a circulating radiotracer. We found that the PMO AuNCs were internalized to a lower 
degree than DNA AuNCs, and additionally, inclusion of a CCR5-targeting ligand on the particle 
surface enhanced cell suface association. Our positive in vitro data prompted us to examine the 
pretargeting system in vivo with tumor-bearing mice. 
 We first tested the ability of PMO AuNCs to localize in tumor tissue and capture a 
complementary radiolabeled RNA strand. Our initial studies focused on optimizing the 
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pretargeting interval of the nanosystem, also known as the “wait time” between injection of the 
non-radioactive capture component and the radioactive cargo. In tumor-bearing mice, our results 
indicated that little 64Cu-RNA accumulated in the tumor tissue four hours after injection of the 
PMO AuNC, with a significant increase in tumor accumulation observed after a 24 or 48 hour 
delay. Using this information, we designed a study to determine the specificity of the 
pretargeting effect by comparing the tumor uptake of a scrambled radiolabeled RNA to a 
complementary radiolabeled RNA, demonstrating that the complementary sequence exhibits 
superior tumor accumulation. In addition, we also sought to compare the pretargeting system 
against a direct-targeted 64CuAuNC SNA, to evaluate whether the pretargeting strategy improves 
tumor uptake of 64Cu and reduces background in off-target organs relative to delivering the 
radiotracer directly in nanocluster form. In addition, their targeting efficiency against CCR5-
positive tissue must be compared to particles without the CCR5-targeting peptide. This study is 
currently underway. Future directions for this work include improving the kinetics of 
hybridization by employing an all-PMO nanosystem (nanocluster, tracer, and competitor) as well 
as studying PEGylation of the tracer to improve circulation time and subsequent tumor 
accumulation. The nanosystem is not limited to PET imaging either; the tracer or competitor 
cargo can also deliver treatment in the form of a cytotoxic drug or a therapeutic radionuclide. 
Lastly, we expect that the biocompatibility of the pre-targeting nanoclusters can be further 
enhanced by switching to copper cores, which do not accumulate in the body like gold, yet can 
still be alloyed with 64Cu for biodistribution and imaging studies.319 
 In Chapter 6, we decided to look more in depth at the chemical and biological properties 
of PMO-based SNAs using the typical array of experiments used to study SNA behavior. 
Commercially-available 10 nanometer gold nanoparticles were used as the core material to 
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generate monodisperse and easy-to-characterize PMO SNAs as a proof of concept, though as 
discussed in previous chapters, virtually any core material could be utilized for clinical 
translation of these nanoconstructs. Optimization of synthetic conditions gave colloidally stable 
PMO SNAs which resisted salt-induced aggregation and exhibited neutral surface charge as 
evidenced by zeta potential measurements. Loading studies indicated that approximately 100 
PMO oligonucleotides could be adsorbed on the surface of a 10 nanometer particle along with 
PEG to impart colloidal stability. The binding kinetics of the resulting PMO SNAs were studied, 
demonstrating exceptionally fast bimolecular rate constants for hybridization with 
complementary oligonucleotides and picomolar binding affinity. The kinetics of the 10 nm PMO 
SNAs were compared with analogous DNA SNAs as well as the AuNC-based SNAs. 
Oligonucleotide charge and surface density were found to play a major role in the rate constants 
for complementary strand capture, in agreement with previously published studies on DNA 
hybridization kinetics with charged and neutral oligonucleotides both in solution and on surfaces. 
The PMO SNAs also exhibited cooperative melting behavior and enhanced melting transition 
temperatures when hybridized with complementary SNAs. These results prompted us to 
investigate whether PMO SNAs interact with cells in the same way as DNA SNAs. 
 Optimization of synthetic conditions (namely the molar ratio and length of coadsorbed 
PEG) afforded PMO SNAs capable of spontaneous cellular entry. By flow cytometry and 
confocal microscopy, PMO SNAs were found to enter mammalian cells at a greater rate than 
single-stranded PMOs, in an analogous fashion to DNA SNAs. Compared to DNA SNAs, 
however, PMO SNAs showed lower cellular uptake. Despite this difference, we decided to test 
the antisense gene regulation capability of PMO SNAs due to the differing mechanisms of gene 
knockdown between DNA and PMOs. DNA binding to mRNA triggers degradation of the 
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mRNA by RNAse-H, preventing ribosomal translation. In contrast, PMO binding to mRNA 
prevents movement of the ribosome along the mRNA, effectively blocking transcription. Due to 
the much higher affinity of PMOs for complementary mRNA, we theorized that PMO SNAs 
could engage in gene regulation despite their modest uptake relative to DNA SNAs. Preliminary 
results suggest the PMO SNAs are capable of knockdown and further studies are underway to 
compare against a panel of validated positive controls targeting the same messenger RNA.  
 Hopefully, this dissertation has conveyed the importance of nucleic acids in 
nanomedicine, as both chemically programmable structural components and bioactive 
therapeutic agents. Specifically, the discovery of spherical nucleic acids has advanced the field 
of biomedicine and enabled new clinically-relevant technologies in gene regulation and 
biodetection. The work presented herein demonstrates a multi-faceted approach to further 
increase the clinical viability of SNAs as therapeutic, diagnostic, and bioorthogonal conjugation 
agents. Detailed studies of SNA core composition as well as oligonucleotide composition have 
led to a better understanding of the basic chemical properties of SNAs, their cellular interactions, 
and their in vivo pharmacokinetics. Ideally, these advances will have major implications in the 
treatment and detection of diseases, especially those with poor prognoses, such as cancers of the 
brain, lung and breast, as well as other afflictions associated with significant mortality such as 
cardiovascular disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy. 
  
132 
 
Appendix  
Chapter 2 Supporting Information 
Figure A2.1. MTT toxicity assay of 3,4-HOPO chelating ligands. 
 
Figure A2.2. Change in hydrodynamic radius upon formation of Fe(DNA)3 complex. 
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Figure A2.3. Crystal structures of Λ-mer-FeL3 (left) and Δ-fac-FeL3 (right) 
 
Figure A2.4. Diffusion-limited binding kinetics of free ligand with Fe3+ compared to DNA-ligand conjugate. 
Conditions: 100 µM ligand, 33 µM Fe(NO3)3·9H2O, 1X PBS, RT 
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Figure A2.4. Uptake of different fractions of fluorescein labeled DNA-Fe3+ nanoparticles in C166 cells compared to 
the free DNA.  
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Chapter 3 Supporting Information 
 
Figure A3.1. MTT toxicity assay of DABA-bis-HP-azide ligand. 
  
Figure A3.2. Left: titration of ligand 4 with iron(III). Right: determination of ε460 of ICP-N3 particles 
  
Figure A3.3. Left: EDX spectrum of background (copper TEM grid and aluminum holder) and ICP-N3 particle. 
Right: TEM image of the same ICP-N3 particle sample. Scale bar = 100 nm. 
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Figure A3.4. AFM and TEM images of ICP particles. Top left: Bare N3-ICPs. Top right: DNA-ICPs. Bottom left: 
Bare N3-ICPs. Bottom right: DNA-ICPs.  
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Figure A3.5. Thermal denaturation of complementary (left) and non-complementary (right) ICP/AuNP-DNA 
conjugates. 
ICP Particle Type ζavg (mV) dH (nm) %A260 DNA 
Bare -18.9 14 ± 2 - 
A-ICP -35.2 31 ± 10 53% 
B-ICP -33.7 32 ± 8 60% 
Her2-ICP -31.1 31 ± 13 61% 
NonTarget-ICP -33.4 31 ± 11 65% 
Cy5-ICP -23.7 n/a* 14% 
Table A3.1. Characterization of DNA-ICP conjugates. *DLS was not suitable for analysis of Cy5-containing 
particles. AFM imaging revealed particles with a similar size distribution. (37 ± 11 nm, NanoScope Analysis 
software) 
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Figure A3.6. Top left: SKOV-3 ovarian cancer cells cells treated with fluorescent ssDNA. Top right: cells treated 
with DNA-ICPs bearing the same sequence. Bottom: flow cytometry analysis comparing untreated SKOV-3 cells 
with Cy5-labeled ssDNA, AuNP-SNAs, and DNA-ICPs. All treatments 100 nM total (DNA basis). 
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Figure A3.7. Cell uptake (C166 mouse endothelial) of Cy5-labeled AuNP-SNAs (top left) compared to free DNA 
(top middle), unreated cells (top right), and CCT-Cy5-DNA ICPs (bottom). All treatments 100 nM total (DNA 
basis). 
 
 
Figure A3.8. Cell uptake (HeLa cells) of Cy5-labeled AuNP-SNAs (top left) compared to free DNA (top middle), 
unreated cells (top right), and CCT-Cy5-DNA ICPs (bottom). All treatments 100 nM total (DNA basis). 
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Chapter 4 Supporting Information 
 
Figure A4.1. Synthetic scheme depicting (a) brush DNA-g-PCL-b-PCL and (b) linear DNA-b-PEO-b-PCL and their 
self-assembly into micelle-SNAs. 
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Figure A4.2. The 1H NMR spectra of (a) poly(α-N3-ɛCL-b-ɛCL) and (b) N3-PEO-b-PCL. 
 
Figure A4.3. FT-IR spectra of as-synthesized azide modified diblock copolymer poly(α-N3-g-ɛCL-b-ɛCL). 
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Figure A4.4. GPC analysis of as-synthesized poly(α-N3-ɛCL-b-ɛCL) and poly(α-Cl-ɛCL-b-ɛCL). 
 
Figure A4.5. Poly acrylamide gel electrophoresis (PAGE) analysis of the DNA-brush block copolymer under 
denaturing condition (1×TBE buffer with 8 M urea, heated at 95 ºC for 10 min before running the gel). (a) Excess 
DNA strands were used to conjugate on the poly(α-N3-ɛCL-b-ɛCL), the as-synthesized DBBC based micelle-SNAs 
could not run into the gel, indicating the high stability of the micelle-SNA structure; (b) With lower ratio of 
DNA/PCL (~ 3) for DNA conjugation, a series of DNA-PCL conjugate strands can be observed on the gel, 
demonstrating  multiple DNA strands can really grafted on a PCL chain. The majority of the DNA-polymer 
conjugates still remain as micelles which migrate extremely slowly on the gel. 
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Figure A4.6. Zeta Potential of linear DBC micelle-SNA (upper panel) and DBBC micelle-SNA (lower panel). 
 
Figure A4.7. AFM images of linear DBC based micelle-SNA and DBBC micelle-SNA samples deposited on mica. 
(a) AFM image of linear DBC based micelle-SNA samples; (b) AFM image of DBBC micelle-SNA samples. 
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Figure A4.8. Cryo-EM image of linear DBC based micelle-SNA nanoparticles frozen in vitreous ice. 
 
Figure A4.9. Particle concentrations of micelle-SNAs determined by Nanoparticle Tracking Analysis (NTA) using 
the Nanosight Instrument. (a) Screenshot of scattering pattern for 20 nm AuNP-SNA particles tracked by NTA, the 
standard sample concentration is 10 nM; (b) Screenshot of scattering pattern for DBBC micelle-SNA nanoparticles 
tracked by NTA instrument, the total DNA concentration for both linear DBC based micelle-SNA and DBBC 
micelle-SNA is 20 µM. 
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Sample NTA 
Experiments 
NTA Counts 
(particle/mL) 
Average 
Counts 
(particle/mL) 
Concentration 
20 nm AuNP-
SNA 
1st run 0.64×108  
0.77×108 
 
10 nM 2nd run 0.85×108 
3rd run 0.82×108 
Linear DBC 
based micelle-
SNA w/ total 
DNA of 20 μM 
1st run 8.60×108  
8.09×108 
 
105 nM 2nd run 8.12×108 
3rd run 7.56×108 
DBBC based 
micelle-SNA w/ 
total DNA of 20 
μM 
1st run 5.16×108  
5.12×108 
 
67 nM 
 
2nd run 5.09×108 
3rd run 5.10×108 
Table A4.1. List of nanoparticle concentrations determined by Nanoparticle Tracking Analysis using Nanosight. 
 
Figure A4.10. Melting transition of binary (2-component) SNA mixture composed of micelle-SNAs and 15 nm 
AuNP-SNAs. (a) Scheme depicting binary SNA system in which two different types of SNAs can associate together 
via DNA linker strategy; (b) After addition of the DNA linker, it hybridizes with the complementary strands on 
either micelle-SNAs or AuNP-SNAs. When the SNAs are mixed, the complementary sticky ends  crosslink the 
particles to form aggregates within minutes; (c) The first derivative of the melting curves reveals the melting 
temperature for DBBC micelle-SNA /AuNP-SNA and linear DBC based micelle-SNA /AuNP-SNA to be 39.5 °C 
and 36.9 °C, respectively. Similar to pure AuNP-SNA binary systems, sharp, elevated melting transitions were 
observed for the aggregates composed of both DBBC micelle-SNA /AuNP-SNA and linear DBC based micelle-
SNA /AuNP-SNA. 
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Figure A4.11. Control experiment of gene regulation by DBBC-based micelle-SNAs with scrambled sequence. 
Western blotting of EGFP expression in C166 cells after treatment with DBBC micelle-SNAs and single-stranded 
DNA with scrambled sequence. Actin is used as an internal reference. Both DBBC micelle-SNAs and single-
stranded scrambled DNA with various total DNA concentrations were incubated with C166 cells overnight. After 72 
h, the cells were collected for western blotting. The effect of gene knockdown can be observed with scrabled 
sequence. 
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Figure A5.1. Biodistribution of 64Cu-labeled PMO/PEG5K SNA nanoclusters at 1, 4 and 24 hours. 
 
Figure A5.2. Representative radio-iTLC trace of purified 64CuAuNCs. 
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Figure A5.3. Representative calculation of AuNC extinction coefficient ε520 by ICP-MS. Slope of linear fit = ε520. 
For a sample of AuNCs of known core size (TEM average), ε520 can be used to calculate [AuNCs]. 
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Figure A6.1. Colloidal stability of DNA SNAs and morpholino/PEG5K SNAs bearing the same oligonucleotide 
sequence at varying salt concentrations  (left standing 3 months).   
 
Figure A6.2. Representative linear fit of concentration of DNA SNAs vs. observed rate constant upon hybridization 
with 100 pM complementary OMe-RNA at 37° C. Each data point represents the mean of 3 experiments. 
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Figure A6.3. Representative linear fit of concentration of PMO SNAs vs. observed rate constant upon hybridization 
with 100 pM complementary OMe-RNA at 10° C. 
T (°C) kon (M-1 s-1) 
E𝑎 =
R∗T1∗T2
(T1−T2)
ln (
𝑘1
𝑘2
)  Ea = 15.6 kJ/mol (3.7 kcal/mol) 10 43,900,000 ± 95,000 
37 78,300,000 ± 1,040,000 
 
Table A6.1. Estimation of Ea for capture of complementary OMe-RNA by PMO SNAs. 
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